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1 Summary 
With the global eradication of important infectious diseases such as smallpox and 
poliomyelitis, vaccination campaigns remain one of the most successful public health initiatives. 
Despite this outstanding progress made in the field of vaccination, there is a crying need for 
vaccines against other diseases. Millions of deaths per annum worldwide are caused by 
infections with malaria, tuberculosis and HIV. Efficacious vaccines are lacking against important 
human viral pathogens such as respiratory syncytial virus (RSV) and hepatitis C virus (HCV). 
Several vaccine strategies fail simply because of lack of precise delivery of their antigenic 
genetic cargo into the appropriate immune components capable of driving the desired immune 
response. DCs are specialized in presenting peptides from processed antigens to CD4
+
 and CD8
+
 
T cells, self and microbial glycolipids to NKT cells and native antigens to B cells. Therefore 
efficient targeting of these specialized immune components remains one of several challenges in 
vaccine development. In addition to targeting the antigenic material to DCs, these cells require 
the concomitant delivery of adequate maturation signals enabling them to be able to fully 
activate immune effector cells.  
Coronavirus-based vectors are currently considered a promising tool to genetically 
deliver multiple heterologous genes to specific target cells. They are the largest known positive 
stranded RNA viruses and can afford a cloning capacity of 6-9 kb. Additionally, their 
transcription strategy allows for the expression of multiple antigens and immunostimulatory 
cytokines. These viruses possess potentially high advantage in the field of vaccination in that 
they infect mainly professional antigen presenting cells (pAPCs) such as dendritic cells (DCs) 
and macrophages. Accordingly, the major aim of the thesis was the development of a 
coronavirus-based vaccine system that permits the delivery of antigenic structures to antigen 
presenting cells, preferably DCs, within secondary lymphoid organs.  
In chapter 5.1 of this thesis, the basic methodology for the generation of recombinant 
coronaviral RNA is described. Based on this methodology, first steps were undertaken to 
develop a mouse hepatitis virus (MHV)-based system that permits the production of virus-like 
particles. Chapter 5.2 describes a first series of experiments in which the structural proteins E 
and M of MHV have been deleted in the vector constructs. A packaging cell line that provides 
the structural proteins in trans has been developed and rescue of replication-deficient, but 
propagation-competent MHV particles could be demonstrated. MHV-based VLPs expressing an 
EGFP-containing antigen cassette were shown to be able to transduce primary DCs in vitro. 
However, since large scale production of VLPs was not possible using this approach, a workable 
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protocol for high titer production of MHV-based VLPs was established. Chapter 6.1 describes 
the construction of a set of murine coronavirus-based vectors which are attenuated by the 
deletion of all the accessory genes, the gene for the structural protein E and in addition encode an 
attenuating deletion in the replicase-encoded non-structural protein 1. Stable inducible packaging 
cell lines capable of providing the virus-deleted structural protein E in trans were generated and 
high titers of virus-like particles (VLPs) were produced using these E-expressing packaging cell 
lines. These VLPs were shown to be stable for at least 12 passages and were propagation-
deficient in wild-type cells.  
Chapter 6.2 describes the generation of a series of VLPs that were designed to mediate 
the expression of different combinations of transgenes. One set of MHV-based VLPs mediates 
the expression of a fusion protein consisting of the immunodominant epitope (GP33-
KAVYNFATC) of the glycoprotein of lymphocytic choriomeningitis virus (LCMV-GP) and the 
green fluorescent protein (GFP) in combination with or without the expression of the immune-
stimulatory cytokine granulocyte macrophage colony-stimulating factor (GM-CSF). The second 
pair of MHV-based VLPs mediate the expression of a human melanoma (melan-A) CTL epitope 
fused to yeast ubiquitin and GFP, again together or without GM-CSF. Efficient targeting of 
dendritic cells and macrophages with vector-mediated antigen expression could be demonstrated 
in vitro and in vivo. Single immunization with doses between 10
4
 – 105 pfu elicited strong and 
long-lasting protective antiviral and antitumor immunity. In conclusion, this novel vaccine 
platform mediates the delivery of antigens and immune-stimulatory cytokines to cellular 
components of the immune system that initiate protective immunity. 
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2 Zusammenfassung 
Die Impfungskampagnen, die zur Ausrottung verschiedener Infektionskrankheiten wie 
z.B. Pocken oder Poliomyelitis geführt haben, stellen eine der erfolgreichsten Massnahmen im 
öffentlichen Gesundheitswesen dar. Trotz dieser grossartigen Erfolge auf dem Gebiet der 
Vakzination, besteht weiterhin dringender Bedarf nach Impfstoffen gegen andere Erkrankungen. 
Aufgrund des Mangels an wirksamen Vakzinen sterben jährlich Millionen von Menschen an 
Malaria, Tuberkulose oder HIV. Effiziente Impfstoffe fehlen ebenfalls gegen weitere virale 
Pathogene, wie das respiratorische Synzitialvirus (RSV) oder das Hepatitis C Virus. Die 
derzeitigen Impfansätze scheitern bei der Induktion von Immunantworten gegen diese Erreger, 
da die relevanten Antigene sehr wahrscheinlich nicht an die entsprechenden zellulären 
Komponenten des Immunsystem geliefert werden. Den wichtigsten Zelltyp in der 
Immunaktivierungskaskade stellen die dendritischen Zellen (DCs) dar, die darauf spezialisiert 
sind, prozessierte Peptide den CD4
+
 und CD8
+
 T-Zellen zu präsentieren, aber auch mikrobielle 
Glykolipide für NK-Zellen sichtbar zu machen und native Antigene den B-Zellen zu 
präsentieren. Daher stellt eine effiziente Belieferung dieser spezialisierten Immunzellen mit 
Antigenen eine besondere Herausforderung für die Vakzineentwicklung dar. Neben der 
spezifischen Antigenbeladung, sollten die DCs auch adäquaten Maturationsstimuli ausgesetzt 
werden, um die vollständige Aktivierungskapazität dieser Zellen zu erhalten.  
Coronavirus basierte Vektoren sind vielversprechende Werkzeuge, um spezifische 
Zielzellen mit Antigenen zu beliefern. Diese Viren sind die Grössten der bekannten, 
positivsträngigen RNA-Viren und stellen eine Klonierungskapazität von 6-9 kb zur Verfügung. 
Zudem ermöglicht ihre Transkriptionsstrategie die Expression verschiedener Antigene und 
immunstimulatorischer Zytokine. Die Viren zeigen den weiteren Vorteil, dass sie bevorzugt 
professionelle Antigen präsentierende Zellen, DCs und Makrophagen, infizieren. Daher war das 
Hauptziel dieser Arbeit die Entwicklung eines Coronavirus basierten Systems, das den Transport 
von Antigenstrukturen hin zu Antigen präsentierenden Zellen, bevorzugterweise DCs, in 
sekundären lymphatischen Organgen gewährleistet. 
Im Kapital 5.1 dieser Arbeit wird die grundlegende Methodologie für die Generierung 
von rekombinanter Coronavirus RNA beschrieben. Basierend auf dieser Methodik wurden erste 
Schritte unternommen, um ein auf dem Maushepatitisvirus (MHV) basierendes System zu 
etablieren, das die Produktion von Virus ähnlichen Partikels (VLPs) ermöglicht. In Kapitel 5.2 
wird eine erste Serie von Experimenten beschrieben, die die Deletion der Strukturproteine E und 
M des MHV in den Vektorkonstrukten zum Ziel hatten. Eine Verpackungszellinie wurde 
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etabliert, die eine Komplementierung der fehlenden Strukturproteine in trans ermöglichte. Mit 
Hilfe dieser Zellinie wurde die Produktion von replikationsdefizienten, aber 
propagierungskompetenten VLPs möglich. Es konnte gezeigt werden, dass MHV-basierte VLPs, 
die eine Antigenkassette mit GFP exprimieren, primäre DCs in vitro transduzieren können. Da 
aber eine Produktion von grösseren Mengen von VLPs in diesem Ansatz nicht möglich war, 
wurde ein Protokoll entwickelt, dass die Generierung von hohen Titern der MHV-basierten 
VLPs ermöglicht. In Kapital 6.1 wird die Konstruktion eines Satzes von MHV-basierten 
Vektoren beschrieben, bei denen eine Attenuierung durch die Deletion aller akzessorischen Gene 
und des Gens für das Strukturprotein E und die funktionelle Ablation des Nichtstrukturproteins 
nsp1 erreicht wurde. Induzierbare Verpackungszellinien, die das virale Protein E in trans 
bereitstellen, wurden generiert und grosse Mengen an VLPs konnten mit Hilfe dieser 
Verpackungszellinien hergestellt werden. Diese VLPs waren stabil über mindestens 12 Passagen 
und waren propagierungsdefizient in Wildtypzellen. 
Im Kapitel 6.2 wird das Design einer Serie von VLPs beschrieben, die verschiedene 
Kombinationen von Transgenen tragen. Das erste Paar dieser VLPs vermittelt die Expression 
eines Fusionsproteins bestehend aus dem immundominanten Epitop (gp33-KAVYNFATC) des 
Glykoproteins des Lymphozytären Choriomeningitis Virus (LCMV-GP) und dem grün 
fluoreszierenden Proteins (GFP), allein oder gemeinsam mit dem immunstimulatorischen 
Zytokine Granulozyten-Makrophagen-Kolonie-stimulierender Faktor (GM-CSF). Der zweite 
Satz von Vektoren kodiert für ein humans CTL Epitop des Melan-A Proteins, das mit 
Hefeubiquitin und GFP fusioniert ist. Auch diese Antigenkassette wurde entweder allein oder 
zusammen mit GM-CSF verwendet. Effiziente Tranduktion von DCs und Makrophagen mit 
Vektor vermittelter Antigenexpression in vitro und in vivo konnte demonstriert werden. 
Einmalige Immunisierung mit Mengen von 10
4
 – 105 pfu führte zu starker und langanhaltender, 
protektiver, antiviraler und antitumoraler Immunität. Zusammenfassend kann festgehalten 
werden, dass diese neu entwickelte Vakzineplattform eine Lieferung von Antigenen und 
immunstimulatorischen Zytokinen zum Wirkort einer erfolgreichen und protektiven 
Immunanwort ermöglicht. 
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3  Introduction 
3.1 The immune system in general 
The provision of immunity towards invading pathogens, infectious diseases and cancer often 
entails a highly orchestrated crosstalk between both arms of the immune system namely the 
innate and the adaptive immune systems. The innate immune system reacts rapidly within 
minutes and distinguishes pathogens from self-components through the use of a wide variety of 
receptors such as Toll-like receptors (TLRs), pattern recognition receptors (PRRs)  properly 
adapted to detect evolutionary conserved signatures from pathogens coined pathogen associated 
molecular patterns (PAMPs) (Barton and Medzhitov, 2002; Gordon, 2002; Iwasaki and 
Medzhitov, 2004). The innate immune system baptized as the body‟s first line of defence is 
armed with physical, anatomical, physiological, phagocytic or endocytic and inflammatory 
barriers that provide the organism with such effective system to prevent entry and or 
colonization by pathogenic microorganisms. However, these nonspecific defence mechanisms 
devoid of any immunologic memory, cannot always eliminate infectious agents and there are 
several pathogens that cannot be recognized for various reasons. Innate immune responses, 
among their many effects lead to a rapid burst of inflammatory cytokines wiring or coding in, the 
activation status for antigen presenting cells such as macrophages and dendritic cells (DCs) 
(Pashine et al., 2005) and thereby assist in shaping the upcoming adaptive immune response.  
The components of the adaptive immune system have evolved to provide a more versatile 
means of defence that in addition provides a heightened protection from a subsequent re-
infection with the same pathogen. Endowed with the properties of antigenic specificity, diversity, 
immunologic memory and the ability to segregate self from nonself (Zinkernagel and Doherty, 
1974), the adaptive immune system typically lags for about five to six days after initial exposure 
to a particular antigen. 
The adaptive immune system is generally comprised of two arms, the cytotoxic immune 
response and the humoral immune response. Cytotoxic T lymphocytes (CTL) eliminate infected 
cells or tumour cells through direct action on the target cells by secretion of perforin and 
granzyme whereas B cells are the main players in humoral immune response and they mediate 
the production of antibodies against pathogen-derived molecules. Both processes are dependent 
on CD4
+
 T cell help. Furthermore, the T-cell receptor (TCR) on the surface of the CTL or T 
helper (TH-) cells forms a complex with the MHC I/peptide epitope complex or the MHC 
II/peptide-epitope complex, respectively and both reactions are aided by the CD8 or CD4 co-
receptor ligation respectively. Since the goal of vaccination is to induce immune responses that 
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can control an infection or cancer, the vaccine should be able to selectively stimulate antigen-
specific CTLs or B cells and TH cells. Better still if the vaccine can stimulate a combination of 
all. 
The proper functioning of the adaptive immune response involves two major groups of 
cells, lymphocytes and antigen presenting cells. The induction of both humoral and cell-
mediated adaptive immune response depends on the engagement of naive CD4
+
 T cells and their 
subsequent activation leading to the production of CD4
+
 TH cells.   
 
3.1.1  Antigen presenting cells (APC) 
A major difficulty for an effective vaccination strategy is the delivery of the intended 
antigenic cargo to specific cellular components of the immune system endowed with the 
potential of steering an efficacious immune response. Furthermore, the effective recognition of 
antigens by lymphocytes necessitates adequate antigen processing and presentation within 
specialized complexes which enables specific receptors on lymphocytes to recognise and ligate 
the so called antigenic determinants or epitopes representing the immunologically active areas of 
a complex antigen.  
Professional antigen presenting cells (mainly B cells, macrophages and dendritic cells) 
(Lassila et al., 1988; Steinman, 1991; Steinman and Cohn, 1973) are cells of hematopoietic 
origin capable of sampling their environment for antigens either by phagocytosis, endocytosis, 
pinocytosis for soluble antigens or by receptor mediated internalization and thereafter migrate to 
secondary lymphoid organs. These specialized cells are able to express MHC class II and MHC 
class I molecules on their surface and are equally able to deliver the necessary co-stimulatory 
signal for TH cell or T cytotoxic (TC) cell activation. The internalized antigen is degraded into 
defined antigenic peptides which are bound to MHC molecules and transported to the cell 
surface for subsequent presentation. In order for macrophages to function as professional antigen 
presenting cells, they must be activated by phagocytosis of pathogens before they express the 
necessary MHC class II molecule or the co-stimulatory B7 membrane molecule. In contrast, B 
cells express MHC class II molecules constitutively but need to be activated to express the B7 
co-stimulatory molecule. In fact, the first reports of B cells as stimulatory APCs involved B cell 
tumour lines and normal B cells stimulated with anti-Ig (Chesnut and Grey, 1981). The main 
feature of B cells as APCs is their ability to use their clonally distributed antigen receptors to 
pick up antigen into their processing machinery. Antigen processing and presentation mediated 
by membrane Ig was first demonstrated using rabbit Ig-primed T cells, resulting in T cell 
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proliferation (Chesnut and Grey, 1981). This receptor-mediated specific antigen uptake and 
presentation has proven to be more efficient than nonspecific antigen presentation 
(Lanzavecchia, 1990). The remarkable efficiency in antigen presentation by antigen-specific B 
cells is highlighted, at least in part, by the degree of specificity of the antibody response. 
 
 
Figure 1: Immature dendritic cells (DCs) induce tolerance. Tissue DCs constantly sample their environment, 
capture antigens and migrate to draining lymph nodes. In the absence of inflammation, DCs remain in an immature 
state and antigens are presented to T cells in the lymph node without co-stimulation, leading to either the deletion of 
the cells or the generation of inducible regulatory T cells (Banchereau and Palucka, 2005). 
 
Finally, dendritic cells, the most potent antigen-presenting cells with a constitutively high 
density of surface MHC class II and co-stimulatory-adhesive molecules (Delon et al., 1998) 
display an extraordinary capacity to stimulate naive T cells and initiate primary immune 
responses. The un-matched capacity of DCs to sample their surrounding, transport apoptotic 
cellular components as well as antigenic entities to secondary lymphoid organs where they make 
specific immunologic contacts with T cells make them an ideal target for a successful vaccine 
approach (Banchereau and Steinman, 1998). In fact, the functional diversity of these „‟master 
planner‟‟ cells, could be traced to the different DC subsets and partly on the functional plasticity 
at the immature stage (Liu, 2001). Immature DCs (figure 1) characterised by their high rate of 
antigen capture and low MHC class II expression can be regarded as the security guards of the 
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body‟s immune system. They are available at all potential entry portals, highly alert to capture 
any intruder and ready to relay specific information concerning the intruder to appropriate 
quarters for subsequent action.  
 
 
Figure 2: Mature DCs induce immunity. Tissue inflammation induces maturation of DCs and the migration of 
mature DCs to draining lymph nodes. The mature DCs express peptide-MHC complexes at the cell surface as well 
as appropriate co-stimulatory molecules. This allows the priming of CD4
+
 T helper cells and CD8
+
 cytotoxic T 
lymphocytes (CTLs), the activation of B cells and the initiation of an adaptive immune response. To control the 
immune response, CD4
+
 CD25
+
 regulatory T (TREG) cell populations are also expanded. ADCC, antibody-dependent 
cell-mediated cytotoxicity; NK, natural killer; TCR, T-cell receptor (Banchereau and Palucka, 2005). 
Furthermore, since DCs can present self antigens and because they persistently provide 
tolerogenic signals to T cells, they have been nick named the „‟police‟‟ of the immune system 
(Mays and Chen, 2007; Steinman et al., 2000; Villadangos and Schnorrer, 2007). This is 
compounded by the fact that, immature DCs continuously pick up apoptotic cell debris as well as 
other self antigens and present them to T cells. Interesting enough, under normal physiological 
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circumstances after capturing self antigens, these immature DCs do not assume immunogenic 
form of maturation. In fact, the versatility of DCs in shaping or reshaping the outcome of an 
immune reaction has been elegantly reported indicating the capacity of DCs to initiate peripheral 
tolerance by specific interactions with CD4
+
 and CD8
+
 T cells (Desai et al., 2007; Luckashenak 
et al., 2008; Probst et al., 2005; Seewaldt et al., 2002) or by inducing the differentiation of IL-10 
producing CD4
+
 cells with regulatory or suppressor properties (Dhodapkar et al., 2001; Jonuleit 
et al., 2000). 
Presentation of antigen by mature dendritic cells depends on the strength and quality of 
the activation signals received during antigen sampling. Since immature dendritic cells have 
various pattern recognition receptors enabling them to recognize and distinguish pathogenic 
antigenic cargo, they properly decode the signals emanating from various activating reactions. 
Thus, the presence of pattern recognition ligands (PRL) within endocytosed or phagocytosed 
cargo provides decisive stimuli to antigen capturing immature dendritic cells picking up such 
PRL loaded material to rapidly undergo maturation into immunogenic forms (Blander and 
Medzhitov, 2006). Therefore, immature DCs mainly function as antigen capturing cells whereas 
mature DCs are specialized in antigen presentation. In vivo, the maturation of DCs is closely 
linked to their migration from the periphery where they scan for antigens to the draining 
lymphoid organs where they make contacts with T cells (figure 2).  
Maturing DCs are  associated with down regulation of endocytic or phagocytic receptors and 
the expression of co-stimulatory molecules like CD40, CD58, CD80 and CD86, changes in 
morphology and lysosomal compartments with down regulation of CD68, expression of LAMP3 
(lysosomal-associated membrane protein 3) and changes in MHC class II compartments. 
Additionally, they produce and secrete pro-inflammatory cytokines such as interleukin-1 (IL), 
IL-6, IL12, IL-18 and IL-23 but also turn on ELC/MIP-3 beta and SLC/6Ckine following the up-
regulation of the chemokine receptor CCR7 which promotes migration to draining lymph nodes 
where mature DCs loaded with MHC class I or II peptides make specific immunogenic contacts 
to T cells (Caux et al., 2000; Geijtenbeek et al., 2000).  
 In fact, the combination of IL-1 and TNF with type I and II IFNs seems to yield more 
potent DCs in terms of secretion of IL-12 and induction of  tumour specific CTLs in vitro 
(Mailliard et al., 2004). Additionally the excellent immune-stimulatory capacity and the ability to 
decode specific molecular pathogenic signals make DCs an efficient means to initiate better 
antibacterial, antiviral or anti tumour immune responses (Banchereau et al., 2001; Steinman and 
Pope, 2002). DCs can be marshalled for the treatment and prevention of cancer because tumours 
are replete with potential antigens and they can become immunogenic if presented by DCs 
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(Banchereau and Palucka, 2005; Figdor et al., 2004), meaning the immune attack on cancer can 
be broad enough to encompass multiple targets including mutant proteins expressed by the 
cancer and not just a single target which may favour immune escape. DCs have a crucial role in 
determining the type of response that is induced. It has been shown that either polarized DCs or 
distinct DC subsets might provide T cells with different signals that determine the type of 
immune response (Shortman and Liu, 2002). Splenic CD8+ DCs in mice prime naïve CD4+ T 
cells to produce TH1 cytokines in an IL-12 involving process meanwhile, splenic CD8
-
 DCs 
prime naïve CD4
+
 T cells to produce TH2 cytokines (Maldonado-Lopez et al., 1999; Pulendran et 
al., 1999). Furthermore, the polarization into different T-cell subsets also depends on the 
information received by a DC (Pulendran et al., 2001).  
Additionally, DCs can activate and expand the different arms of cell-mediated resistance 
such as natural killer, NKT, T and T cells each of which recognizes different alterations in 
cancer cells. The immunogenicity of antigens delivered by DCs has been shown in patients with 
cancer (Davis et al., 2003; Nestle, 2000) or chronic HIV infection (Lu et al., 2004), thereby 
providing proof of principle that using DCs as vaccines can work. 
 Preclinical experiments in mice have demonstrated that anti-tumour activity can be 
induced using DCs exogenously pulsed with tumour peptides (Ossevoort et al., 1995; Zitvogel et 
al., 1996), incubated with crude tumour cell lysates (Ashley et al., 1997), transfected with total 
RNA derived from tumour cells (Boczkowski et al., 1996) or even infected with recombinant 
viruses (Song et al., 1997; Specht et al., 1997). The translation of these preclinical experimental 
experiences into clinical trials have demonstrated that the use of DCs is safe and that some 
significant clinical efficacy can be obtained using this method. However, some important 
limitations impeach these approaches such as the possibility of tumours to escape from specific 
immune responses if too few antigens are presented (Nestle, 2000), the suboptimal delivery of 
cellular antigens to DCs or inappropriate co-stimulation (Brossart et al., 2000).  
Actually, the efficacy of DC vaccines can be greatly improved if appropriate signals to 
induce DC maturation and effective activation of T cells are provided. It may thus be efficacious 
to target a combination of antigens and immune-activators to DCs (Figdor et al., 2004). These 
activators should be such that increase the expression of antigen-binding receptors, antigen 
processing, major histocompatibility complex molecule synthesis and chemokine receptor 
expression in DCs. Important inducers of maturation are most of the pathogen-derived products 
(such as LPS, viral dsRNA, and CpG DNA), T cell derived stimuli (CD40), secreted pro-
inflammatory stimuli (IL-1 and 2) and tumour necrosis factor (TNF)-α. Interferon- (IFN-) 
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could be used to generate mature DCs for use in vaccines where a long lasting memory CD8
+
 
response is needed (Dubois et al., 2002).  Furthermore, some workers fused the antigen to heat 
shock proteins that enters DCs via CD19, activating the DCs and targeting the antigen to the 
MHC processing pathway (Srivastava, 2002; Srivastava, 2000). Additionally, the maturation of 
DCs via Toll-like receptors has been demonstrated to enhance cytomegalovirus and HIV specific 
T cell responses in vitro (Lore et al., 2003). 
It would be interesting to identify stimuli that produce a desired DC-maturation 
programme that could lead to the induction of tumour-specific CTLs while inhibiting the 
induction of TReg cells in various human DC subsets. For example, Toll-like receptor in 
combination with a T-cell like signal delivered through CD40 might enhance DC function (Reis 
e Sousa, 2001). Indeed, TLR-mediated signals are involved in the control of CD4
+
 T cell 
activation (Pasare and Medzhitov, 2004). Interestingly, the differential expression of TLRs on 
distinct DC subsets (TLR-9 pDCs, TLR-2 and TLR-4 myeloid DCs) (Kadowaki et al., 2001), 
might confer distinct maturation signals yielding distinct types of immune response. 
Additionally, distinct maturation and or activation signals (such as prostaglandin E2) 
(Luft et al., 2002; Scandella et al., 2002) might induce the preferential expression of CC-
chemokine receptor 7 (CCR7) by DCs, thereby increasing the capacity of these DCs to respond 
to the appropriate ligands CC-chemokine ligand 19 (CCL-19) and CCL21, which are expressed 
in lymphatic vessels and secondary lymphoid organs (Sallusto et al., 1998b). 
 
3.1.2 T Lymphocytes 
The recirculation of naïve T lymphocytes in search of antigen displayed on antigen-
presenting cells, through the blood stream and the lymphoid organs is orchestrated by adhesive 
effects between lymphocytes and cells of the endothelium (Picker and Butcher, 1992). In 
principle, the expression of different sets of chemokine receptors, integrins and selectins provide 
lymphocytes with a precise navigation system for exit at specific sites and retiring at various 
locations in the body (Butcher et al., 1999; Campbell and Butcher, 2000; Sallusto et al., 1998a). 
The initiation of any T cell immune response emanates within the secondary lymphoid organs 
with the establishment of contact between the T cell and antigen-presenting cell representing 
signal 1 followed by binding of an adequate co-stimulation representing signal 2 (Salomon and 
Bluestone, 2001) . This contact takes place in a central space termed the immunological synapse 
surrounded by adhesion molecules in which the T cell receptor (TCR) and the co-stimulatory 
molecules congregate  (Dustin and Cooper, 2000). Engagement of the TCR by MHC-peptide 
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complexes at the immunological synapse initiates some kind of conformational change or 
aggregation of the TCR-CD3- (Lanzavecchia et al., 1999) complex releasing a signaling 
cascade of which the duration and strength dictates entry of the naïve T cell into the cell cycle 
(Lanzavecchia and Sallusto, 2001). In principle, the efficiency of the immunological synapse to 
function as a signal transduction platform depends on the developmental stage of the T cell and 
the activation status of the particular APC. After this primary interaction of the TCR with its 
specific peptide-mounted MHC, the expression of CD28 and CD40L is turned on. The non-
antigen specific co-stimulatory signal is provided by engagement of one or more T cell surface 
receptors CD40 or CD28 with their respective ligands CD40L, B7.1 (CD80) and B7.2 (CD86) on 
APC. Though the particular cytokine microenvironment may influence naïve T cell 
differentiation, it has been demonstrated that the strength of the TCR signal may determine the 
co-stimulatory requirements for Th1 and Th2 CD4
+ 
T cell polarization (Tao et al., 1997). In fact, 
T cells that receive a prolonged TCR stimulation in the presence of IL-4 or IL-12 may be 
committed and terminally differentiate into Th1 cells producing IFN- or differentiate to Th2 
cells producing IL-4, IL-15 and IL-13 (Abbas et al., 1996; O'Garra, 1998; Seder and Paul, 1994). 
After their activation, differentiated T cells extravasate to the inflamed (Campbell et al., 1998) 
peripheral nonlymphoid tissue as effectors guided by the expression of adhesive ligand 
molecules such as L-selectins, LFA-1, VLA-4 and Mac-1 which interacts with activated 
adhesive molecules of the endothelium such as P- and E-selectins VCAM-1 and ICAM-1.    
Furthermore, this activation phase may lead to up-to 1000-fold expansion of the primary 
effector cells within a few days (Goldrath and Bevan, 1999). However, after the invading 
pathogen such as LCMV has been checked, more than 90% of the expanded primary effector T 
cells are eliminated in the second phase by apoptosis (Lin et al., 2000) via FasL-Fas or TNF-a-
TNF-R mediated interaction (Zheng et al., 1995). This massive down regulation is necessary to 
maintain homeostasis and prevent autoimmunity (Lenardo et al., 1999). The final phase is 
composed of long-lasting „‟memory‟‟ T cells that maintain their antigen specificity and can 
persist later on in reduced numbers for the life time of the host (Sallusto et al., 2000; Sprent and 
Surh, 2001; Zinkernagel, 2000). 
Interestingly, memory T cell burst in an immune response as compared to the primary 
response is characterised by its ability to rapidly generate larger number of antigen specific T-
helper cells and CTLs. Studies in mice suggest that CD8
+
 memory CTLs are derived from the 
same initial pool of expanding effector T cells (Kaech and Ahmed, 2001; Mercado et al., 2000; 
van Stipdonk et al., 2001) and these CTLs express effector molecules like granzyme B (Jacob 
and Baltimore, 1999) , perforin (Opferman et al., 1999) and cytokines (Saparov et al., 1999). 
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There is growing evidence suggesting that naive, effector and at least two types of memory T 
cell population namely central-memory and effector-memory T cells exist in mice and human 
(Campbell et al., 2001; Potsch et al., 1999; Reinhardt et al., 2001; Sallusto et al., 1999). Some 
workers have demonstrated that during the activation phase, cycling CD8
+
 T cells are CD27
+
 in 
contrast to terminally differentiated perforin ripe CTLs which are CD27
-
 (Hamann et al., 1997; 
Roos et al., 2000), suggesting the loss of CD27 could be a marker for effector and effector 
memory CTL (Campbell et al., 2001; Hamann et al., 1997). Based on the homing characteristics 
and their effector function, two types of memory T cells have been described within the CD4
+
 
and CD8
+
 T cell population. T central-memory (TCM) cells express CD62L and CCR7 whereas T 
effector memory (TEM) cells do not express CCR7 and CD62L (Sallusto et al., 1999). Indeed, in 
humans and mice, CD4
+
 TCM and CD8
+ 
TCM locate within the lymphoid organs (Masopust et al., 
2001; Reinhardt et al., 2001; Sallusto et al., 1999). Upon restimulation, CD4
+
 TCM divide rapidly 
and secrete IL-2 and IL-10 (Reinhardt et al., 2001; Sallusto et al., 1999) whereas CD8
+
 TCM  
retains ability to secrete IL-2 but needs re-priming to regain perforin killing function and IFN- 
production (Masopust et al., 2001).  
There is sufficient evidence that CD8
+
 T cells autonomously divide and acquire cytotoxic 
function in the absence of further antigen stimulation when once they have been committed, thus 
elaborating an imprinted clonal expansion and differentiation instruction in naïve CD8
+ 
T cells 
during a brief encounter with the antigen-presenting cell (Kaech and Ahmed, 2001; van Stipdonk 
et al., 2001).   
In summary, memory T cells are very important components of the immune system and 
form the basis for the success of many vaccines because the TEM cells provide immediate 
protection against re-infection or reactivation of disease at sites of infection whereas TCM cells 
residing primarily in the lymphoid tissue can rapidly expand and differentiate to resupply the 
effector T cells at the periphery. 
 
3.1.3 B cells and neutralizing antibodies 
The humoral immune response begins when antigen cross-links membrane-bound antibody 
molecules on B cells. Some of these antigens become internalised by receptor mediated 
endocytosis, shuffled for procession through the endocytic pathway and combined to MHC class 
II molecules which are subsequently transported and presented on the B cell membrane. Mature 
naive B cells that have picked up antigen and are activated, must travel towards the interface 
between the primary follicle and the T-cell zones in order to present their antigenic cargo to 
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antigen specific T helper cells (Monson, 2008). The initial priming of antigen specific CD4
+ 
T 
cells requires signals mediated by interactions with ligated MHC class II-peptide complexes and 
members of the B7 family of co-stimulatory molecules (Constant, 1999). This binding activates 
the CD4
+ 
T helper cells to secrete cytokines such as IL-2 and express surface molecules such as 
CD40L (Banchereau et al., 1994; Oxenius et al., 1996; Parker, 1993) that are important stimuli 
of B cell proliferation and differentiation into memory B cells and effector or antibody secreting 
plasma cells. Additionally, anti-lipid antibody production by B cells has been shown to involve 
help from a CD1d-instructed lipid-specific invariant natural killer T cell (Florence et al., 2008; 
Leadbetter et al., 2008; Speak et al., 2008). Long-lived antibody-secreting plasma cells may also 
contribute to immunological memory (Manz et al., 1997). Furthermore, the quality, strength and 
rapidity of memory responses are often different from the primary immune response to antigen. 
Memory B cells express membrane immunoglobulins of the IgA, IgE and IgG classes on their 
surface allowing quick recognition followed by reaction to free antigen (Julius et al., 1972).  
Existing evidence implicate basophils and antigen-specific B cells to be the only leukocyte 
populations that can bind substantial amounts of intact antigen on their surface after 
immunization (Mack et al., 2005). Basophils trap antigen-specific IgE antibodies present in the 
plasma after immunization by expression of the high affinity IgE receptor (Mack et al., 2005). 
These cells have been shown to induce a TH2 phenotype in CD4
+
 T cells in vitro (Hida et al., 
2005; Oh et al., 2007) and in vivo (Sokol et al., 2008). Recognition of the appropriate antigen 
specific to the bound IgE antibodies months after immunization demonstrates the long term 
persistence of an antigen-specific IgE response, suggesting that basophils may be involved in the 
development of memory immune responses. More recent reports actually implicate basophils to 
profoundly enhance B cell proliferation and immunoglobulin production in a CD4
+ 
T-cell-
dependent manner (Denzel et al., 2008), summarising that basophils could be important 
contributors to humoral memory immune responses.  
The effector function of plasma B cell secreted antibodies is mediated by binding to antigens 
and neutralizing them and or facilitating their elimination by various means including 
phagocytosis, complement activation and opsonization.  
In fact, the importance of B cells in the generation of neutralizing and non-neutralizing 
antibodies cannot be under-estimated in assuring immunity against certain viral pathogens. The 
ease of generating neutralizing antibodies varies extremely and convincing arguments that 
repetitive viral surface antigens induce the most potent antibodies to virions have been brought 
to book (Bachmann and Zinkernagel, 1996, 1997). For example the densely packed, highly 
organized glycoprotein of vesicular stomatitis virus (VSV-G) is capable of inducing a strong 
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neutralizing T help independent antibody response whereas its soluble form as an immunogen 
fails to compete (Bachmann and Zinkernagel, 1996). Therefore, a native form of VSV either 
attenuated or killed should make a good vaccine from an antibody point of view. In principle 
antibodies can act against free virus as well as virus infected cells.  
The term neutralization defined as loss of infectivity results when antibodies bind to a 
virus particle and prevent its ability to infect a cell. The binding of antibodies to virus infected 
cells can lead to several antibody mediated antiviral immune properties. Most fundamental of all 
is that binding of antibodies to virus infected cells can effectively inhibit release of progeny 
virions (Gerhard, 2001) and thereby preventing cell-to-cell transmission (Burioni et al., 1994; 
Pantaleo et al., 1995). The binding of antibodies on viral proteins or molecules expressed on the 
membranes of infected cells, could through signal transduction initiate mechanism that inhibit 
virus replication inside the cells as demonstrated in virus infected neurons (Fujinami and 
Oldstone, 1979; Levine et al., 1991). 
Furthermore, the antibody Fc-mediated effector activity can lead to antibody-dependent 
cellular cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC). Additionally, 
antibody-Fc mediated effector functions can affect the activity of free virus particle in the 
organism. The Fc and complement receptor can bind antibody or complement coated virions 
leading to phagocytosis followed by inactivation of the virion in an intracellular compartment of 
the phagocyte. This is believed to be an important in vivo mechanism against Foot and mouth 
disease virus (FMDV) (McCullough et al., 1988). 
It should be recalled that vaccine –induced antibodies that interfere with viral entry and 
spread are the protective correlates of most existing prophylactic vaccines today. However, the 
situation remains elusive with highly variable viruses such as HIV-1 where the ability to induce 
neutralizing antibodies by vaccination has proven to be futile.  
 
3.2 History of Vaccination 
The act of variolation or the deliberate induction of immunity originally used by the 
Chinese and Turks was greatly improved by the British physician Edward Jenner in 1798. 
Surprised by the fact that the milk maids who had contracted cowpox were eventually immune to 
smallpox, Jenner reasoned that introducing fluid from a cowpox pustule into people by 
inoculation could protect them from smallpox. To test this, he inoculated an eight-year old boy 
with fluid from a cowpox postule and later infected the boy with smallpox. The boy was immune 
to small pox as predicted. Louis Pasteur performed similar trials using the bacteria thought to 
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cause cholera in chickens and demonstrated protection of previously injected chickens after 
challenge with fresh virulent stock. He coined his attenuated strain a vaccine (from the Latin 
vacca, meaning „‟cow‟‟) in honor of Jenner‟s work with cowpox.  
Since these pioneering efforts, vaccination has until now become one of the most 
successful public health initiative ever achieved with the global eradication of childhood diseases 
such as smallpox and poliomyelitis. Nevertheless, efficient vaccines for several diseases such as 
tuberculosis (TB), leprosy, and parasitic diseases such as leishmania, malaria and 
schistosomiasis remain a dream. Efficacious vaccines against human immunodeficiency virus 
(HIV-1), herpes simplex virus (HSV), dengue, cytomegalovirus (CMV) and several tumours are 
lacking (Zinkernagel, 2003). Furthermore, the protective capacity of some antiviral vaccines 
such as those against measles and mumps are in doubts because viral breakthroughs may occur 
(Wild, 1999).  Most vaccines currently in clinical use have been developed using mainly 
empirical approaches (Lambert and Siegrist, 1997). The protection provided by these vaccines is 
antibody based, rendering the quality of the response and the antibody avidity the factors 
determining the efficacy whereas the durability of protection relies to a large extent on B cell 
memory.  
Despite the outstanding progress made in the field of vaccination, there is a serious need 
for vaccines against several diseases. Infections caused by parasitic agents induce some of the 
most devastating and prevalent diseases of humans, livestock and companion animals. In fact, 
malaria is a serious problem globally, responsible for the third most common cause of human 
mortality (Gardiner et al., 2005). Other similarly devastating parasitic diseases of humans 
include amoebiasis, filariasis, schistosomiasis, cysticercosis, toxoplasmosis and leishmaniasis, 
which cause untold morbidity and mortality (Brooker et al., 2006; Schwartz et al., 2006; White 
and Garcia, 1999). Millions of deaths per annum worldwide are caused by diseases such as 
malaria, tuberculosis, cancer and HIV-1 for which no effective vaccines exist. It is estimated by 
world health organization (WHO) that some 16000 people a day or some 5.8 million a year 
become infected with HIV-1. Furthermore, the WHO estimates that 20%-35% of infant deaths in 
the world are because of diseases that could be easily prevented if vaccines existed for these 
ailments.  
Therefore the development of alternative and better vaccine strategies that will refine the 
delivery of specific immunogenic antigens and immunostimulatory vaccine components to the 
appropriate determinants of an effective immune response with the hope of eliciting a strong 
primary immune response and a durable immunological memory remains a priority 
(Zinkernagel, 2003). Despite the wealth of information on microbial pathogenesis and host 
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defense mechanism currently available, antigenic variation and strain diversity represent only the 
tip of an iceberg of the complicating factors affecting the vaccinologist. 
 
3.2.1 Today’s successful vaccines 
Successful vaccines that provide proven protection are vaccines that elicit neutralizing 
antibody responses of long duration usually after about three boosts. Such vaccines include the 
smallpox, poliovirus vaccine I, II, III, rubella, tetanus vaccine and bacteria toxins. In contrast, 
vaccines that do not work satisfactorily or fail to induce long term protection are vaccines against 
pathogenic infections usually establishing persisting infection in non-lymphoid cells that require 
a strong CTL response for elimination of the pathogen.  
Good examples of unsuccessful vaccines involve some viral infections including human 
immunodeficiency virus, herpes viruses and hepatitis C virus as well as most of parasitic 
infections such as malaria, leishmaniasis, schistosomiasis and some bacterial infections like TB 
and leprosy. Induction of neutralizing antibodies in such infections is not sufficient to eliminate 
or keep these infections in check, signaling that an effective vaccine against most of such 
infections will require T cell mediated effector mechanisms in addition to protective antibodies. 
Interestingly, T cell mediated protection against leprosy or TB mostly depends on constantly 
activated effector T cells to check reemergence, expansion and spread of the infection 
(Mackaness, 1969). High levels of protective CD8
+
 T cell memory depends on persistent 
infection and T cell activation whereas CD4
+
 T cell could be maintained by non replicating 
antigen stored as complexes on follicular dendritic cells or granulomas. Since the endogenous 
pathway ensuring MHC class I peptide loading generally depends on intracellular synthesis and 
generation of peptides, many successful vaccines could be attempted employing special tricks 
(Ochsenbein et al., 2000; Yewdell et al., 1999). 
 
3.2.2 Major challenges of vaccine development   
The road to successful development of a vaccine that can be approved for human use 
manufactured at reasonable cost and efficiently delivered to at-risk populations is costly, long 
and tedious. Production of material that can be tested in humans and how these tests are 
performed in clinical trials are tightly regulated. Even those candidate vaccines that survive the 
initial scrutinization and are approved for use in human trials are not guaranteed to find their way 
into common usage. 
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Induction of measurable antibodies by immunization has often been used as a landmark 
for predicting vaccine efficacy (Roost et al., 1995) and antibody-mediated protection is an 
essential component of all working vaccines.  
The ability for a vaccine antigen to generate protection is a major complex challenge that 
is beyond the antibody response itself and in particular the development of a global vaccine 
against any pathogen is made difficult by the degree of variability that exists within the species 
of pathogen or amongst different serotypes of that pathogen. In fact the success of the first 
vaccines is because those organisms had little variability. Vaccines against stable diseases such 
as smallpox, measles and rubella were very effective in conferring protection. Furthermore, 
vaccines against organisms with a single virulence determinant have been very effective. 
Additionally, though the genomes of diphtheria causing agent, tetanus and pertussis (Preston et 
al., 2004) may vary considerably, the major virulence factor in each of these is a single toxin. 
Thus the neutralization of these toxins by antibodies efficiently prevents disease. 
The development of polio vaccine already was much more difficult because it needed 
three strains of viruses to acquire global coverage, but at least these strains are relatively stable 
(De Jesus, 2007). Though the degree of variability in influenza virus is quite high between one 
year and the next, the infection period is also very short making a yearly vaccination with the 
correct strain very effective (Carrat and Flahault, 2007). However, the capacity of influenza virus 
to reassort its genome with other strains during co-infection in animal hosts leads to the 
generation of virulent pandemic strains to which exist no prior immune priming (Hilleman, 
2002). Generally, variation in viruses with RNA genomes largely depend on the inaccurate 
replication since these usually lack proof reading during replication or in the case of influenza 
virus to genome reassortment, usually driven by immune pressure and selection. More so, 
viruses such as HIV vary even within a single host during a single infection and therefore have 
successfully resisted all attempts to date to succumb to a vaccine (Korber et al., 2001).  
HCV vaccine development is also marred by rapid mutation particularly in the hot spots 
within the E2 structural gene which leads to alteration of the immuno-type of the virus even 
within a single infected host thus it is actually not clear whether the immune response induced by 
infection with HCV can prevent re-infection. Additional to the genetic variability, HCV (Frazer 
et al., 2007) as well as EBV (Stanberry et al., 2002) vaccine development have been hindered by 
the lack of tractable animal models of infection. 
On the other hand bacterial antigenic variation accounts for most of the difficulties 
encountered by vaccinologists in developing vaccines capable of conferring a broad protection, 
especially in serotypes with very high capsular polysaccharide antigen variability and where 
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there is very limited cross-protection between serotypes. Pneumococcus, a good example, has 
over ninety serotypes with little cross-protection (Lipsitch and O'Hagan, 2007). Prophylactic 
vaccines against uropathogenic E. Coli are under study (Stapleton, 2003), but none is in 
advanced development. Vaccines against nosocomial Gram-negative opportunists remain 
unlikely because of the diversity of species potentially involved and the fact that many high risk 
patients are unable to mount a strong immune response (Livermore, 2007).  
Parasites often exhibit various immune evasion strategies such as antigenic variation, 
molecular mimicry and sequestration at both the individual and infective population levels. 
Additionally, they exhibit complex life cycles and other biological characteristics which pose a 
real challenge and complicate vaccine development against them (Good et al., 2004). 
Furthermore, any immunologic memory must be generated such that upon any future re-
exposure to the same pathogen, adequate specific antibodies generated will be fast and localized 
to the site of the pathogen. 
Failure of several vaccine strategies could be explained by the lack of precise delivery of 
their antigenic genetic load into the appropriate immune components capable of driving the 
much desired response. Dendritic cells possess precise systems (Guermonprez et al., 2002; 
Trombetta and Mellman, 2005) with several binding receptors capable of delivering antigens to 
the correct processing compartments (Dudziak et al., 2007; Trombetta and Mellman, 2005). DCs 
are specialized in presenting peptides from processed antigens to CD4
+
 and CD8
+
 T cells, self 
and microbial glycolipids to NKT cells and native antigens to B cells. Therefore efficient 
targeting of these specialized immune components is a crucial milestone in efficacious vaccine 
development. In addition to targeting the antigenic material to DCs, these cells require the 
concomitant delivery of adequate activation-maturation signals that enables them to migrate, 
process and deliver the antigenic components at the correct address for subsequent action. Some 
viruses such as influenza (Cella et al., 1999) can promote the maturation of DCs and still other 
viruses may fail to do so though engineering of these viruses to utilise or express receptors that 
promote maturation of DCs has been attempted with some success (Molinier-Frenkel et al., 
2003; Okada et al., 2001). 
In the case of viruses that exist in multiple strains or can rapidly undergo mutation due to 
immunologic pressure, either the antibodies must be targeted against a conserved epitope shared 
between strains or unlikely to mutate or the vaccine must include antigens from each relevant 
strain. Vaccine strategies based on live or inactivated viruses, attenuated or vectored viruses 
which may naturally have the tropism to various immune components may be ideal candidates 
since they have evolved the natural mechanism to enter these cells. Compounded by the risk of 
22
                                                                                                                                               Introduction 
 
reversion to wild type because of co-infection or incomplete inactivation, live or inactivated 
viruses will be neglected in preference to vaccines based on viral vectors. An essential property 
of viral vectors is the ability to non-specifically activate the immune system (Truckenmiller and 
Norbury, 2004). Thus by triggering pattern recognition receptors such as those of the TLR 
family (Akira, 2004; Beutler et al., 2003; Peiser et al., 2002) or the scavenger receptor family 
(Peiser et al., 2002), the efficiency of antigen presentation can be improved so that the efficiency 
to generate potent CD8
+
 T cells can be increased (Schwarz et al., 2003). Furthermore, alphavirus 
vector has been reported to break tolerance by the induction of signalling through protein kinase 
receptors that led to a productive CD8
+
 T cell response (Leitner et al., 2003). 
Since adjuvant may be used to increase or fine tune the immune response to an antigen, 
the particular adjuvant choice may make a difference in a particular vaccine formulation 
depending on the desired outcome. Despite the evaluation of a variety of adjuvant, aluminium 
salts are currently the only adjuvants in mass usage. The function of aluminium salts originally 
thought to form a depot of the antigen has been recently questioned (Flarend et al., 1997). 
However, since the use of aluminium salts as adjuvant has been predominantly involved in the 
induction of antibody responses, the discovery of new adjuvants for the development of vaccines 
necessitating cell-mediated immune response is crucial (Hunter, 2002; Ulmer et al., 2006). The 
heightened stringency on vaccine safety has plunged new vaccines into a situation that is often 
linked to lower immunogenicity compared to previous whole cell or virus-based vaccines. This 
situation calls for the necessity to employ adjuvant to induce potent and durable immune 
responses with additional benefit that less antigens and fewer injections may be needed (Guy, 
2007). Currently, there is an evaluation spree for cytokines as adjuvant in vaccines as against 
most chemical entities because cytokines are likely to represent the direct proximal mediators of 
the „classical‟ adjuvant (Pashine et al., 2005).  
Therefore, one challenge is to chemically develop adjuvant or code in natural adjuvant 
that would be effective, yet do not induce extremely vigorous immune response either 
systemically or at the local injection site, causing sequelae such as granuloma formation (Cox 
and Coulter, 1997; Gupta and Siber, 1995). The best would be adjuvants that are effective and 
can be used either singly or in combination in promising upcoming vaccine strategies such as in 
the multigene RNA vaccine vector strategy (Thiel et al., 2003) which could in principle represent 
the design of a „perfect mix‟(Guy, 2007),  an optimal, safe combination of cytokines that will not 
only yield an additive but a synergistic effect, to eventually drive the desired immune response. 
Indeed, a major pitfall to the success of most vaccines in chronic infections as well as 
cancer vaccines might be the presence of regulatory/suppressor T cells (Sakaguchi, 2000; 
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Shevach, 2000). In fact a huge amount of experimental evidence implicate these T cells for 
suppressing anti-tumour immunity and pointing out that the removal of these cells leads to 
tumour clearance (Steitz et al., 2001; Sutmuller et al., 2001). Furthermore, more recent reports 
suggest the involvement of these cells in restricting memory CD8
+
 T cell responses (Kursar et 
al., 2002; Li and Wu, 2008; Todryk et al., 2008). Additionally, an increased frequency of CD4
+
 
CD25
+
 T cells has been observed in the blood and tissue of patients with cancer (Viguier et al., 
2004; Wang et al., 2004; Woo et al., 2001). Distinct DC maturation stimuli will have different 
capacities to induce such regulatory T cells therefore, a carefully designed vaccine incorporating 
components that will dampen such regulatory T cell effects might be instrumental to the efficacy 
of such a vaccine. 
The safety of all vaccines must be a priority most especially if the vaccine is intended for 
human use. The attenuated live measles vaccine (Edmonston strain) approved in the early 1960s 
was used for over a decade though it caused a high incidence (20%-40%) of fever unless it was 
administered together with immunoglobulins.  However, an inactivated version of this same 
vaccine that was also administered in conjunction with a live vaccine was reported to be less 
effective despite avoiding the side effects of the live vaccine. Vaccinees not only showed 
immunity of shorter duration but were at risk for atypical measles infection (Lampe et al., 1985). 
Thus an efficacious vaccine must provide the necessary protection and still be very safe.  
 
3.3 Viral vectors as vaccines 
Viruses have evolved highly efficient mechanism to get into cells and thus utilizing the 
cellular machinery for the production of virally encoded proteins. Therefore, viral vectors are 
naturally preferred vehicles for heterologous gene delivery into cellular components of the 
immune system for induction of an optimal immune response. Some viruses specifically interact 
with receptors or some carbohydrate parts on the surface of APCs and directly infect them, 
though this is not a guarantee for an effective vaccine or immunotherapeutic vector. This is 
because it is well known that humoral responses can develop even if antigen is not made by an 
APC but through the mechanism of cross presentation whereby a cell expressing an antigen can 
transfer the antigen to professional antigen presenting cells for the generation of MHC class I-
restricted cytolytic T lymphocyte responses (Gauvrit et al., 2008; Howland et al., 2008).  
During the past few years, several vectors tailored to efficiently carry and deliver genes 
for immunization have been developed with the added advantage that infections by these natural 
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immunogens will mimic real life offering at least the possibility of tickling both arms of the 
immune system (Esposito and Murphy, 1989; Murphy, 1989; Taylor and Paoletti, 1988). The 
failed efforts to develop effective vaccines against HIV-AIDS and malaria led to an explosive 
development of a myriad of innovative viral vectors capable of delivering antigens and induce 
immune responses (Girard et al., 2006; Gluck et al., 2005; Sutter and Staib, 2003). Safety and 
immunogenicity an important recurrent issue for the development of live-attenuated vaccines 
demands a striking balance between both. Thus, most replication competent viral vectors have 
not been considered sufficiently safe to enter human clinical trials, inspiring the development of 
several DNA and RNA viral vaccine vectors engineered to be replication-incompetent (Oertli et 
al., 1996; Schindler et al., 1994; Warden and Weir, 1996). Furthermore, engineered vectors 
originating from non-human viruses with low prevalence within the human population or from 
viruses originating from discontinued vaccines may be considered attractive since they have 
almost no pre-existing immunity in humans. However, it is not clear whether pre-existing 
immunity could be generalized to all vectors. It was demonstrated earlier that pre-existing 
antibodies to measles virus did not preclude induction of cellular and humoral immunity after 
revaccination (Zuniga et al., 2007). In addition to proven efficacy and safety, a prerequisite for 
every vaccine is the feasibility to be manufactured in large scale while maintaining the genetic 
stability of the vaccine vector over several viral generations even after vaccine administration 
and residual propagation in vaccinees. It should be emphasized here that each specific 
technological platform exhibits some advantageous features and potential limitations depending 
on the intended application.  
 
3.3.1 Adenovirus vectors 
Adenoviruses are DNA viruses that cause diseases ranging from subclinical infections to 
diseases of multiple organ systems particularly in immune compromised individuals. These 
viruses are generally quite species-specific offering a complication for preclinical studies in 
humans since many people have been previously infected with adenoviruses especially during 
infancy. Adenoviruses have been exploited as vectors for gene delivery either as vaccine or gene 
therapy because of their extensive tropism and their growth kinetics (Danthinne and Imperiale, 
2000). They get into target cells by the use of the coxsackie/adenovirus receptor (Bergelson et 
al., 1997) or by internalization after binding to cellular integrins notably αvβ5 (Wickham et al., 
1993). 
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 Adenovirus vectors can be of different flavours notably, either replication-incompetent 
due to the complete deletion of E1 or E1 and E3 and complemented in trans in cell culture or 
replication-competent. The replication competent vectors can afford a cloning capacity of 3-4 
kilo bases (kb) while the replication-incompetent counterparts can afford a trans-gene capacity of 
7-8 kb. The cloning capacity for heterologous genes can be increased depending upon how many 
original early regions are deleted. There exist some safety concerns with adeno-vectors that 
relate to the inflammatory response generated by the vectors. Additionally, there are disturbing  
concerns about possible integration even though the wild type virus has been reported not to 
integrate into the genome of the infected cells (Harui et al., 1999).  
The most explored for vaccine development is the serotype 5 but has been reported to 
have the highest seroprevalence in the world (Shiver and Emini, 2004). Therefore adenoviruses 
from poorly circulated strains or even from chimpanzee provide an alternative as vaccine and 
gene therapy vectors.  
To avoid pre-existing immunity and the possibility of hampering vaccine efficacy, novel 
strategies are being developed utilizing altered surface proteins or chimeric virus carrying the 
surface proteins of another serotype (Nanda et al., 2005; Roberts et al., 2006; Thorner et al., 
2006; Xin et al., 2005). Adenovectors have been developed and tested for ailments ranging from 
infectious diseases to cancer for both animal and humans. 
The first  licensed gene therapy product, Genedicine (Peng, 2005) approved in China in 
2003 is based upon an adenovector encoding tumor suppressor p53 for use in the treatment of 
squamous cell head and neck cancer. Vaccines based on Adenoviruses are being developed for 
malaria (Li et al., 2007), SARS (Chunling et al., 2006; Zhi et al., 2006) and Ebola (Sullivan et 
al., 2003). Furthermore, a nasal application of an adenovirus vector expressing an influenza gene 
has demonstrated safety and immunogenicity in humans. Adenovectors are also being 
investigated as vaccines for animal diseases such as rabies (Culp et al., 2006) and foot and mouth 
disease (Liu et al., 2006). 
 
3.3.2 Adeno-Associated Virus (AAVs) 
Adeno-associated viruses (AAVs) are non-enveloped, single stranded DNA viruses with 
a genome size of 4.7 kb belonging to the parvoviridae family that depend on helper virus 
functions for replication. Although AAV has so far not been linked to any human disease, there 
are 11 serotypes (from humans to primates) defined by AAV-specific antibodies (preferentially 
to AAV-2) which have been detected in 70% - 80% of the human population (Romano, 2005). 
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Recombinant AAV vectors (rAAVs) are capable of inducing trans-gene expression in a broad 
range of tissues. Unlike the wild type AAV, rAAVs may insert their genome into the safe 
AAVS1 site of the host cell chromosomes owing to deletion of the rep gene. However, rAAVs 
may insert their DNA randomly into the host-cell genome and thereby silence tumor-suppressor 
genes (Romano, 2003, 2006). The genomes of rAAVs are basically composed of an expression 
cassette, with a limited insertional capacity of 5 kb, flanked by the inverted terminal repeats 
taken from wild type viruses. Therefore, production of viral particles is dependent on cells that 
contribute the Rep, Cap and virus helper function in trans.  
In fact, the generation of vaccine candidates acceptable for human clinical applications 
involves extensive purification of rAAV particles using the method of chromatography (Merten 
et al., 2005; Morenweiser, 2005). Intramuscularly injected rAAV expressing SIV antigens in pre-
clinical studies demonstrated protective, persistent antibody and T-cell responses towards SIV 
antigens (Johnson et al., 2005). Interestingly, rAAV particle vaccine candidates geared against 
AIDS have been developed using targeted genetics. These vaccines have been reported to have 
passed Phase I trials in Europe, India and are currently undergoing Phase II evaluation in Africa 
(Girard et al., 2006).    
 
3.3.3 Vesicular stomatitis virus 
Vesicular stomatitis virus (VSV) is an arthropod borne rhabdovirus (a family also 
containing rabies virus) with a single stranded negative-sense RNA genome of about 11kb that 
normally infects domestic animals causing a rarely fatal disease. It exist in several serotypes and 
in humans the virus causes mild and self-limiting flu-like symptoms although more serious 
conditions such as encephalitis may occur (Quiroz et al., 1988). Generally livestock infections 
are associated with either serotype VSV Indiana or VSV-New Jersey.  
VSV was rescued from cDNA like measles Virus using reverse genetics. The genome can 
be engineered to encode heterologous antigens and recombinant VSV vectors grow to high titers 
and are genetically quite stable. They have a replication strategy that is strictly limited to the 
cytoplasm of the infected cell, precluding any risk of viral derived nucleic acid recombining with 
the host cell chromosomal DNA. An HIV-vaccine based on live-attenuated VSV vector 
expressing HIV env and gag genes was successfully tested in the simian/human 
immunodeficiency virus (SHIV)/macaque model. Since VSV is among the neurotropic viruses, 
serious safety concerns are considered for a mucosal application of rVSV in human clinical 
trials. Intranasal vaccination of young mice with the vectors did induce encephalitis (Reiss et al., 
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1998) which provoked the development of a new generation of vectors by reshuffling viral genes 
within the VSV genome or by truncating the cytoplasmic tail of  VSV encoded G protein. VSV 
vectors devoid of the entire G gene were generated in cell lines providing the G protein in trans 
(Publicover et al., 2005). Amazingly, these single-cycle vectors expressing HIV-env induced 
primary and memory CD8
+
 T cell responses that were comparable to replication-competent 
rVSV. The expression of VSV G is toxic to most mammalian cells which may limit the 
development of complementing cell lines at the industrial level (Chen et al., 1996). 
 
3.3.4 Measles virus 
Measles virus (MV), a negative, single-stranded RNA virus with a genome size of 15894 
nucleotides is being exploited as vaccine vectors in the HIV-1 vaccine arena. In fact, several 
recombinants encoding several other important viral genes have been constructed, including 
immunogenic genes of hepatitis B, mumps, West Nile virus, and severe acute respiratory 
syndrome coronavirus (SARS) (Liniger et al., 2007).  
The measles virus as vaccine vector has several qualities making it attractive for 
HIV/AIDS vaccine. Experience with the live-attenuated measles vaccine demonstrate the 
possibility to induce life-long immunity composed of cellular and humoral immunity that persist 
for up to 25 years (Zuniga et al., 2007). The ability of measles virus to infect dendritic cells and 
macrophages may be responsible for this property. The virus replicates in the cytoplasm, 
therefore precluding integration into the host cell genome. The helical structure of the 
nucleocapsid permits the vector to accommodate up to 5 kb of heterologous gene insert. 
Additionally, a high stability after several passages has been demonstrated for this virus in vitro 
(Zuniga et al., 2007).  Interestingly, it was also shown that SIV/HIV antigens do not incorporate 
into measles virus virions and therefore did not alter their tropism (Zuniga et al., 2007). About 
90% of the human population has been in contact with measles or its vaccine during infancy. 
Despite this exposure, the presence of antibody and cellular immunity seem not to significantly 
inhibit a booster vaccination 10 years after the primary infection or vaccination (Brave et al., 
2007). A measles virus recombinant encoding the HIV envelope glycoprotein elicited high titer 
antibodies and HIV envelop specific CD8
+ 
and CD4
+ 
cells following a single injection. The 
antibodies were able to neutralize the HIV neutralizing strain as well as several other 
heterologous isolates (Lorin et al., 2004). Similar results have been reported after vaccination of 
humanized mice for MHC class I HLA-A0201 (Lorin et al., 2005). In fact, the quality and 
magnitude of antibodies induced by recombinant measles vaccines were comparable to those of 
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the conventional measles vaccine. However, it remains to be seen whether the replacement of the 
current measles components of the globally accepted MMR regimen is feasible from a regulatory 
and licensing stand point (Liniger et al., 2007). 
 
3.3.5 Herpes virus  
Herpes simplex virus (HSV)-1 a highly pathogenic virus infecting a variety of tissue 
types but also targeting mucosal epithelial surfaces. Lysis of infected cells leads to infection of 
sensory neurons during which the virus typically enters into a lytic or a latent phase and in the 
worst scenario may cause encephalitis. This double-stranded DNA virus with a genome of 152 
kb contains 81 genes encoding for at least 84 polypeptides (Marconi et al., 1996; Marconi et al., 
1999).  
After deletion of the non-essential genes, HSV-1 offers a cloning capacity of about 50 kb. 
Currently, two basic approaches for the development of HSV-based vaccine vectors include 
amplicons and recombinant viruses. Amplicons work by transfection of plasmid DNA into a cell 
line equally transfected with a helper virus providing the necessary structural and regulatory 
proteins in trans (Spaete and Frenkel, 1982). HSV-1 amplicon expressing HIV-1 gp120 induced 
cellular and humoral immune responses in immunized mice (Hocknell et al., 2002). Replication-
deficient vaccine vectors based on HSV-1 have been constructed as vaccine vectors against HIV-
1.  
These replication deficient vaccines expressing Env, Gag and a Tat-Rev-Nef fusion 
protein of SIV were able to induce robust anti-Gag and anti-Env cellular immune responses in 
macaques (Kaur et al., 2007).  A limitation in the use of HSV-1-based vectors could be the high 
pre-existing immunity within the human population. Furthermore, mass vaccine production may 
be difficult because of technical difficulties to achieve high titers (Dudek and Knipe, 2006). 
 
3.3.6 Poxviruses 
The excellent success of vaccinia virus in the eradication of smallpox increased the 
interest to exploit the poxvirus as vaccine vectors. Poxviruses are double stranded DNA viruses 
with a genome of 150-300 kb, replicating in the cytoplasm. The first live recombinant vaccines 
developed were based on vaccinia virus as a vector (Arlen et al., 2005; Mastrangelo et al., 2000). 
The advantage is that Poxvirus vectors easily grow to high titers and are genetically easy to 
manipulate. However, because of safety concerns on the use of replicating vectors in immune 
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suppressed individuals, safer non-replicating vectors have been at the center of recent 
developments. These include the modified vaccinia Ankara (MVA) which due to serial passages 
in chicken embryo fibroblast has lost about 15% of its genome, and NYVAC, derived from the 
Copenhagen strain of vaccinia made replication incompetent by 18 specific deletions (Parrino 
and Graham, 2006). Fowl-pox (FPV) and canary-pox virus (ALVAC) vectors that usually do not 
replicate in humans are now undergoing some clinical trials. The FPV and ALVAC will certainly 
not face the limitation of pre-existing immunity. In clinical trials ALVAC-HIV recombinants 
demonstrated safety but induced only modest HIV-specific cellular immune responses. In fact, a 
phase II study of a multi-gene ALVAC-HIV vaccine candidate failed to elicit a CD8
+
 CTL 
frequency of 30% in healthy volunteers despite a boost with recombinant gp120 (Russell et al., 
2007). Despite the moderate immunogenicity profile recorded in clinical trials with recombinant 
poxvirus-based vaccines, these vectors may only be attractive as booster components in 
heterologous prime-boost regimens (Girard et al., 2006; Naslund et al., 2007; Robinson, 2002). 
 
3.3.7 Alphavirus vectors 
Alphaviruses are positive sense single stranded RNA viruses with a genome size of 
approximately 12 kb. They include Semliki Forest (SFV), Venezuelan equine encephalitis virus 
(VEEV) and Sindbis virus (SIN) belonging to the Togaviridae family.  The high interest in the 
development of Alphavirus-based vaccine vectors stems from the attractive intrinsic 
characteristics such as their replication which is limited to the cytoplasm, therefore excluding 
any integration of virus derived sequences into the host cell genome, their ability to infect a wide 
variety of cells including mammalian cell types and the capability to transiently express high 
amounts of viral proteins or heterologous proteins. Furthermore, the complete lack of antivector 
immunity in the human population heightens their attractiveness (Schlesinger and Dubensky, 
1999; Strauss and Strauss, 1994).  
Engineered Alphavirus-derived replicon vaccines have been developed by replacing viral 
genes with heterologous genes. The formation of virus-like particles (VLPS) necessitated a 
packaging cell system through which the necessary structural proteins required for virus particle 
formation were provided in trans (Polo et al., 1999). Indeed attractive for the vaccinologist, these 
vectors retained their capacity to express genes and replicate in cells but completely lost the 
ability to infect neighboring cells. This led to the coinage of single-cycle vectors (Liljestrom and 
Garoff, 1991; Tubulekas et al., 1997). Furthermore, particles derived from these vectors have 
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been directly implicated to interact efficiently with antigen-presenting cells such as dendritic 
cells (Gardner et al., 2000).  
VEEV-SIV replicon particles demonstrated protective immune responses against simian 
immunodeficiency virus (SIV) in primates (Davis et al., 2000; Perri et al., 2003). Clinical 
experimental trials with the VEEV replicon particles will be of high interest to demonstrate the 
potential of these particle vaccines encoding a clade C HIV-1-gag gene (Alphavax).  These 
vectors may encounter serious regulatory difficulties at the level of obtaining a cGMP-grade 
manufacturing cell line that will enable mass production of the vaccine for commercial purposes.  
 
3.4 Coronavirus biology and their exploitation as vaccine vectors 
The entry of coronaviruses into susceptible cells is implicated to the spike glycoprotein 
peplomers on the membrane of the virion. The spike is responsible for ligating into specific 
receptors on susceptible cells leading to a conformational change which subsequently leads to 
the fusion of the two membranes liberating the viral genome into the cytoplasm. Coronaviruses 
are enveloped, positive-stranded RNA viruses with a size of approximately 30 kb and possess the 
ability to replicate autonomously in susceptible target cells. More than two third of the genome 
encodes the replicase gene while the remaining one third encodes mostly the structural and the 
nonessential genes depicted in figure 3 below. The replicase gene is composed of two large open 
reading frames (ORFs), ORF1a and ORF1b which can be translated into two polyprotein (pp) 
precursors, ppIa and ppIab. Translation of the complete replicase polyprotein ppIab necessitates 
a (-1) ribosomal frame shift. Extensive processing of this large polyprotein by virus-encoded 
proteinases leads to the production of viral proteins which together with some undetermined 
cellular components assemble to form an active replicase-transcriptase complex.  
In addition to replicating the genomic RNA, this unique transcription machinery produces 
a nested set of six to eight sub-genomic mRNAs (sgmRNA). These sgmRNAs are produced in 
constant but nonequimolar ratios and appear structurally polycistronic though they are 
functionally monocistronic.   
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Figure 3: Genome organization and expression of the MHV-A59 prototype virus. The structural relationships of the 
MHV-A59 genome and the subgenome length mRNAs are depicted. The virus ORFs are shown in teal (nsp1-nsp16 
genes), blue (ns2, ns4a, ns4b, and ns5a genes), and green (S, E, M, N and I structural genes). The ORFs are defined 
by the genomic sequence of MHV-A59 (Coley et al., 2005). The open red box represents the common 59-nucleotide 
leader sequence and the barred circle represent the programmed (-1) frame shifting element. The translation 
products of the genome and subgenome length mRNAs are depicted and the autoproteolytic processing of the ORF 
1a and ORF 1a/ORF1b (Sawicki et al., 2007).  
 
This therefore generates a gradient-like synthesis of the subgenomic mRNAs with the 
highest amount closest to the 3‟ terminus of the genome (Hofmann et al., 1993; Konings et al., 
1988; Sethna et al., 1989) with exceptions to transmissible gastroenteritis virus (TGEV) and the 
feline infectious peritonitis virus (FIPV) where the smallest sgmRNA is produced in much 
smaller amounts than the next smallest (de Groot et al., 1987; Sethna et al., 1989). Most of the 
structural genes and the nonessential genes can be replaced by genes encoding antigens and 
immunostimulatory molecules. Therefore, this specialized transcription machinery enables a 
multi-heterologous protein expression amenable to exploitation for multi-gene vaccine 
development. Furthermore, one important advantage is that, coronaviruses have the largest 
known positive-stranded RNA genome and thus can afford a cloning capacity of 6-9 kb of 
heterologous genes though no one has actually attempted demonstrating the limits. Additionally, 
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it is possible to steer these viruses to target specific immune components by manipulating the 
spike glycoprotein implicated for tropism. 
Currently, several coronaviruses of medical and veterinary importance have been 
characterised. They infect various animal species, causing respiratory, gastrointestinal, 
cardiovascular and neurological ailments. In humans, coronaviruses have been associated mostly 
with common cold, diarrhoea and most recently the severe acute respiratory syndrome (SARS) 
epidemic which highlighted the importance of coronaviruses. 
Despite the enormous intrinsic advantages and promising qualities that coronaviruses 
possess, not much has been exploited of this „‟Gold mine‟‟. Therefore not much is known on 
coronaviruses as vectors for vaccines or immunotherapy probably because of the former 
technical limitations to conduct effective mutagenesis on these large and complex RNA 
genomes. Furthermore, almost nothing is known about the immunogenicity of coronavirus-based 
vectors and their characteristics. 
 
3.4.1 Immunobiology of coronavirus infection 
Coronaviruses infect several animals including humans and induce diseases ranging from 
mild common cold, enteric infections, hepatitis, demyelinating disease of the central nervous 
system (CNS) (Weiner, 1973) to acute and chronic respiratory diseases. Some of these ailments 
have engraved serious economic losses and even death in the human population (Stadler et al., 
2003). While little is known about the pathogenesis of any of the human coronaviruses (229E, 
OC43, HKU1, NL63, and SARS-CoV), there have been detailed studies of the pathogenesis of 
some animal coronaviruses. Some examples of these include the porcine coronavirus, avian 
coronavirus, feline coronavirus, bovine coronavirus and the murine coronavirus (Drosten et al., 
2003). Murine coronavirus (MHV) is the most studied of all coronaviruses, with several strains 
exhibiting differences in tropism and levels of virulence. The commonly used laboratory strains 
infect primarily the liver and the brain providing excellent models for encephalitis and hepatitis 
as well as the immune-mediated demyelinating disease (Perlman, 1998). MHV infection is 
regarded as one of the best animal models for the study of demyelinating disease such as 
multiple sclerosis (Barthold et al., 1993). 
Compared to other models of infection and virus-induced encephalitis (Dorries, 2001; 
Griffin, 2003), intranasal or direct intracranial MHV infection induces a vigorous CNS 
inflammatory response composed of both innate and adaptive immune components (Bergmann et 
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al., 2003; Zhou et al., 2003). Furthermore the part played by the immune response to MHV 
infection in viral clearance and pathogenesis in the CNS has been analyzed (Koren et al., 2003). 
To protect against coronavirus infections both cell-mediated and antibody immune 
responses are needed. During the acute phase of the infection CD4
+ 
and CD8
+
 T cells are 
required for clearance of the virus (Beauchemin et al., 1999; Belay et al., 2005; Bergmann et al., 
1993) mainly utilizing perforin-mediated killing from astrocytes and microglia while IFN- has 
been implicated in virus clearance from oligodendrocytes (Parra et al., 1999). Additionally, most 
CD8
+
 T cells and CD4
+
 T cells during the height of T cell accumulation within the CNS are virus 
specific (Bergmann et al., 1999; Marten et al., 2001). The accumulation of virus specific CD8
+
 T 
cells in the CNS is 10-fold more than in the periphery and are of the phenotype CD44
hi
, CD62L
-
/Lo
, CD11a
hi
 and CD49d consistent with their function in controlling acute MHV replication 
(Bergmann et al., 1999; Marten et al., 2003).  
Mapping of MHV T cell epitopes have been localized to several structural proteins 
though there might be additional epitopes in the two third part of the genome encoding the 
replicase gene products that may warrant examination. The spike of MHV which is implicated in 
virus tissue tropism and is responsible for cell-to-cell fusion during infection has been identified 
with CD8
+
 T cell epitopes. Within the MHV spike is located an immunodominant CD8
+ 
T cell 
epitope  (S510-S518) and a subdominant CD8
+
 T cell epitope (S598-S605) in C57BL/6 mice. 
Furthermore, in BALB/c mice, MHV nucleocapsid protein is associated with a CD8
+
 T cell 
epitope (N318-N326) (Bergmann et al., 1993). Additionally, CD4
+
 T cell epitopes have been 
mapped in the spike (van der Veen, 1996), membrane protein (M) (Xue et al., 1995) and the 
nucleocapsid protein (N) (van der Veen, 1996). Interestingly, B-cell epitopes essential for 
neutralizing antibody formation have been mapped as well in the spike protein while non 
neutralizing antibodies have been identified in other structural proteins (Daniel et al., 1993; 
Daniel et al., 1994; Talbot and Buchmeier, 1985). The clearance of MHV in the CNS is 
primarily executed by cell-mediated immune response while antibodies may be important in 
preventing re-emergence of the virus.  
Infection with the neurovirulent JHM strain is identified with a strong and durable IFN-
/ response with high levels of chemo-attractants such as CCL3 (MIP-Iα), CCL4 (MIP-Iβ) and 
CXCL2 (MIP-2) as well as CXCL10 and CXCL5 (RANTES) (Laude et al., 1992). This increase 
in chemokine secretion correlates with high numbers of macrophages, neutrophils and natural 
killer (NK) cells during the acute phase of the infection and also in the later stages of the 
demyelinating disease (Glass et al., 2002). Studies with recombinant viruses implicate the 
34
                                                                                                                                               Introduction 
 
infiltration of macrophages to be a likely influence of the spike protein (MacNamara et al., 
2005). 
Infection of the CNS with other neurotropic viruses such as lymphocytic 
choriomeningitis virus (LCMV) and measles virus induces a similar chemokine-gene-expression 
profile to MHV, meaning that CNS resident cells may respond to viral infection in a similar 
fashion, which could be linked to their expression of the type-1interferons (Asensio and 
Campbell, 1997; Salazar-Mather et al., 2002). 
 
3.4.2 First steps towards a coronavirus-based vaccine 
Coronaviruses are the largest enveloped, positive-stranded RNA viruses known to date, with 
a genome size of approximately 30 kb and belonging to the family Coronaviridae in the order 
Nidovirales. Their genome is 5‟ capped, 3‟ polyadenylated and infectious (Lai and Cavanagh, 
1997) upon transfection into target cells. The genome organization is such that the essential 
genes are arranged in the order 5‟-replicase-S-M-E-N-3‟ and has interspersed between the 
structural genes, a varying number of non-structural or group-specific genes. These group-
specific genes were shown not to be essential at least in tissue culture for the group I coronavirus 
feline infectious peritonitis virus and for the group II coronavirus mouse hepatitis virus (MHV) 
(de Haan et al., 2002a).   
 Coronaviruses are endowed with natural characteristics which make them attractive as 
vaccine candidates. The extraordinary large genome size indicates that these viruses may have a 
large cloning capacity and in addition their unique transcription mechanism which allows for the 
production of 6-8 sub-genomic mRNAs, implicating these viruses as promising candidates for 
multi-gene RNA vectors (Enjuanes et al., 2001; Thiel et al., 2003). The fact that the accessory 
genes are dispensable for viral replication ascertains the provision of space for cloning large 
heterologous genes which can be typically inserted downstream of the so called coronavirus 
transcription regulatory sequences (TRS) (Curtis et al., 2002; Enjuanes et al., 2001; Fischer et 
al., 1997; Thiel et al., 2003). The core consensus TRS sequence for MHV has been mapped to 
the 9-nucleotide motif 5‟-AAUCUAAAC-3‟ (Lai and Cavanagh, 1997). Additionally the 
deletion of the nonessential or group-specific genes of coronaviruses has been reported to be 
attenuating in the natural host (de Haan et al., 2002a).     
Furthermore, the species and tissue tropism of coronaviruses can be easily modified by                                                                                                                                                                                                                                                                                                              
manipulating the spike protein which is responsible for targeting. In fact, by exchanging the 
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ectodomain of the MHV spike with that for FIPV, the murine virus was retargeted to feline cells 
losing its ability to infect murine cells (Haijema et al., 2003; Kuo et al., 2000) and the reverse 
was demonstrated for FIPV (Haijema et al., 2003). Similar ectodomain exchanges of the S 
protein led to changes in tissue tropism of MHV and transmissible gastroenteritis virus (TGEV) 
respectively (Enjuanes et al., 2001; Navas et al., 2001; Phillips et al., 1999). The deliberate 
rearrangement of the conserved order of the coronavirus genes has been demonstrated (de Haan 
et al., 2002b) and this further improves safety of these viruses as vaccine vector candidates. 
Furthermore, since the replication of coronaviruses is restricted to the cytoplasm, this precludes 
any risk of integration of virus derived sequences into the host cell genome.  
The development of coronaviruses as potential vectors for vaccine or immunotherapy had 
been perishing in the depths of all potential viruses thought to be of interest as vector candidates 
due to technical impediments. The extremely large size of the coronavirus genome and more 
especially the instability of plasmids carrying coronavirus replicase genes hampered the 
construction of a full length cDNA clone (Masters, 1999). Lately, there has been an explosive 
demonstration of technical improvement, following reports of successful construction of full 
length infectious coronavirus cDNA clones (Almazan et al., 2000; Thiel et al., 2001a; Yount et 
al., 2000) providing an invaluable tool to study coronavirus virus-host interaction, replication, 
transcription and the exploitation for possible vector generation. Not long after this 
demonstration of a reverse-genetic system for coronaviruses, were reports of the first 
coronavirus-based vectors described and coined to be replication-competent but propagation 
deficient (Curtis et al., 2002; Ortego et al., 2002) based on transmissible gastroenteritis virus 
(TGEV). The rational of this idea was to generate coronavirus replicons by deleting one or more 
structural gene(s) and to introduce a system for the production of virus-like particle (VLPs) by 
complementing the structural gene(s) in producer cells in trans. This was elegantly demonstrated 
by two independent groups who reported the production of a recombinant TGEV lacking the 
small envelope protein gene E (E-TGEV) (Curtis et al., 2002; Ortego et al., 2002). Both groups 
reported that efficient propagation of TGEV vectors lacking the E gene was dependent on E 
expression in trans, demonstrating the absolute dependence of TGEV virus on the presence of 
TGEV-E protein for efficient propagation. 
Similar observations were recorded for MHV E though this study pointed that MHV E was 
not absolutely important for virus replication (Kuo and Masters, 2003). Nonetheless, E vectors 
can be considered to be safe since recombinant MHV devoid of the E gene replicates only to 
reduced titers. Additionally, despite the provision of TGEV E or MHV E in trans in order to 
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efficiently propagate these vectors, there has been no evidence of recombination with the E 
provided by the packaging system, leading to wild type reversion.  
To further step up the safety of these vectors, it is possible to rearrange the structural genes 
(de Haan et al., 2002b) or by using a strategy which allows a reconnection of the transcription 
circuit (Yount et al., 2006). Noteworthy, is the fact that the group-specific genes have been 
earmarked as not essential for replication at least in tissue culture and that their deletion is 
attenuating in the natural host (de Haan et al., 2002a; Haijema et al., 2004), with implication that 
safety of coronavirus vectors can be further improved by deleting all the group-specific genes.  
A multigene vector construct was demonstrated (Thiel et al., 2003) in which three 
cytoplasmic reporter genes namely chloramphenicol-acetyltransferase (CAT) gene, firefly 
luciferase (LUC) and green fluorescent protein (GFP) were encoded by a coronavirus-based 
vector. Furthermore, vector-mediated expression of these genes was shown both at the RNA 
level and by protein assay with the respective reporter protein assaying techniques (Thiel et al., 
2003) . A helper virus was employed in this situation to provide the necessary structural proteins 
for packaging of the RNA into VLPs, providing a potential source of VLP stock contamination.  
A critical consideration for viral vaccine vector is the potential for efficient delivery of 
the encoded genetic cargo to specific target cells of the immune system. An attractive concept is 
to deliver vaccine antigens to antigen presenting cells such as DCs through binding of specific 
receptors on DCs along with stimuli that would influence DC maturation since DCs control a 
spectrum of the innate and adaptive immune responses (Steinman and Banchereau, 2007). 
Remarkably, the receptor for human coronavirus-229E (HCoV-229E), human amino-peptidase-
N (h-APN or CD13) and for MHV, carcinoembryonic antigen-related cell adhesion molecule 
(CEACAM) 1 are expressed at high levels on human and mouse dendritic cells, respectively. 
Furthermore, using HCoV-229E based multigene VLPs it was possible to efficiently transduce 
mature and immature DCs as demonstrated by VLP-mediated heterologous gene expression 
(Thiel et al., 2003). Additionally, MHV has been implicated for targeting and infecting murine 
DCs by several groups (Cervantes-Barragan et al., 2007; Zhou and Perlman, 2006). 
The concept of coronavirus-based vectors has been adapted to the murine system. In fact, 
MHV-based vector RNAs lacking the structural genes E and M have been produced and 
propagated using E-M complementing packaging cells (Eriksson et al., 2006a). Interestingly, 
VLPs containing MHV-based vector RNAs were used to transduce murine DCs and 24hrs later 
vector mediated expression of GFP in those DCs was evident. The murine model of coronavirus-
based vectors represent a very important tool for the development and evaluation of the system 
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and may be instructive for the development, evaluation and adaptation of coronavirus-based 
vaccine vectors for human ailments (Eriksson et al., 2006b). 
 
3.4.3 Attenuation of coronavirus-based vectors (NspI, NS2, HE, gene4/5a and E) 
3.4.3.1 Non-structural protein 1 (NspI) 
Mouse hepatitis coronavirus replicase encoded gene products when accurately processed 
yield 16 mature non-structural proteins (Nsp). The expression of nsp1 the N-terminal most gene 
1 protein has been implicated to have a pathogenic role in MHV infection (Zust et al., 2007), 
SARS (Kamitani et al., 2006; Wathelet et al., 2007). Nsp1 was generally found to inhibit host 
protein synthesis by promoting host mRNA degradation (Kamitani et al., 2006; Zust et al., 2007) 
and inhibiting translation (Narayanan et al., 2008). Additionally, Rotavirus nsp1 inhibits 
expression of type 1 interferon by antagonizing the function of interferon regulatory factor -3, 5 
and 7 (Barro and Patton, 2007) indicating that this might be a general mechanism to interfere 
with the first wave of immune response to the advantage of the virus. Amazingly, nsp1 can be 
partially deleted without perturbing viral replication in tissue culture (Brockway and Denison, 
2005). Furthermore, the deletion of 99-nucleotides from MHV-A59 nsp1 resulted in a mutant 
(MHV-99) which grew to comparable wild type MHV-A59 titers in tissue culture. 
Interestingly, like the wild type MHV-A59, this nsp1 mutant virus still retained its ability to 
infect professional antigen presenting cells. MHV-A59 is hepatotropic and is known to cause 
hepatitis in the natural host, nonetheless, when a high dose, 5000 pfu of the MHV-nsp1 mutant 
was used to infect mice, the mutant demonstrated compounding attenuation in the murine host as 
compared to the wild type (Zust et al., 2007). The MHV-nsp1 mutant could not be detected in 
the liver only after extremely high doses of 5 x 10
6
 pfu were applied, then it was found at day 2 
post infection (p.i.) with no liver damage as confirmed by the serum alanine aminotransferase 
(ALT) level. Following this unprecedented in vivo attenuation strategy of knocking out a major 
pathogenicity determinant, we postulated that, including this strategy in coronavirus-based 
vaccine vectors will tremendously improve the safety profile.       
 
3.4.3.2 NS2a gene 
MHV ORF2 encodes a polypeptide of about 30 kd molecular weight with no potential N-
glycosylation site and lacking all the credentials of a membrane protein (Luytjes et al., 1988; 
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Shieh et al., 1989). The gene product of ORF2 now designated as ns2 (Cavanagh et al., 1990) 
was detected by in vitro translation of mRNA2 (Leibowitz et al., 1982; Siddell, 1983). A protein 
of same size was seen in MHV infected cells but its identity was yet established (Siddell et al., 
1981). An ns2-specific polyvalent antiserum confirmed the identity of ns2-gene product and 
showed its localization to the cytosol (Bredenbeek et al., 1990; Zoltick et al., 1990) of MHV 
infected cells. As with most non-structural proteins, the actual function of the ns2 gene product is 
not known but was proposed to have a role in replication, possibly as an RNA binding protein 
(Luytjes et al., 1988). This proposal was contrasted when it was demonstrated that the ns2-gene 
products were not essential for virus replication in transformed murine cells (Schwarz et al., 
1990). Hence, we reasoned that deleting the ns2 gene will first and foremost not affect 
replication of the vector in cell culture and will add to the attenuation of the vector in vivo 
thereby improving the safety while making life difficult for the vector in an eventual coinfection 
with wild type virus. Furthermore, this deletion will increase the vector cloning capacity by 
providing space. 
 
3.4.3.3 Hemagglutinin-Esterase (HE) 
The presence of this glycoprotein on the virion surface of coronaviruses appear to be optional 
since it is present in Bovine coronavirus (BCV), Turkey coronavirus (TCV), Human coronavirus 
(HCV) and some strains of MHV but absent in Infectious bronchitis virus (IBV) and the 
Transmissible gastroenteritis virus (TGEV) (Deregt et al., 1987; Garwes and Reynolds, 1981; 
Hogue and Brian, 1986; King et al., 1985; Stern and Sefton, 1982). Coronavirus HE proteins are 
sialic acid-binding type I envelope glycoproteins showing sialate-O-actylesterase activity (Smits 
et al., 2005). For BCV, both HE and the spike recognise the same receptor determinant of 9-O-
acetyl-neuraminic acid on host cells (Popova and Zhang, 2002). The HE protein is expressed by 
a minority of MHV strains such as the MHV-S, some isolates of JHM (Yokomori et al., 1991) 
while the tissue adapted MHV-A59 genome encodes an HE which because of multiple mutations 
does not get expressed at the protein level and the gene is referred to as a pseudogene (Shieh et 
al., 1989). Additionally, expression of the viral HE is not necessary for virulence in vivo as the 
MHV-A59 still causes hepatitis, encephalitis as well as demyelination though it does not express 
HE. The fact that HE expression is nonessential for the viral life cycle, indicate that this protein 
may have a role during infection of the host (Smits et al., 2005). There have been speculations 
that HE may be important in acute and or chronic disease induced by MHV, possibly by 
influencing the cellular tropism (Yokomori et al., 1995; Yokomori et al., 1993) or may help 
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spread the virus by increasing attachment or exit from the cell (Kienzle et al., 1990). 
Additionally, an increased mortality and increased infection observed in neurons was associated 
with a JHM variant that expressed high levels of HE as against a variant that expressed less HE 
(Yokomori et al., 1995). The pathogeneses of isogenic recombinant viruses expressing either a 
wild-type HE, or HE with the acetyl esterase activity knocked out or no HE expression at all, 
were compared. Interestingly both viruses that expressed HE polypeptides with or without a 
functional acetyl esterase activity were more virulent when inoculated intracranially into mice 
(Kazi et al., 2005). This outcome would support a model in which HE may enhance virus 
attachment and spread through sialic acid lectin receptors (Kienzle et al., 1990) and could be 
suggestive that the sialic acid binding domain is separate from the acetyl esterase domain. 
However, since the MHV HE displays 30% homology to the HA1 subunit of the hemagglutinin-
esterase fusion protein of influenza C virus (Luytjes et al., 1988) and because a recent report 
show that the specificity of the neuraminidase (esterase) for a particular type of sialic acid 
determines the cell subtype infected within the respiratory tract and hence the pathogenic 
outcome (Matrosovich et al., 2004), the HE may play a significant role in coronavirus biology. 
Additionally, the optional nature of this protein suggest that it is dispensable and may serve an 
unknown luxury function that could be costly (Lissenberg et al., 2005). Furthermore, since the 
MHV-A59 HE is not essential for replication in tissue culture, we reasoned that its eventual 
deletion will improve vector safety as well as provide additional space for heterologous antigen 
cloning. 
 
3.4.3.4 ORFs 4 and 5a 
 Group 2 coronaviruses largely represented by MHV possess four group specific genes, 
two (genes 4 and 5a) of which are located between the 3‟ end of the spike (S) gene and the small 
envelope (E) gene and the other two (NS2a and HE) located between the 3‟ end of the replicase 
1b and the 5‟end of S gene. The functions of these genes in MHV biology have not been clearly 
defined. In an elegant report using RNA targeted recombination, it was clearly demonstrated that 
the deletion of these genes from the MHV genome did not affect the viability in cell culture but 
was attenuating in the natural host (de Haan et al., 2002a).  
 In view of the stringent scrutiny for safety of candidate vaccine vectors and in order not 
to compromise our vaccine vectors, we out rightly further deleted the remaining two group 
specific genes namely genes 4 and 5a from the vector genome. This action further improves the 
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safety profile of MHV-based vectors and increases the cloning capacity for heterologous gene 
insertion. 
 
3.4.3.5 The small envelope gene (E) 
 Coronavirus E protein is an integral membrane protein and a minor component in the 
virus particle with a size range of 76 – 109 amino acids (Godet et al., 1992; Liu and Inglis, 1991; 
Yu et al., 1994). Infectious bronchitis virus (IBV) E was reported to localize at the Golgi when 
expressed on its own or when co-expressed with IBV M protein in IBV infected cells (Corse and 
Machamer, 2000) and the C-terminal of this protein is implicated to target the  Golgi (Corse and 
Machamer, 2002). Furthermore, whereas the SARS E protein has been shown to localize at the 
Golgi at least during early infection (Liao et al., 2006), MHV E was found to locate at the ER-
Golgi intermediate compartment (Raamsman et al., 2000). 
 Biochemical characterization indicates that coronavirus E protein may undergo post 
translational modifications. In deed all E proteins have conserved cysteine residues located on 
the carboxy side of the long hydrophobic domain implicating a functional importance. For 
example the IBV and SARS E are both palmitoylated on one or more cysteine residues (Corse 
and Machamer, 2002; Liao et al., 2006). Until recently, the status of MHV E post translational 
modification was not defined. Almost simultaneously, two groups reported observations that 
MHV-A59 E protein lacking all three cysteines exhibited an increased rate of degradation 
compared to the wild-type protein, suggesting that palmitoylation is crucial for the stability of 
the protein and for it to function as a vesicle morphogenetic protein in order for the assembly 
subunit to assume configurations that can mobilize into secretory lipid vesicle and virion 
(Boscarino et al., 2008; Lopez et al., 2008).  
 Coronavirus E protein is crucial for virion assembly. Expression of coronavirus E and M 
proteins together led to the formation of VLPs which were morphologically indistinguishable 
from the coronavirions (Baudoux et al., 1998; Bos et al., 1996; Corse and Machamer, 2000; Lim 
and Liu, 2001; Vennema et al., 1996). Furthermore, expression of E protein on its own was 
shown to release E containing membrane vesicles (Maeda et al., 1999). Though the exact 
function of E protein in virion assembly is yet established, its low abundance in virion and VLPs 
might imply a function in membrane curvature. More recently the transmembrane domain of 
IBV E was shown to be required for efficient release of viral particles (Machamer and Youn, 
2006). 
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 The E proteins of MHV and SARS have been implicated to induce apoptosis (Yang et al., 
2005). More so the involvement of E protein in virion morphogenesis was demonstrated using 
targeted RNA recombination in which mutations were introduced at the C terminal hydrophilic 
tail of MHV-E protein. This led to the production of thermolabile mutants that appeared aberrant 
and heterogeneous in morphology (Fischer et al., 1998). Furthermore, a mutant MHV with 
deletion of the E protein showed tiny plaques with low growth rate and titers (Kuo and Masters, 
2003) demonstrating the importance of E protein for efficient propagation of a E-coronavirus. 
 In summary, due to the pivotal role impacted by MHV E protein in VLPs formation, it 
was necessary to delete this gene from the newly generated MHV-based vaccine vectors in order 
to increase safety by producing particles that are replication competent but propagation deficient. 
The deletion of the E gene also allowed additional cloning space for heterologous antigen or 
immunostimulatory cytokine insertion. We have therefore constructed coronavirus-based vectors 
with the MHV-A59 background carrying the following deletions replicase encoded nsp199-
NS2a-HE-gene4-gene5a and E. We are confident to crown these vectors as highly 
biosafe vaccine vectors because in case of any eventual attempt to revert into wild-type, we 
anticipate at least five rounds of recombination and in addition, these vectors will have to 
compensate the 99 nucleotides deletion in the MHV-nsp1 coding region.   
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4 Aims and scientific questions addressed in this project 
 The major aim of this project was to develop recombinant murine coronavirus-based 
vectors expressing different combinations of model antigens and immunostimulatory cytokines. 
This was to be achieved through cloning of well-characterized antigens and immunostimulatory 
molecules which can be properly evaluated due to the availability of established experimental 
protocols. The selection of a particular combination of antigens and cytokines was intended to 
provide efficient insights into some pertinent questions pertaining to the evaluation of any 
promising vaccine candidate vector.  
Second, in order to package the vector RNA into virus-like particles (VLPs) that could be 
employed for immunization studies, a stable packaging system had to be developed.  
Thirdly, we aimed to assess the immunogenicity of MHV-based vectors in well-defined 
animal models: The LCMV gp33 epitope system has been chosen to assess both antiviral and 
antitumour responses in mice. Furthermore, the human Melan-A epitope has been selected to test 
relevant antitumour immune responses in humanized HLA-transgenic mice. 
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Generation of Recombinant Coronaviruses Using
Vaccinia Virus as the Cloning Vector and Stable Cell
Lines Containing Coronaviral Replicon RNAs
Klara Kristin Eriksson, Divine Makia, and Volker Thiel
Abstract
Coronavirus reverse genetic systems have become valuable tools for studying the
molecular biology of coronavirus infections. They have been applied to the generation
of recombinant coronaviruses, selectable replicon RNAs, and coronavirus-based vectors
for heterologous gene expression. Here we provide a collection of protocols for the gen-
eration, cloning, and modification of full-length coronavirus cDNA using vaccinia virus
as a cloning vector. Based on cloned coronaviral cDNA, we describe the generation of
recombinant coronaviruses and stable cell lines containing coronaviral replicon RNAs.
Initially, the vaccinia virus-based reverse genetic system was established for the generation
of recombinant human coronavirus 229E. However, it is also applicable to the generation
of other coronaviruses, such as the avian infectious bronchitis virus, mouse hepatitis virus,
and SARS coronavirus.
Key words: Coronavirus; RNA virus; reverse genetics; vaccinia virus; full-length
cDNA; in vitro transcription; recombinant coronaviruses
1. Introduction
Theextraordinarily largesizeof thepositive-strandedcoronavirusRNAgenome
posed a significant obstacle for the establishment of coronavirus reverse genetic
systems based on cloned full-length cDNA. Conventional cloning techniques
using plasmid DNA cloning vectors were not suitable to stably accommodate large
coronaviral cDNAs. Moreover, in numerous cases, specific coronaviral cDNA
sequences turned out to be resistant to cloning in conventional plasmid DNAs or
From: Methods in Molecular Biology, vol. 454: SARS- and Other Coronaviruses,
Edited by: D. Cavanagh, doi: 10.1007/978-1-59745-181-9 18, C© Humana Press, Totowa, NJ
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were unstable upon propagation in prokaryotic hosts. Finally, however, several
laboratories succeeded in establishing coronavirus reverse genetic systems based
on full-length cDNA (1–3). Not surprisingly, those researchers had to solve the
problem of “cDNA instability” and, accordingly, the solutions they provided are
all based on nonconventional approaches.
The reverse genetic system described here is based on the use of a vaccinia
virus as a cloning vector that replicates in eukaryotic cells. Vaccinia virus is a
large DNA virus with a genome size of approximately 200 kbp that is able to
stably accommodate foreign DNA sequences of coronavirus genome size (27–
31 kb). The basic techniques required to clone (Section 3.1), modify (Section
3.2), and rescue (Section 3.3) recombinant coronaviruses are described. One
application of the system, namely, the generation of coronavirus replicon RNAs
and cell lines, is described in Section 3.4.
2. Materials
1. QiaexII Gel elution kit (Qiagen).
2. Buffer A (10 mM Tris-Cl pH 9.0, 1 mM EDTA).
3. MagNA Lyser Instrument, MagNa Lyser Green Beads (Roche).
4. Phosphate-buffered saline (PBS).
5. 0.25% (w/v) trypsin.
6. 36% sucrose.
7. Sorvall or Beckman ultracentrifuge, AH-629 or SW-28 rotors.
8. RNase-free DNase.
9. Proteinase K, PCR grade (Roche).
10. Proteinase K digestion buffer (1X concentration: 100 mM Tris-Cl pH 7.5, 5 mM
EDTA, 0.2% (w/v) SDS, 200 mM NaCl).
11. RNase-free water.
12. T4 DNA Ligase (high-concentrate; Fermentas).
13. Pulse field gel instrument and equipment.
14. Lipofectin, Lipofectamine2000 (Invitrogen).
15. Sonication water bath (Branson 3210).
16. RiboMax large-scale RNA production system—T7 (Promega).
17. m7G(5’)ppp(5’)G cap analog (30 mM).
18. LiCl solution (7.5 M LiCl, 50 mM EDTA pH 7.5).
19. Sodium dodecylsulfate (SDS).
20. Electroporation instrument (e.g., BioRad Gene Pulser, 0.4-cm electroporation
cuvettes.
21. Cell culture medium chemicals for GPT+ selection: (a) mycophenolic acid
(MPA), 10 mg/ml in 0.1 M NaOH (400X stock); (b) xanthine, 10 mg/ml in 0.1 M
NaoH (40X stock) and (c) hypoxanthine, 10 mg/ml in 0.1 M NaOH (667X stock).
22. Cell culture medium chemicals for GPT– selection: 6-thioguanine (6-TG), 1 mg/
ml (1000X stock).
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23. Cells: BHK-21, CV-1, D980R (4).
24. Viruses: Vaccinia virus vNotI/tk (5), fowlpox virus.
3. Methods
3.1. Cloning of Coronavirus cDNA in Vaccinia Virus
This section describes the steps involved in the cloning of a full-length
coronavirus cDNA. Starting from viral RNA, a set of plasmid DNAs should
be generated together covering the full-length coronavirus genomic sequence.
The plasmid insert cDNAs are then assembled by in vitro ligation to obtain a
full-length coronavirus cDNA fragment. This fragment will be inserted into a
vaccinia virus genome, again by in vitro ligation. The cloned full-length coro-
navirus cDNA in vaccinia virus is then amenable to mutagenesis by vaccinia
virus-mediated homologous recombination.
3.1.1. Generation of Plasmid DNAs Covering a Coronavirus
Full-Length cDNA
1. Analyze the coronavirus genome for useful naturally encoded endonuclease
restriction sites that can later be used to ligate cloned cDNA inserts. Preferably
use restriction enzymes that produce nonpalindromic sticky ends with at least
three nucleotide (nt) overhangs. Avoid the use of restriction enzymes that generate
blunt ends, since ligation efficiencies of blunt end fragments are low. If there are
no useful sites available at particular regions of the cDNA sequence, restriction
sites may be generated that introduce silent nucleotide changes. Alternatively,
introduce sites at the border of the coronavirus cDNA fragments for restriction
enzymes that cleave outside of their recognition sequence and orientate the sites
so that cleavage occurs in the coronavirus cDNA region (Fig. 1A).
2. Generate a set of plasmid DNAs covering the entire coronavirus cDNA using stan-
dard plasmid DNA cloning techniques. cDNA insert fragments should have a size
of approximately 5 kbp. Make sure that the cDNA fragment borders are flanked
by appropriate endonuclease restriction sites in order to release the cloned cDNA
fragments by endonuclease digestion (see above). If particular plasmid clones
appear unstable upon propagation in Escherichia coli, change the plasmid back-
bone, preferably to a low copy plasmid. If plasmid DNAs remain unstable upon
propagation proceed with the cloning of the remaining part of the coronavirus
cDNA and insert the respective unstable cDNA sequence on the vaccinia virus
level by vaccinia virus-mediated recombination using RT-PCR cDNA fragments
(see Section 3.2).
3. The cDNA fragments corresponding to the 5’- and 3’-end of the genome should
contain additional sequences as follows (Fig. 2). To facilitate cloning into the
vaccinia virus genome by in vitro ligation with NotI-cleaved vaccinia virus DNA
(see Section 3.1.4) both end fragments should contain an EagI or Bsp120I site.
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A
B
BsaI digestion,
ligation
CN
AGN CCAG
T GGTC
CT ATTTG AAAT
GA TAAAC TTTA
BsaIcoronavirus cDNA
CG T N
C GC GA
CG T
A N TAGA
CT AT CAA ATTT
GTT TAAA
BsaI coronavirus cDNA
CT AT CAA ATTTTTG AAAT
GA TAAAC TTTA GTT TAAA
ligated coronavirus cDNA
P 5'
P5'
Ligation
P 5'
Ligation
Fig. 1. Strategies to minimize the number of possible ligation products: (A) Lig-
ation of two coronavirus cDNA fragments using BsaI restriction endonuclease. BsaI
recognition sequences can be engineered adjacent to the coronavirus cDNA to obtain
BsaI-cleaved cDNA ends without heterologous sequences. The sticky ends are not
palindromic and are comprised of a coronavirus-encoded sequence. The subsequent
ligation reaction is directional and gives rise to only one possible reaction product.
(B) The use of alkaline phosphatase to reduce the number of possible ligation products
is illustrated. The left panel shows a conventional ligation using cDNA fragments with
palindromic sticky ends. In this case three different ligation products are possible. The
right panel shows a ligation reaction if one cDNA fragment has been dephosphorylated
with alkaline phosphatase prior to the ligation reaction. In this case only two ligation
products are possible.
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CC G T
C CG GG
GG C
C A TATT
A A AT AGC ACTC
TCG TGAG
EagI CoV 5'end
C T ATA TATG GAA
GA TAT ATAC CTT
T7 promoter
AT G A
C CA T T
GG A
C T TGAT
A T AC C A20-40
T20-40G
EagICoV 3'end
GGCNN NNN N GCC
CCG CGG
polyA
unique
site
NN NNN N
Fig. 2. Structure of 5’- and 3’-ends of cloned full-length coronavirus cDNA.
Upstream of the coronavirus 5’-end there should be an EagI or Bsp120I restriction
endonuclease site to allow insertion of the cDNA into the NotI site of the vaccinia
virus genomic DNA by in vitro ligation. Between the EagI or Bsp120I site and the
5’-end of the coronavirus cDNA sequence there should be a bacteriophage T7 RNA
polymerase promoter and one G nucleotide (if not yet present at the 5’-end of the coron-
avirus genome) for the initiation of the in vitro transcription reaction. Downstream of the
3’-end of the coronavirus genome, a stretch of 20–40 A nucleotides (synthetic poly(A)
tail) and a unique (i.e., not present in the coronavirus genomic sequence) restriction
endonuclease site should be cloned. The unique restriction site is needed for the gen-
eration of runoff in vitro transcripts. Furthermore, an EagI or Bsp120I site is needed to
insert the cDNA into the NotI site of the vaccinia virus genome by in vitro ligation. If
the coronavirus sequence does not encode an EagI or Bsp120I site, the unique site is
not needed since EagI or Bsp120I cleavage can be done to produce templates for the
generation of runoff in vitro transcripts.
(DNA cleaved with EagI or Bsp120I can be ligated with NotI cleaved DNA.) Fur-
thermore, the 5’-end fragment should contain a promoter for the bacteriophage T7
RNA polymerase and one G nucleotide (if not yet present at the genomic 5’-end
of the coronavirus genomic RNA) for the proper initiation of the in vitro transcrip-
tion. The 3’-end fragment should encode a stretch of A nucleotides (approximately
20 nt) followed by a restriction site that is not present in the coronavirus cDNA
sequence.
3.1.2. Assembly of Long cDNA Fragments by in Vitro Ligation
1. Design a strategy for the sequential assembly of cloned cDNA inserts. Examples
have been described for the construction of full-length human coronavirus 229E
(HCoV-229E), avian infectious bronchitis virus (IBV), and mouse hepatitis virus,
strain A59 (MHV-A59) cDNAs (3,6,7).
2. Liberate cloned insert cDNA fragments from plasmid DNAs by restriction endonu-
clease cleavage. Start with 50–100 g plasmid DNA. Isolate the cDNA fragments
by gel purification using standard agarose gels. Avoid exposure of cDNA frag-
ments to UV light during the isolation process (see Note 1). If palindromic sticky
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ends are present at the cDNA fragment termini, the number of possible ligation
products can be reduced by dephosporylation of one ligation partner by alkaline
phosphatase treatment (Fig. 1B). Note that the ends of cDNA fragments corre-
sponding to the 5’- and 3’-genomic end should be cleaved with EagI or Bsp120I
and dephosphorylated by alkaline phosphatase treatment.
3. Ligate cDNA fragments in analytical scale using high-concentrate T4 DNA ligase.
Leave ligation reaction overnight at room temperature. Analyze ligation products
on standard agarose gels. The samples should be heated to 65◦C for 5 min before
loading on the gel.
4. If the ligation reaction worked efficiently in the analytical scale, use the same
conditions for a preparative scale ligation. Analyze an aliquot of the reaction on
a standard agarose gel. If inefficient ligation is encountered repeatedly, revise the
assembly strategy by using alternative restriction sites.
5. If the preparative ligation reaction was efficient, purify the desired ligation frag-
ments by gel purification (avoid UV exposure; see Note 1) using the QiaexII gel
elution procedure (Qiagen).
6. Use the ligated and purified cDNA fragments from step 5 for further ligation reac-
tions with further cDNA fragments until a full-length cDNA fragment has been
obtained. Alternatively assemble fragments to obtain a set of not more than two
or three cDNA fragments together encompassing the entire coronavirus cDNA
sequence (see Note 2).
3.1.3. Preparation of Vaccinia Virus DNA
This section describes the preparation of purified vaccinia virus DNA that can
be used: (i) for the in vitro ligation with the assembled coronavirus full-length
cDNA (see Section 3.1.4), and (ii) as template for in vitro transcription reactions
(see Section 3.3.1). The protocol describes the vaccinia virus purification and
subsequent DNA preparation in a preparative scale (virus derived from 10 to 20
150-cm2 flasks of infected BHK-21 cells). However, the protocol can also be
down-scaled.
1. Grow 10 to 20 150-cm2 flasks of BHK-21 cells to 80% confluency and infect
with vaccinia virus. Vaccinia virus infection should be done with an appropri-
ate multiplicity of infection (MOI) to obtain complete a cytopathic effect (CPE)
3 days postinfection (p.i.).
2. Three days p.i. freeze cells by putting the flasks into a freezer for at least 2 h.
Thaw, collect, and pellet cells (1000 rpm, 5 min, 4◦C). Wash cell pellet with
PBS. Resuspend concentrated infected cells in 1 ml Buffer A per 150-cm2 tissue
culture flask.
3. Fill MagNA Lyser green bead tubes to maximum filling level of 1 ml.
4. Homogenize using MagNA Lyser machine speed 5000 1 × 20 sec (see Note 3).
5. Centrifuge at 1000 rpm 4◦C for 2 min.
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6. Pipette supernatant into a clean fresh tube. Treat supernatant with 0.1 volume
0.25% (w/v) trypsin and incubate at 37◦C for 20 min.
7. Adjust the trypsin-treated cell homogenate with buffer A to a volume of 18 ml
and carefully overlay an 18-ml 36% (w/v) sucrose cushion in a 36-ml ultra-
centrifugation tube and centrifuge (13,500 rpm at 4◦C for 80 min; Sorvall or
Beckman ultracentrifuge, Rotor AH 629 or SW 28).
8. Discard the supernatant and resuspend the pellet in 0.4 ml Buffer A.
9. Digest with RNase-free DNase (1–5 U) for 20 min (see Note 4) and then stop
DNase treatment by adjusting the solution to 10 mM EDTA and incubate for
10 min at 65◦C.
10. Add 1 vol of 2X Proteinase K digestion buffer (final concentration is 1X pro-
teinase K digestion buffer) and 4 l proteinase K; incubate at 50◦C for 2 h.
11. Extract DNA with 1 vol phenol/chloroform/isoamylalcohol (25:24:1), mix gently
(do not vortex! See Note 5), and centrifuge (14,000 rpm, 5 min, room tempera-
ture, Eppendorf centrifuge). Take the water phase and perform a second round
of DNA extraction with 1 vol chloroform/isoamylalcohol (24:1), mix gently (do
not vortex!) and centrifuge (14,000 rpm, 5 min, room temperature, Eppendorf
centrifuge).
12. Take the water phase and add 2.5 vol 100% ethanol, mix gently (do not vortex!),
and pellet the DNA by centrifugation (14,000 rpm, 5 min, room temperature,
Eppendorf centrifuge) (see Note 5).
13. Discard the supernatant and wash the DNA with 70% ethanol; centrifuge again
(14,000 rpm, 5 min, room temperature, Eppendorf centrifuge).
14. Discard the supernatant completely and resolve the DNA in 50–200 l RNase-
free water.
3.1.4. Ligation of Insert cDNA with Vaccinia Virus DNA
This section describes the integration of the assembled coronaviral cDNA
fragments (Section 3.1.2) into the vaccinia virus genome by in vitro ligation.
Inserted DNA fragments can be a full-length coronavirus cDNA or two or three
cDNA fragments that can be ligated just prior to the ligation to the vaccinia virus
genomic DNA. As parental virus we recommend the vaccinia virus vNotI/tk that
encodes a unique NotI cloning site (5).
1. Set up a standard in vitro ligation reaction if the insert DNA consists of more
than one fragment. This procedure is only recommended if the number of possi-
ble ligation products is limited (e.g., by avoiding palindromic sticky ends or by
limiting the number of possible ligation products by using one dephosporylated
DNA end per ligation reaction). The reaction should include a standard ligation
buffer (including ATP) and can have a volume of up to 100 l. Let the reaction
go for 1–2 h at room temperature while preparing the NotI-cleaved vaccinia virus
DNA (step 2). We recommend a molar ratio of insert:vaccinia virus DNA of 1:1
and a prior test of the reaction on an analytical scale.
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2. Cleave vaccinia virus vNotI/tk DNA with NotI for 1–2 h at 37◦C. The volume of
the reaction can be up to 50 l.
3. Mix the ligation reaction and the NotI restriction reaction and adjust buffers to
1X concentrations (1X ligation buffer and 1X NotI restriction buffer). Add fresh
T4 ligase and NotI enzymes and incubate overnight at room temperature (see
Note 6).
4. Heat the reaction to 65◦C for 5 min, centrifuge (14,000 rpm, room temperature,
Eppendorf centrifuge). Take the supernatant, add fresh NotI enzyme, and incubate
at 37◦C for 1–2 h (see Note 7).
5. Analyze the reaction products (or an aliquot thereof) on a pulse field gel. Prior to
loading the sample(s) heat to 65◦C for 5 min to achieve appropriate separation of
DNA fragments in the pulse field gel.
6. Store ligation products at –20◦C.
3.1.5. Rescue of Recombinant Vaccinia Viruses Containing Full-Length
Coronavirus cDNA Insert
1. Seed CV-1 cells in a six-well dish 1 day before transfection. Cells should be 80%
confluent for optimal transfection efficiency.
2. Infect 80% confluent CV-1 cells with fowlpox virus (MOI 1–10) for 1–2 h (see
Note 8).
3. Transfect ligation reaction from Section 3.1.4 (without any further purification)
into fowlpox virus-infected CV-1 cells using Lipofectin as described by the man-
ufacturer (Invitrogen). Do not vortex at any time and use cut pipette tips when
handling vaccinia virus DNA (see Note 5).
4. After 3–4 h trypsinize cells and seed them together with fresh (uninfected) CV-1
cells (4:1 excess of fresh CV-1 cells) into a 96-well plate.
5. At 5–10 days posttransfection collect cells and medium from wells displaying
CPE (this is the first vaccinia virus stock) (see Note 9).
6. Transfer half of the first vaccinia virus stock to fresh CV-1 cells plated in a six-well
dish. Wait until full CPE becomes apparent and collect the second vaccinia virus
stock.
7. To analyze the obtained recombinant vaccinia viruses take half of the second vac-
cinia virus stock, pellet cells, and prepare DNA from the cell pellet according to
Section 3.1.3, steps 10–14 (use 1X Proteinase K buffer).
8. To confirm the identity of recombinant vaccinia viruses perform Southern blot,
PCR, and/or sequencing analyses.
3.2. Modification of Coronavirus cDNA by Vaccinia Virus-Mediated
Homologous Recombination
The cloned coronavirus cDNA is amenable to mutagenesis by vaccinia virus-
mediated homologous recombination. Two steps of homologous recombination
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Fig. 3. Modification of the coronavirus cDNA. The modification of the cloned coro-
navirus cDNA by vaccinia virus-mediated homologous recombination is illustrated. The
parental vaccinia virus vMHV-inf-1 is used in combination with a targeting plasmid to
target the region of interest in the clone cDNA. Upon gpt+ selection an intermediate
clone is obtained that is subjected to a second round of recombination with a mutage-
nesis plasmid encoding the mutation of choice. The final mutant cDNA clone can be
obtained after gpt– selection. Note that the intermediate clone can also be used to intro-
duce other mutations in the targeted region by using a different mutagenesis plasmid.
are performed using appropriate plasmid DNAs (Fig. 3). The first “targeting”
plasmid DNA contains a sequence of approximately 500 bp corresponding to a
region encoded upstream of the region that should get targeted for mutagenesis
(left flank), the E. coli guanosin-phosphoribosyltransferase (gpt) gene located
downstream of a vaccinia virus promoter and a sequence of approximately
500 bp corresponding to a region encoded downstream of the region that should
be targeted for mutagenesis (right flank).
The targeting plasmid is used to target the region of interest for a second
round of recombination using a “mutagenesis” plasmid that contains the left
and right flank of the targeting plasmid and, between the flanks, the region
of interest encoding the desired mutation. Both plasmids can be constructed
by standard cloning techniques. We routinely use the plasmid pGPT-1 (4) that
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is based on pBluescriptKS+ (Stratagene) and contains a fragment encoding
the E. coli gpt gene downstream of a vaccinia virus promoter cloned into the
pBluescriptKS+ multiple cloning site. The plasmid pGPT-1 is available from the
authors upon request. Note that vaccinia virus-mediated homologous recombi-
nation also works when a linear DNA fragment, such as an RT-PCR product, is
used instead of a plasmid DNA (7).
3.2.1. Vaccinia Virus-Mediated Homologous Recombination
This section describes the procedure of vaccinia virus-mediated homologous
recombination. The protocol is used to generate a “transfection” stock con-
taining recombined viruses at a ratio of approximately 1:1000 (recombinant
viruses:parental viruses). The transfection stock is subsequently subjected to
plaque purification under gpt+ or gpt– selection (see Sections 3.2.2. and 3.2.3)
to obtain stocks of recombinant vaccinia virus clones.
1. Seed CV-1 cells in a six-well dish so that they are 80–95% confluent on the day
of infection.
2. Infect with parental vaccinia virus at an MOI of 1. Incubate for 1–2 h at 37◦C.
3. At 1–2 h postinfection transfect 5 g of the targeting or mutagenesis plasmid using
Lipofectin or Lipofectamine 2000 according to the manufacturer’s (Invitrogen)
instructions.
4. Wash cells at 3–6 h posttransfection and culture cells for 2–3 days until full CPE
becomes apparent.
5. Prepare a virus stock (which is the “transfection stock”) from the infected/
transfected culture by scraping the cells off the plate in 0.5 ml of the culture
medium. Store at –20◦C.
3.2.2. Targeting the Region of Interest: Selection of Recombinant gpt+
Vaccinia Viruses
1. Seed CV-1 cells in a six-well dish so that they are 80–95% confluent on the day
of infection.
2. Replace culture medium with gpt+ selection medium (MEM containing 5% FCS,
antibiotics and 25 g/ml MPA, 250 g/ml xanthine, and 15 g/ml hypoxanthine)
at least 6 h prior to infection.
3. Freeze-thaw the vaccinia virus transfection stock (see Section 3.2.1.) three times
using dry ice on ethanol and sonicate for 1–5 min immediately prior to infection
(see Note 10).
4. Infect CV-1 cells with different dilutions (10–2, 10—3, and 1024) of the transfection
stock (see Note 11).
5. Culture cells for 2–3 days in the gpt+ selection medium. Pick plaques as soon as
they are easily detectable (usually on day 2 p.i.) by marking them at the bottom of
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the dish, followed by scraping the cells of the plaque off the dish, and aspirate in
100 l of medium using a standard pipette (see Note 12).
6. Perform another two rounds of gpt+ plaque selection (steps 4 and 5) by infect-
ing the CV-1 cells with 5–20 l of a picked plaque. Always perform freeze-thaw
cycles and sonication prior to infection.
7. After the third round of plaque selection infect CV-1 cells in a six-well dish with
half of a picked plaque and culture cells until full CPE. Store half of this stock
for further use and use the other half for DNA preparation and analysis of the
recombinant vaccinia virus clone (i.e., PCR, Southern blot, sequencing).
3.2.3. Inserting the Mutation of Choice: gpt Negative Selection
1. Seed D980R cells in a six-well dish so that they are 60–80% confluent on the
day of infection (see Note 13). Cells can be seeded in gpt– selection medium
containing 0.5 g/ml 6-TG. The cells should be cultured in gpt– selection for at
least 6 h prior to infection.
2. Perform plaque selection as described in Section 3.2.2. steps 4–7. The only differ-
ences are the cells (D980R cells) and the gpt– selection medium.
3.3. Rescue of Recombinant Coronaviruses from Cloned
Full-Length cDNA
The rescue of recombinant coronaviruses is based on two steps. First, a full-
length coronavirus RNA is produced using the genomic DNA of a vaccinia
virus containing the full-length coronavirus cDNA insert as a template for in
vitro transcription. Second, the recombinant full-length RNA is transfected into
eukaryotic cells. Within these cells the coronavirus replication cycle will be
initiated by translation of replicase gene products from the transfected RNA
and, finally, recombinant coronaviruses are released into the tissue culture super-
natant.
3.3.1. Generation of Infectious Full-Length Coronavirus RNA by in Vitro
Transcription
1. Prepare vaccinia virus DNA from purified virus stocks as described in Sec-
tion 3.1.3.
2. Cleave the vaccinia virus DNA (1–10 g) with the restriction enzyme for which
a unique recognition site downstream of the synthetic poly(A) tail has been intro-
duced (Fig. 2).
3. Extract DNA with 1 vol phenol/chloroform/isoamylalcohol (25:24:1), mix gen-
tly, and centrifuge (14,000 rpm, 5 min, room temperature, Eppendorf centrifuge).
Take the water phase and perform a second round of DNA extraction with 1 vol
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chloroform/isoamylalcohol (24:1), mix gently, and centrifuge (14,000 rpm, 5 min,
room temperature, Eppendorf centrifuge).
4. Take water phase and precipitate the cleaved vaccinia virus DNA by adding 1/20
vol of 5 M NaCl and 2.5 vol of 100% ethanol and centrifuge (14,000 rpm, 5 min,
Eppendorf centrifuge). Do not overdry vaccinia virus DNA.
5. Wash DNA pellet with 70% ethanol; centrifuge again.
6. Completely remove the supernatant and resolve the DNA in 10–20 l RNase-free
water.
7. Set up the in vitro transcription reaction using the RiboMax Kit (Promega) as
follows (see Note 14):
5X transcription buffer 10 l
m7G(5’)ppp(5’)G cap analog (30 mM) 5 l
GTP (100 mM) 0.7 l
ATP, CTP, UTP (100 mM), each 3.75 l
Template DNA (1–10 g) x l
RNase-free water y l
Enzyme mix (RNasin, T7 RNA pol.) 5 l
Total 50 l
7. Incubate at 30◦C for 2 h.
8. Add 2 ml of RNase-free DNase, incubate at 37 ◦C for 20 min. Either store the
reaction at –80 ◦C until transfection or (optional) precipitate the RNA (steps
9–11).
9. Add half the volume of LiCl solution and freeze the sample for at least 30 min.
10. Pellet RNA by centrifugation (14,000, 15 min, 4 ◦C, Eppendorf centrifuge)
11. Wash RNA pellet (should appear yellowish) with 70% ethanol and resolve in
RNase-free water. Store at –80 ◦C.
12. Analyze the RNA on an agarose gel containing 1% SDS. Stain the RNA after gel
electrophoresis with ethidium bromide.
3.3.2. Rescue of Recombinant Coronaviruses
1. One day before RNA transfection seed BHK-21 (see Note 15) cells so that there
are 5 × 106 to 1 × 107 BHK-21 cells for each transfection. RNA transfection will
be performed by electroporation.
2. Trypsinize, collect, and pellet 5 × 106 to 1 × 107 BHK-21 cells (centrifuge
1000 rpm, 5 min, 4 ◦C). Perform all further steps on ice.
3. Wash cells with 20 ml ice-cold PBS. Make sure that cells are well separated. Take
one drop to count the cells and pellet the rest again (1000 rpm, 5 min, 4 ◦C).
4. Resolve 5 × 106 to 1 × 107 BHK-21 cells in 0.8 ml ice-cold PBS and fill into a
0.4-cm electroporation cuvette.
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5. Add RNA and electroporate with two pulses (settings on BioRad Gene Pulser:
Resistance = ∞, 230 V, high-capacity 1000 F) (see Note 15).
6. Transfer the electroporated cells from into a 10-cm culture dish with 10 ml warm
culture medium and add 1 × 106 fresh cells that are susceptible for the coronavirus
that should be rescued (e.g., murine 17Cl1 cells for MHV rescue, human MRC-5
cells for the rescue of HCoV-229E).
7. Change the medium after 3–6 h when cells have attached to the bottom of the
culture dish.
8. Recombinant coronaviruses should be released into the tissue culture medium
between days 1 and 3 postelectroporation. Check for released virus on days 1–3
by transferring part of the supernatant onto susceptible fresh cells. Store culture
supernatant for further analysis at –80 ◦C.
3.4. Coronavirus Replicon RNAs
Replicon RNAs are autonomously replicating RNAs encoding: (i) all replica-
tive proteins required for the expression of a functional replication complex, and
(ii) cis-acting elements required for the recognition of the replicon RNA by the
replicase complex. Usually replicon RNAs are devoid of sequences leading to
production of progeny particles. Coronavirus replicon RNAs differ from those
of other positive-stranded RNA viruses in that they have to encode the nucleo-
capsid protein, which has been shown to be important for efficient coronavirus
RNA replication (8,9).
It has been shown for HCoV-229E and SARS-CoV replicons that stable
cell lines can be generated if the replicon RNA mediates the expression of
a selection marker (4,10). Two selection markers, conferring neomycin/G418
(4) or blasticidin (10) resistance, have been used successfully for establishing
stable coronavirus replicon cell lines. The HCoV-229E replicon RNA encodes
the neomycin resistance gene inserted downstream of the nonstructural protein
(Nsp) 1 and a sequence encoding a “2A-like” autoprocessing peptide. The 2A-
like autoprocessing peptide mediates a co-translational liberation of a slightly
modified Nsp1 carboxyterminus and subsequent translation of the neomycin
resistance gene. In order to ensure translation of the remaining Nsps of the
replicase gene (Nsps 2–16), an internal ribosomal entry site (IRES) derived
from the encephalomyocarditis virus (EMCV) has been placed upstream of the
Nsp2-coding sequence.
The SARS-CoV replicon RNA contains a gene encoding a fusion protein
comprising the green fluorescent protein (GFP) and the blasticidin deaminase
(GFP-BlaR) that has been cloned downstream of the replicase gene as a sepa-
rate transcription unit under the control of the transcription regulatory sequence
(TRS) of the SARS-CoV spike gene. In both cases, transfection of in vitro
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synthesized replicon RNA into eukaryotic cells and subsequent selection using
G418 or blasticidin resulted in the establishment of stable cell lines contain-
ing actively replicating coronavirus replicon RNAs. To facilitate the detection
of replicon-containing cell lines, green fluorescence resulting from replicon-
mediated GFP expression has been used. For the SARS-CoV replicon RNA
this has been achieved by the use of the GFP-BlaR fusion protein (10). To
achieve GFP expression by the HCoV-229E replicon RNA, the GFP gene has
been inserted as a separate transcription unit downstream from the replicase
gene, driven by the TRS of the HCoV-229E spike gene (4).
Coronavirus replicon cell lines can be used as a noninfectious system to
analyze coronavirus replication and transcription or to identify and evaluate
replicase inhibitors. The following protocols describe the generation of coron-
avirus replicon cell lines and their use in the evaluation of coronavirus replicase
inhibitors.
3.4.1. Generation of Coronavirus Replicon Cell Lines
1. Based on a full-length coronavirus cDNA cloned in vaccinia virus, a replicon
RNA-encoding cDNA can be generated using vaccinia virus-mediated homolo-
gous recombination as described in Section 3.2.
2. Generate replicon RNA by in vitro transcription as described in Section 3.3.1.
3. Introduce the replicon RNA into a host cell line of choice (see Note 16) by elec-
troporation as described in Section 3.3.2 (steps 1–5).
4. Plate the transfected cells in normal growth medium. Change the medium after
3–6 h when cells have attached to the bottom of the culture dish and continue to
culture the cells for 1–2 days in growth medium without selection pressure. Split
if necessary.
5. Start the selection of stable lines at antibiotic concentrations only slightly above
the level at which nontransfected cells die (see Note 17).
6. Increase the antibiotic concentration gradually during the following 2–3 weeks
until resistant colonies appear.
7. Pick colonies for subculture in separate wells and test them for maintenance of
replicon RNA. Expression of a reporter protein, such as GFP, by the replicon RNA
facilitates the screening of replicon RNA-containing resistant colonies.
8. When stable clones have been obtained, further culturing can be done under low
selection pressure (see note 18). Replicon cells can be stored in liquid nitrogen.
3.4.2. Identification and Evaluation of Coronavirus Replicase Inhibitors
Using Replicon Cell Lines
1. Seed the replicon cells in selection medium so that they are 50–70% confluent on
the next day. You can use 96- , 24- , or 6-well dishes.
2. Prior to adding antiviral compounds, wash the cells and culture them in standard
medium without selection drugs.
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3. Add graded doses of antiviral compound(s) to the cells and culture them for
1–3 days (see Note 19). For comparison include nontreated cells and culture them
under identical conditions.
4. In order to assay for cytotoxicity of candidate inhibitors and to determine the
selectivity index, include a cytotoxicity/cell viability test. This can be done with
replicon cells or the respective parental cell line.
5. Determine GFP expression on days 1, 2, and 3 posttreatment by fluorescence
microscopy and flow cytometry (see Note 20).
4. Notes
1. We found that DNA that has been exposed to UV light is difficult and sometimes
impossible to clone into vaccinia virus DNA. When purifying DNA fragments
from agarose gels, cut small slices at the edges of the fragment band out of the
gel and stain them with ethidium bromide. Use UV light to visualize the borders
of the DNA band in the slices and mark the position. Insert the slices back into
the gel and cut the piece of agarose between the two marked positions out of the
gel. The DNA recovered from those agarose pieces have not been exposed to UV
light and are easily clonable in vaccinia virus.
2. It is possible to insert more than one DNA fragment into the vaccina virus
genome by in vitro ligation (37). Up to three DNA fragments can be ligated prior
to adding NotI-cleaved vaccinia virus DNA (see Section 3.1.4, step 1). However,
we recommend this procedure only if the fragments can be efficiently ligated
(a full-length cDNA fragment should be visible in agarose gels). Furthermore,
the number of possible ligation products should be minimized using strategies
illustrated in Fig. 1.
3. In order to prepare vaccinia virus, DNA the virus particles have to be liber-
ated from cells and cell debris. This can be achieved by using a tight Dounce
homogenisator or, as described here, by using the MagNA Lyser protocol. To
establish appropriate conditions we recommend doing a pilot experiment in
which several conditions are compared. After homogenization check for virus
titers and decide for the most vigorous homogenization conditions that still leave
the virus particles intact.
4. This step results in DNase digestion of free DNA (mostly of cellular origin) and
will leave the DNA in virus particles intact.
5. Vaccinia virus genomic DNA has a size of approximately 200 kbp. Standard
pipette tips are usually too narrow and pipetting will result in shearing the DNA.
To avoid this, cut the pipette tips to generate an opening of about 2–3 mm and
avoid vigorous pipetting. Avoid drying the DNA. If the large vaccinia virus DNA
is overdried it will no longer be possible to dissolve it in water.
6. The ligation of insert DNA fragment(s) and the NotI-cleaved vaccinia virus arms
is facilitated by adding NotI into the ligation reaction (11). Religated vaccinia
virus arms are recleaved by the NotI enzyme allowing a new round of ligation.
The 5’- and 3’-ends of the insert fragment are cleaved with EagI or Bsp120I
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and dephosphorylated. Therefore: (i) insert-insert ligation is not possible (owing
to dephophorylated ends), and (ii) Eag or Bsp120I-NotI ligation products (i.e.,
insert-vector ligation) are not recleavable with NotI. As a result the ligation-
restriction reaction will drive the overall reaction toward an accumulation of
insert-vector ligation products.
7. The ligation-restriction reaction may still contain a small proportion of unre-
cleaved vector-vector ligation products. These products may lead to functional
vaccinia virus genomes without the insert cDNA fragment and may cause a high
background in the rescue of recombinant vaccinia viruses (Section 3.1.5). We
therefore recommend an additional NotI cleavage reaction after the ligation-
restriction reaction.
8. Since the vaccinia virus genomic DNA is not infectious, a helper virus has to
be provided to rescue recombinant vaccinia viruses from DNA. We recommend
fowlpox virus as a helper virus, since a fowlpox virus infection is abortive
in mammalian cells, but can still serve to rescue vaccinia virus from DNA.
Therefore, the recovered viruses will be vaccinia virus only (and no fowlpox
virus).
9. On days 2–4 p.i. the cells may look heavily infected, most likely owing to
fowlpox virus infection. However, recombinant vaccinia virus cannot yet be
expected in the cell culture. Just continue to cultivate the cells; most cell layers
will recover. Usually, the first vaccinia virus-mediated CPE can be expected on
day 5 p.i. and a peak is observed around day 7 p.i.. If cells get too confluent the
medium can be changed.
10. Freeze-thawing and sonication is needed to release and separate vaccinia virus
particles from the cells and cell debris. For selection of pure recombinant vac-
cinia virus this procedure is critical.
11. A ratio of 1:1000 of recombinant vaccinia viruses:parental vaccinia viruses can
be expected. Thus, under selection pressure, single plaques should appear on
CV-1 cell layers that have been infected with a 10–3 dilution of the transfection
stock. At 2 h p.i., an overlay of 1% low-melting agarose in selection medium
can be made. This is done to reduce the risk of contamination of recombinant
plaques with parental virus. Because most vaccinia virus is contained within an
infected cell within the time frame (2–3 days) of the selection, agarose overlays
are usually not necessary.
12. Six plaques is a reasonable number to pick. There is a limited risk of picking
“false” plaques or plaques contaminated by parental virus that necessitates selec-
tion of a few plaques in parallel.
13. D980R cells grow fast and vaccinia virus plaques are not as easily recogniz-
able as on CV-1 cells. During the selection it is necessary to keep cells in good
condition to facilitate the formation of easily detectable plaques. The risk of
overgrowth can be reduced by seeding cells at a lower density, and cell death
from starvation can be reduced by replacing the medium with fresh selection
medium on day 2 p.i..
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14. It is possible, although not recommended by the manufacturer, to use the
Promega RiboMax Kit to generate capped in vitro transcripts. One simply has
to add a cap structure analog to the reaction. In the given in vitro transcription
protocol the ratio of m7G(5’)ppp(5’)G cap analog to GTP is 2:1.
15. The optimal conditions for the electoporation of long RNA molecules are depen-
dent on the cells and the electroporation device. BHK-21 cells are known to be
suitable for efficient RNA electroporation and should be the first choice. We
recommend doing a pilot optimization to determine optimal conditions for RNA
transfection. It is now well established that the coronavirus nucleocapsid (N)
protein facilitates the rescue of recombinant coronaviruses in several systems
(2,6,7). We recommend co-electroporating an mRNA encoding the coronavirus
N protein (5–10 g N mRNA produced by in vitro transcription). It is even more
efficient to generate and use a BHK-21-derived cell line stably expressing the
N protein (7).
16. We observed replicon RNA replication in a wide variety of eukaryotic host cells.
Although coronaviruses are usually species specific, coronavirus replicon RNAs
are able to replicate in many cell lines once introduced into the host cell cyto-
plasm by transfection. Cell lines tested in our laboratory (using the HCoV-229E
replicon) include cells of human (e.g., MRC-5, HeLa cells) and animal (e.g.,
BHK-21, 17clone1, L929 cells) origin.
17. We recommend determining the lowest concentration of the selection drug where
nontransfected cells die for the cell line of choice.
18. Replicon cell lines based on commonly used cells such as baby hamster kidney
(BHK) or Chinese hamster ovary (CHO) cells are generally easy to culture. To
increase the number of cells expressing a high level of replicon-derived tran-
scripts it is important to split the lines often enough to maintain them constantly
subconfluent. GFP is a convenient marker to determine the percentage of GFP-
expressing cells by flow cytometry.
19. Depending on the cell density and the stability of the compound it might be
necessary to change the medium daily.
20. GFP is a valuable reporter protein to determine the percentage of green fluores-
cent cells as a marker for the percentage of cells with actively replicating RNA
or to determine the mean fluorescence as a value that indicates GFP expression
levels. Some inhibitors may lead to a reduced overall number of green fluores-
cent cells, whereas some inhibitors may just reduce the mean fluorescence. To
generate more quantitative data on the inhibitory effect of a compound and to
gain some insight into the kinetics of inhibition, other reporter proteins, such as
luciferase proteins or alkaline phosphatase, may be used.
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Towards a coronavirus-based HIV multigene vaccine
KLARA K. ERIKSSON, DIVINE MAKIA, REINHARD MAIER, BURKHARD LUDEWIG, &
VOLKER THIEL
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Abstract
Human immunodeficiency virus (HIV) infection represents one of the major health threats in the developing world. The costly
treatment of infected individuals with multiple highly efficient anti-HIV drugs is only affordable in industrialized countries.
Thus, an efficient vaccination strategy is required to prevent the further spread of the infection. The molecular biology of
coronaviruses and particular features of the human coronavirus 229E (HCoV 229E) indicate that HCoV 229E-based vaccine
vectors can become a new class of highly efficient vaccines. First, the receptor of HCoV 229E, human aminopeptidase N
(hAPN or CD13) is expressed mainly on human dendritic cells (DCs) and macrophages indicating that targeting of HCoV
229E-based vectors to professional antigen presenting cells can be achieved by receptor-mediated transduction. Second,
HCoV 229E structural genes can be replaced by multiple transcriptional units encoding various antigens. These virus-like
particles (VLPs) containing HCoV 229E-based vector RNA have the ability to transduce human DCs and to mediate
heterologous gene expression in these cells. Finally, coronavirus infections are associated with mainly respiratory and enteric
diseases, and natural transmission of coronaviruses occurs via mucosal surfaces. In humans, HCoV 229E causes common cold
by infecting the upper respiratory tract. HCoV 229E infections are mainly encountered in children and re-infection occurs
frequently in adults. It is thus most likely that pre-existing immunity against HCoV 229E will not significantly impact on the
vaccination efficiency if HCoV 229E-based vectors are used in humans.
Keywords: AIDS, vaccination, coronavirus, HIV
Abbreviations: HIV, human immunodeficiency virus; DCs, dendritic cells; AIDS, acquired immunodeficiency syndrome;
HCoV, human coronavirus; MHV, mouse hepatitis virus
Introduction
Prophylactic vaccines against several viral infections
have been developed over the last centuries leading to
the eradication of smallpox and protecting many
people from diseases such as measles, rubella, mumps
and polio. However, a number of diseases remain
against which current vaccines are suboptimal or
unavailable. Furthermore, there is growing need to
develop therapeutic vaccines which may boost specific
immune response to persistent viruses such as human
immunodeficiency virus (HIV). The critical first step
in the development of antiviral vaccines is the
identification of the dominant antigens contributing
to the different stages of the infection, i.e. initial
replication at the site of entry, spread in the host and
establishment of a persistent infection. The metho-
dology for the identification of antigens and the
characterization of immunodominant epitopes is well-
established and has been further advanced by
approaches from the fields of proteomics and
genomics (Chakravarti et al. 2000). However, the
major bottle-neck in the development of new and
effective vaccines is the delivery of antigens to cellular
components of the immune system that initiate
protective antiviral immunity. The unmatched
capacity of dendritic cells (DCs) to sample antigen
at sites of pathogen entry, transport pathogens and
their immunogenic components to secondary
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lymphoid organs and to initiate activation of T cells
make them the ideal target cell for antimicrobial
vaccines (Steinman and Pope 2002). The excellent
capacity of DCs to prime antiviral T cell responses can
be readily shown in vitro, i.e. few DCs can activate
large numbers of virus-specific T cells in a mixed
lymphocyte culture (Macatonia et al. 1989; Nonacs
et al. 1992). An important prerequisite for the
initiation of immune responses in vivo is the
translocation of antigens from peripheral sites into
secondary lymphoid organs (Zinkernagel et al. 1997).
The high potency of DCs to induce protective antiviral
immunity against the non-cytopathic lymphocytic
choriomeningitis virus (LCMV) in vivo has been
shown in studies where only 100–1000 DCs present-
ing a specific viral antigen have to reach secondary
lymphoid organs for the induction of protective
antiviral T cell responses (Ludewig et al. 1998;
Ludewig et al. 2000b). DC-induced CTL responses
develop rapidly and DC-immunized mice are pro-
tected against acute systemic and peripheral viral
challenge (Ludewig et al. 1999). Likewise, adoptive
transfer of DCs pulsed with inactivated HIV-1 into
severely immunocompromised mice reconstituted
with human PBL resulted in the induction of
protective anti-HIV-1 responses (Lapenta et al.
2003). Moreover, vaccination of SIV-infected rhesus
monkeys with a cellular DC vaccine significantly
suppressed viral replication (Lu et al. 2003). A recent
study in untreated HIV-1 infected individuals revealed
that DC-based vaccination can elicit potent immune
responses against immunodeficiency viruses in
humans (Lu et al. 2004).
The efficacy of vaccines can be enhanced if optimal
activation/maturation of DCs is achieved. For
example, DC maturation via toll-like receptor ligands
augments the activation of cytomegalovirus- and HIV-
specific T cell responses in vitro (Lore et al. 2003).
Likewise, the efficiency of various vaccine formats can
be greatly enhanced if activation of DCs in vivo is
mediated via co-delivery of immunostimulatory
oligonucleotides (Sparwasser et al. 1998; Ludewig
et al. 2000a) or binding to heat shock proteins
(Cho et al. 2000). Incorporation of DC-activating
chemokines or factors prolonging DC survival into
genetic vaccines has been shown to enhance the
immune response against recombinant rabies virus
(Pinto et al. 2003) or HIV gp120 (Biragyn et al. 2002).
A potent and effective HIV vaccine should thus
directly deliver antigens to DCs and induce their
activation/maturation.
HIV infection and immunity
Prevention of HIV infection. The thorough knowledge of
the biology of HIV that has been generated over the last
two decades has paved the way for a rational vaccine
design. Furthermore, the progress in the understanding
of the basic immunological mechanisms underlying
antigen presentation (Steinman and Pope 2002),
lymphocyte trafficking and activation (Luther and
Cyster 2001), and immunological memory (Kaech
et al. 2002) has been instrumental for the identification
of the relevant parameters that ensure the induction
of protective antiviral immunity. Accordingly, an
efficient HIV vaccine should induce long-lasting,
broad humoral and cellular responses against the
immunodominant HIV antigens. In particular, the
vaccine should (i) target and activate DCs, (ii) contain
the immunodominant antigens recognized by CTL and
Th cells, (iii) be able to display antigenic determinants
that induce broadly neutralizing antibody responses,
and (iv) be applicable via mucosal surfaces.
HIV-specific CTL and Th cell responses. CTL responses
crucially contribute to control of immunodeficiency
virus infection. Broad virus-specific CTL responses can
be found in peripheral blood of HIV-infected humans
(Betts et al. 2001; Addo et al. 2003) and the decline of
plasma viral RNA during primary HIV infection is
associated with the appearance of HIV-specific CTL
(Borrow et al. 1994; Koup et al. 1994). Furthermore,
transient in vivo depletion of CD8 T cells lead to a
massive increase in viral load in SIV-infected monkeys,
whereas extension of the depletion for more than 28
days eliciteda progressive AIDS-like syndrome(Jinet al.
1999; Schmitz et al. 1999). HIV-specific Th cells can be
detected in infected individuals (Pitcher et al. 1999). It
is, however, not yet clear whether these cells extert direct
antiviral effects. However, the good correlation of
functional CD4 T cell responses against HIV
(Rosenberg et al. 1997) or SIV (McKay et al. 2003)
with the clinical status strongly supports the notion that
intact Th cell responses are instrumental for long-term
virus control. This is most likely mediated indirectly by
stimulation of virus-specific CTL. Since most patients
develop T cell responses against the HIV proteins env,
gag or nef (Betts et al. 2001; Addo et al. 2003), a broadly
applicable vaccine should elicit immune responses
(at least) against these three immmunodominant
antigens.
Broadly neutralizing antibodies. Non-neutralizing
antibodies directed against viral proteins appear early
after HIV infection, whereas neutralizing antibodies
appear usually rather late after primary infection
(Pilgrim et al. 1997). Furthermore, sera from HIV-
infected individuals usually display only weak
neutralizing activity against primary isolates (Moore
et al. 1995). The fact that depletion of B cells in
Rhesus monkeys significantly delayed the appearance
of neutralizing antibodies but did not impact on the
early viral clearance (Schmitz et al. 2003) supports the
notion that neutralizing antibodies do not contribute
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significantly during initial HIV infection. However,
the presence of neutralizing antibodies may alter the
clinical course of SHIV infection in macaques and
prevents peripartal infection (Baba et al. 2000).
Conventional vaccination approaches consistently
failed to induce broadly neutralizing antibody
responses (McMichael and Hanke 2003).
Nevertheless, distinct monoclonal antibodies have
been described that are capable of neutralizing a
broad range of different HIV isolates, suggesting that
such antibody responses might be induced once an
adequate vaccination strategy has been developed
(Moore et al. 2001). For example, altering the
immunodominance pattern by using CD4-HIV
envelope fusion constructs that expose normally
occluded and conserved antigenic regions represents
such an approach for the induction of broadly
neutralizing antibodies (Fouts et al. 2003).
An alternative strategy for the induction of antibodies
that inhibit the infection of primary T cells with
different primary HIV-1 isolates has been reported
recently. This promising approach takes advantage of
the highly conserved caveolin-1 binding domain of
HIV-1 glycoprotein 41. Neutralization of the
caveolin-1 binding site in gp41 efficiently blocks
HIV-1 entry in a wide range of primary cells
(Hovanessian et al. 2004).
Mucosal vaccination. HIV is predominantly transmitted
via mucosal surfaces (Pope and Haase 2003). For
example, SIV rapidly crosses the epithelial layers in the
cervical mucosa and infects predominantly DCs and
CD4 T cells (Spira et al. 1996). Following primary
infection, the virus gains access to lymphoid organs and
establishes persistent infection in CD4 T cells and
macrophages. It appears that constant low-level
exposure to virus (via mucosal surfaces?) is associated
with resistance to HIV infection (Zhu et al. 2003).
Mucosal vaccination may block transmission of
intravaginally or intrarectally applied SIV (Amara
et al. 2001; Belyakov et al. 2001; Veazey et al. 2003)
indicating that an HIV vaccine should prevent the early
stage of infection and elicit long-lasting mucosal
immunity.
Coronavirus biology and suitability as viral
vectors
Although immunogenic peptides or naked nucleic acid
can elicit immune responses against HIV antigens, the
use of viral vectors represents a superior strategy to
deliver HIV antigens and/or immunostimulatory cyto-
kines to specific target cells. However for several
reasons, many virus vector systems are still limited in
their ability to induce a broad and long-lasting antiviral
immune response capable to prevent HIV infection
and/or to reduce viral load. Moreover, the safety of
DNA-based vectors such as adeno-associated-, retro- or
lenti-viruses is a matter of concern, because they can
integrate into the host cell genome (Dobbelstein
2003). Recombinant adenoviruses have been studied
intensively as HIV vaccine candidates mainly because
they can be produced to high titers. Nevertheless, high
doses of recombinant adenovirus vectors have to be
applied to induce antiviral immune response, most
probably because they target antigens mainly to non-
lymphoid organs such as the liver (Krebs et al. 2005).
In contrast to viral vectors based on DNA viruses, the
use of positive-stranded RNA virus-based vectors
that replicate in the cytoplasm are considered as safe
vectors because it is unlikely that sequences from these
vectors can integrate into the host cell genome.
Moreover, the safety is well documented for vectors
based on widely used vaccine strains such as poliovirus
(Crotty et al. 1999) or virus-like particles (VLPs) that
contain replicon RNAs devoid of structural genes
(Davis et al. 2000; Harvey et al. 2003). Although
some of these vectors are able to target DCs and/or
to induce mucosal immunity, their cloning capacity
is generally restricted and the expression of multiple
HIV antigens and/or immunostimulatory cytokines is
limited.
Coronaviruses display a number of features that
may be advantageous to overcome these limitations
and, therefore, represent promising candidate vaccine
vectors. Coronaviruses are enveloped viruses that are
associated mainly with respiratory and enteric
diseases. For example, human coronavirus 229E
infects the mucosa of the upper respiratory tract and
can cause common cold. Coronavirus genomes are the
largest known autonomously replicating RNAs with a
size of approximately 30 kb. About two thirds of the
positive-stranded genome encode the replicase gene,
which is comprised of two large open reading frames
(ORFs). Upon infection, translation of the genomic
RNA results in the synthesis of replicase gene-encoded
polyproteins that are extensively processed by viral
proteinases leading to the formation of a functional
replicase–transcriptase complex within the cytoplasm
of the infected cell (Ziebuhr et al. 2000). A hallmark of
coronavirus genome expression is their unique
transcription strategy. This strategy leads to the
synthesis of multiple 30 co-terminal subgenomic
mRNAs, encoding mainly structural proteins. It has
been shown that the synthesis of each subgenomic
mRNA involves a discontinuous step by which the so-
called 30 body sequence is fused to the genomic 50
leader sequence (Spaan et al. 1983). The fusion of
leader and body sequences during discontinuous
transcription is determined, at least in part, by cis-
acting elements, termed transcription–regulatory
sequences (TRS, also referred as transcription
associated sequences). These elements are located at
the 50 end of the genome and at various 30 proximal
sites corresponding to the individual transcription
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units. Although many studies have been performed to
identify cis-acting sequences required for coronavirus
transcription, exact borders of TRS elements have not
yet been elucidated (Pasternak et al. 2001). However,
short stretches of not more than 5–7 nucleotides
within the TRS, called “core sequence”, have been
identified to determine the site of leader-body fusion
of coronavirus subgenomic RNAs.
Because of the (molecular) biology of coronaviruses,
coronavirus-based vectors are currently considered
a promising system to genetically deliver multiple
heterologous genes to specific target cells. First,
coronaviruses are positive-stranded RNA viruses
replicating in the cytoplasm without a DNA inter-
mediary, making insertion of viral sequences into the
host cell genome unlikely. Second, coronaviruses have
the largest RNA genome known so far. Therefore, a
cloning capacity of more than 6 kb is expected. Third,
coronaviruses display a unique transcription process
resulting in the synthesis of 6–8 subgenomic mRNAs,
encoding mainly the structural genes. These genes,
encoded at the 30 third of the genome, can be replaced
by multiple heterologous genes, e.g. immunogenic HIV
antigens and/or immunomodulatory genes. Fourth, the
receptors of human and murine coronaviruses (HCoV
229E and mouse hapatitis virus (MHV)) are expressed
on human and murine DCs, respectively, indicating
that efficient delivery (i.e. receptor-mediated uptake of
VLPs) of heterologous genes to DCs can be achieved.
Finally, the mucosal route is the natural way of
coronavirus transmission.
Establishment of a reverse genetic system for
coronaviruses
We have established a reverse genetic system for
coronaviruses that allows the generation of recombinant
coronaviruses (Thiel et al. 2001a, 2003; Coley et al.
2005). One of the main advantages of our system is that
the cloned full-length coronavirus cDNAs are amenable
to site-directed mutagenesis using vaccinia virus-
mediated homologous recombination. This technique
is well established and has been proven to represent
an efficient and precise (on the nucleotide level) method
to genetically modify recombinant coronavirus cDNAs.
In Figure 1, we show one example to demonstrate
the ease of using vaccinia virus-mediated recombination
to genetically modify coronavirus cDNA inserts.
Generation of coronavirus-based multigene vector
RNAs—transduction of human DCs. With the reverse
genetic systems available, it is now possible to make
use of the unique characteristics of coronavirus
transcription to develop coronavirus expression
vectors. The rationale of expressing heterologous
genes using coronavirus-mediated transcription is to
insert a transcriptional cassette, comprised of a
coronavirus TRS located upstream of the gene of
interest, into a coronavirus genome, minigenome or
vector RNA. We have shown for human coronavirus
vector RNAs that a region of at least 5.7 kb is
dispensable for discontinuous transcription (Thiel
et al. 2001b). This region contained all structural
genes and, therefore, our vector RNAs are not
infectious. We could demonstrate that it is possible
to construct a human coronavirus vector RNA capable
to mediate the expression of multiple heterologous
proteins. Noteworthy, this vector RNA can be
packaged to VLPs if the structural proteins are
expressed in trans (Thiel et al. 2003). These results
indicate that coronavirus-based vector systems might
be useful for heterologous gene expression, especially
for longer and multiple genes.
Figure 1. Mutagenesis of cloned coronavirus cDNA using vaccinia virus-mediated homologous recombination. (A) The generation of the
recombinant vaccinia virus vVec-GN containing a HCoV 229E-based vector construct is illustrated. Two steps of recombination using the E.
coli guanine phosphosribosyltransferase (gpt) as marker for positive and negative selection were performed. (B) The result of a PCR analysis
from vaccinia viruses vHCoV-inf-1 (parental clone), vRec-1 (intermediate clone) and vVec-GN (desired final clone) is shown. PCR primers
used in this analysis are located upstream and downstream of the region where recombination took place. Lanes 1–12 show 12 randomly
picked recombinant vaccinia virus plaques obtained after gpt-negative selection, indicating the 100% recovery of desired genotypes. Notably,
one vVec-GN clone was subjected to sequencing analysis of the entire coronavirus-based cDNA insert and no nucleotide changes were
detected.
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An important consideration for viral vaccine vectors
is their potential for efficient delivery of their genetic
material to specific target cells. For example, targeting
of viral vaccine vectors to DCs is highly desirable in
order to optimize vaccine efficacy. It is important to
note that the HCoV 229E receptor, human amino-
peptidase N (hAPN or CD13), is expressed at high
levels on human DCs (Summers et al. 2001). This
implies that HCoV 229E-based VLPs could be used to
efficiently (receptor-mediated uptake) transduce these
cells. We could demonstrate that HCoV 229E-based
VLPs can be used to transduce immature and mature
human DCs (Thiel et al. 2003). Therefore, this new
class of safe, multigene vectors, based on HCoV 229E,
represents a particularly promising tool to genetically
deliver multiple antigens and immunostimulatory
cytokines to human DCs.
A reverse genetic system for mouse hepatitis
virus (MHV)—establishment of a murine model
to assess the efficacy of coronavirus-based
vaccine vectors
In order to study the efficacy of coronavirus-based
vectors in vivo, a small animal model is desirable.
Therefore, we first established a reverse genetic system
for MHV. Again we made use of vaccinia virus as
cloning vector to stably propagate the full-length cDNA
of MHV (strain A59). Recombinant viruses obtained
from this cDNA clone were indistinguishable from the
parental MHV-A59 strain in tissue culture (growth
kinetics, plaque size and RNA synthesis) and in MHV-
related disease models in mice (Coley et al. 2005).
With the reverse genetic system for MHV it is now
possible to generate MHV-based multigene vectors
that resemble their HCoV-229E counterparts. Like all
coronaviruses, MHV mediates the expression of
multiple subgenomic mRNAs in the infected cell.
Therefore, it is possible to use the coronavirus
transcription mechanism for the generation of multi-
gene MHV vectors. Furthermore, MHV is one of the
best-studied coronaviruses in vitro and in vivo. MHV
grows to high titers in tissue culture (.109 pfu/ml)
and the requirements for the generation of VLPs are
well understood. MHV also allows for the usage of a
collection of well characterized inbred and transgenic
mice and a variety of established immunological
techniques, indispensable for the analysis of vector-
induced immune responses. Finally, it has been shown
that MHV-A59 can infect murine DCs (Turner et al.
2004) and therefore, recombinant MHV vectors in the
context of a murine model can serve as a paradigm for
the development and evaluation of coronavirus
vaccine vectors.
An important prerequisite to study the efficacy of
coronavirus vaccine vectors is the availability of VLPs
that can be produced to high titers. Therefore,
packaging cell lines must be established which mediate
the expression of coronavirus structural proteins in
trans. To this end, we have generated several cell clones
derived from murine 17-clone1 cells, which stably
express the MHV structural proteins E and M
(EM-cells). These clones have been analysed for the
expression of E and M by PCR using genomic DNA as
template and RT–PCR using poly(A)-containing
RNA as template (Figure 2A), and immunofluorescent
Figure 2. Packaging cell lines for the production of MHV VLPs. (A) Genomic DNA (left) or polyA-containing RNA (right) from cell clones
(#2,4,8,9,12 and13) that were stably transfected with a plasmid DNA encoding the MHV E and M genes on separate transcription units were
analyzed by E and M gene-specific PCR and RT–PCR, respectively. Control lanes are genomic DNA or polyA-containing RNA from parental
murine 17-clone1 cells, plasmid DNA encoding E and M and polyA-containing RNA from MHV-infected 17-clone1 cells. (B)
Immunofluorescence analysis of 17-clone1-EM13 cells using specific sera against MHV structural proteins E (left) and M (right). (C)
Packaging strategy for the production of MHV VLPs using the MHV prototype vector MHV-Vec-A and the E- and M-expressing cell lines.
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microscopy (Figure 2B). Five out of six cell clones
were found to contain and express both, E and
M. Noteworthy, two considerations have been made
before the construction of the EM cell line. First, the
E and M genes in these cell lines are expressed by
the cellular transcription of two separate mRNAs to
minimize the possibility of reconstitution of infectious
viruses by recombination of the MHV vector RNA with
E andM gene mRNAs (Figure 2C). Second, in order to
achieve high titer MHV VLP production, we decided to
use a mouse cell line which is susceptible to MHV
infection (17-clone1) for the stable transfection of
MHV E and M genes. In this case, the packaging cells
are susceptible to VLP-infection and we expect spread
of MHV vector RNA throughout the tissue culture.
The E- and M-expressing cell lines can now be
used to package MHV vector RNAs that encode
(in addition to the replicase gene and the 50 and 30
cis-acting elements required for replication) the MHV
structural proteins S and N (nucleocapsid protein).
Therefore, we have generated a prototype MHV
vector, designated MHV-Vec-A, containing the repli-
case gene, the 50 and 30 cis-acting elements required for
replication, the structural protein S, the immunodo-
minant CTL epitope GP33 of LCMV glycoprotein as
a fusion protein with the green fluorescent protein
(GP33-GFP) and the nucleocapsid protein. This
vector RNA is currently being used to thoroughly
assess the efficacy of VLP production in individual
EM-packaging cells.
Our first experiments using MHV-Vec-A RNA for
the transfection of the packaging cell line clone “17-
clone1-EM13” showed that the transduction of these
cells yields green fluorescent plaques indicating that
our construct is functional, i.e. that the replicase
complex, and the GP33-GFP fusion protein are
produced. As expected, we could also observe syncytia
in vector-transfected packaging cells, suggesting that
a functional, cell fusion-mediating MHV S protein
is present (Figure 3, left panel). Most importantly,
the production of MHV VLPs is shown by the fact
that transfer of supernatants from vector-transfected
17-clone1-EM13 cells to primary DC cultures leads
to GFP expression in the target cells (Figure 3,
right panel). Overall, these experiments provide
proof-of-principle that the generation of MHV VLPs
is feasible and that transgenes expressed by these
replication-incompetent viruses can be targeted to
DCs. We are currently in the process of testing the
efficacies of MHV VLP production using the different
17-clone1-EM cell clones in order (i) to identify the
best packaging cell clone; and (ii) to establish an
optimized protocol for high titer VLP production.
Conclusions
The human immunodeficiency virus (HIV) pandemic
with approximately 40 million people infected world-
wide and more than 4 million deaths per year,
represents a major human health problem. The
majority of the infections occur in Africa and HIV-
induced AIDS is the leading cause of death among
adults aged 15–49 years in this region. Furthermore,
the numbers of infections in developing countries such
as India and China have been dramatically growing
over the recent years. Antiviral drug treatment has
increased life expectancy and quality in western
countries, but this expensive medication is usually
not accessible for infected individuals in developing
countries. There is thus an urgent need for an efficient
and affordable vaccine.
Figure 3. Generation of MHV VLPs and in vitro transduction of primary dendritic cells. MHV-Vec-A RNA was transfected into 17-clone1-
EM13 cells by electroporation. Green fluorescence was detectable after 24 h (left). Supernatants from 17-clone1-EM13 cells were collected
between 48 and 72 h following transfection and used to transduce primary DCs in vitro. Again, green fluorescence became apparent after 24 h
(right) indicating that functional MHV VLPs have been produced in the 17-clone1-EM13 packaging cell line and that these VLPs can be used
to transduce murine DCs.
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We believe that coronaviruses have tremendous
capability as tools to deliver prophylactic and
therapeutic proteins to disease-relevant target cells in
human. In addition, this inherently safe vector system
offers the opportunity to deliver multiple proteins in
combination with immunostimulatory substances.
The primary goal of the outlined approach is the
establishment of the coronavirus vector system and its
validation in a small animal model. If this approach is
feasible and effective, we should commence with the
development of HCoV 229E replicon-based VLPs
encoding several HIV antigens (env, gag and nef) in
combination with immunostimulatory molecules. The
successfully established packaging strategy will be
adapted to the HCoV 229E system and should allow
production of recombinant HCoV 229E VLPs.
Alternatively, pseudotyped MHV-based VLPs dis-
playing a tropism for human DCs may be used for
further studies. Safety and efficacy of this vaccine
preparation should be tested in an adequate non-
human primate model.
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Abstract 
Coronavirus-based vectors are currently considered a promising means to genetically deliver 
multiple heterologous genes to specific target cells. Coronaviruses are positive-stranded RNA 
viruses replicating in the cytoplasm without a DNA intermediary, making insertion of viral 
derived sequences into the host cell genome unlikely. Coronaviruses have the largest known 
RNA genome therefore a cloning capacity of more than 6 kb is expected. They possess a unique 
transcription strategy resulting in the synthesis of 6-8 subgenomic mRNAs encoding structural 
and accessory genes, these genes can be replaced by multiple heterologous genes encoding 
antigens and cytokines. Finally, coronaviruses have the ability to infect professional antigen 
presenting cells such as dendritic cells (DCs) and macrophages. Here we report the construction 
and efficient propagation of murine coronavirus-based vectors that are devoid of all accessory 
genes, one structural gene (E) and have a deletion in the replicase-encoded non-structural protein 
1(NspI) gene region. In order to produce virus like particles (VLPs) containing the vector RNA, 
a packaging cell line was made in which the gene encoding the deleted structural protein E was 
provided in trans. VLP production (10
6
/ml) was successful, using the packaging cells. In vitro 
transduction experiment using these VLPs indicated efficient receptor mediated transduction of 
murine DCs.  
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Introduction 
 
Vectored vaccines based on recombinant viruses or attenuated live virus vaccines 
represent the most effective immunogen mimicking real-life infection. Furthermore, recent 
concepts in immunology implicate a link between innate and adaptive immune responses arguing 
that the quality, quantity and longevity of adaptive immune responses is imprinted very early on 
after infection or vaccination (Pulendran and Ahmed, 2006). Therefore, for a successful vaccine 
approach, immunologically important cells such as DCs and macrophages that have the 
extraordinary ability in sensing pathogen-associated molecular patterns and orchestrating the 
upcoming immune responses involving both innate and adaptive arms of the immune system 
represent prime targets to deliver antigens and immunostimulatory molecules. 
Coronaviruses are endowed with the intrinsic prowess of specifically targeting 
professional antigen presenting cells (pAPCs) capable of shaping the upcoming immune 
responses. Noteworthy, is the fact, that the receptors for most coronaviruses are expressed at 
high levels on pAPCs such as dendritic cells and macrophages. For example, the receptor for 
human coronavirus (HCoV) 229E, human amino peptidase N (CD13) and that of the mouse 
hepatitis virus (MHV), carcinoembyonic antigen cell adhesion molecule (ceacam) 1a, are both 
expressed on human and murine pAPCs respectively.  
The biological properties of coronaviruses as depicted by the prototype MHV-A59 with a 
positive non-segmented RNA genome size of about 31kb which is infectious, capped and 
polyadenylated (Lai and Cavanagh, 1997) make this group of viruses particularly promising as 
vaccine vectors. The genes located downstream of the replicase gene encode mainly the 
structural and nonessential proteins, most of which can be deleted and replaced by heterologous 
antigens as reported for HCoV 229E (Thiel et al., 2003). Interestingly, MHV-A59 like other 
coronaviruses has its replication and transcription restricted to the cytosol of the infected cell 
without a DNA intermediary, therefore, highlighting the absence of any risk of integration of 
virus-derived nucleic acid sequences into the host cell genome. Furthermore, their transcription 
machinery mediates the production of a 3‟ coterminal nested set of 6-8 subgenomic mRNAs 
(sgmRNAs). It has been shown that coronavirus sgmRNAs are transcribed from negative-strand 
RNA templates involving the fusion of non-contiguous sequences (Sawicki et al., 2007; Spaan et 
al., 1983). These mRNAs all contain a common leader sequence identical to the 5‟ end of the 
genome and a body sequence composed of various lengths of the genomic 3‟ end. This model of 
RNA synthesis termed discontinuous extension during subgenomic-length minus-strand 
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synthesis (Sawicki and Sawicki, 1998; Sawicki et al., 2007) is thought to involve small cis-acting 
elements known as transcription regulating sequences (TRS) that serve as transcription 
termination or pausing signals during negative-strand synthesis. Accordingly, the expression of 
heterologous genes by this transcription mechanism is achievable in the context of coronavirus 
genome, minigenome or replicon. This has been demonstrated in that the insertion of a 
transcriptional cassette composed of a gene of interest located downstream of a TRS element 
results in the synthesis of a corresponding subgenomic mRNA encoding the protein of interest 
(Alonso et al., 2002b; Curtis et al., 2002; Fischer et al., 1997; Thiel et al., 2001b; Thiel et al., 
2003). Furthermore, though not fully understood, it is clear that different TRSs mediate different 
expression levels of mRNAs hence, coronavirus-based vectors could be used to simultaneously 
express differential amounts of multiple genes by simply cloning them downstream of various 
particular TRSs (Alonso et al., 2002a). Having the largest RNA genome known so far, 
coronaviruses can provide a capacity of 6-9 kb to clone multiple heterologous genes such as 
antigens and cytokines. 
In a deliberate attempt to exploit basic immunological knowledge coupled to the natural 
biological characteristics of coronaviruses as promising vaccine candidates we report here the 
design and generation of multigene-RNA vaccine vectors based on MHV-A59. In the design of 
these vectors we have given priority to the safety of the vectors, considered the ability to 
manipulate the immune system in order to enhance immunogenicity and finally the possibility to 
produce higher titers for large scale immunization. 
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Material and Methods 
 
Cells. CV-1, BHK-21 and L929 cells were purchased from the European collection of cell 
cultures (http://www.ecacc.org.uk/). CHO Tet-Off cells were purchased from Clontech, 
17Clone1 (17Cl1) cells were kindly provided by S.G. Sawicki, Medical University of Ohio, 
Toledo, Ohio, USA, and D980R cells were a kind gift from G. L. Smith, Imperial College 
London, United Kingdom. Unless otherwise indicated all cells were maintained in minimal 
essential medium supplemented with 10% fetal calf serum (FCS) and 500u penicillin/ml, 100u 
streptomycin/ml (MEM-10). 
 
Recombinant DNA and viruses. MHV-A59 was generated from a molecularly cloned cDNA 
(Coley et al., 2005) based on the Albany strain of MHV-A59. Coronaviruses and recombinant 
vaccinia viruses were propagated, titrated and purified as described (Coley et al., 2005; Hertzig 
et al., 2004; Thiel et al., 2001a). Mutant vaccinia viruses are based on the recombinant vaccinia 
virus vMHV-inf-1 (containing the full length MHV-A59 cDNA) and were generated using the 
reverse genetic system established in our laboratory as described previously (Coley et al., 2005; 
Eriksson et al., 2008). To perform vaccinia virus-mediated homologous recombination, the 
recombination plasmids were used in a first step to introduce the Escherichia coli guanine-
phosphoribosyltransferase (GPT) gene into a genetically tailored region of the MHV cDNA 
backbone followed by a second recombination step using a plasmid with similar 5' and 3' 
homologous recombination sequences separated by a specific target gene of interest cloned 
downstream of a coronavirus TRS element.  
Briefly vaccinia virus-mediated homologous recombination was done as follows. CV-I cells (5 
x10
5
) were infected (m.o.i=1) with vaccinia virus followed by transfection of 5µg plasmid DNA 
1hr post infection using Lipofectin transfection reagent (Invitrogen) according to the 
manufacturer‟s recommendation. Cells were washed 4 hrs post transfection, overlaid with MEM-
10 and incubated at 37°C for 2-3 days. When full cytopathic effect (cpe) became apparent the 
transfection stock was collected and recombinant vaccinia virus was selected by three rounds 
plaque purification under gpt positive or negative selection as appropriate. In order to isolate gpt 
positive vaccinia virus clones, gpt positive selection was done on CV-I cells in the presence of 
mycophenolic acid (25 µg ml
-1
; Sigma), xanthine (250µg ml
-1
; Calbiochem) and hypoxanthine 
(15 µg ml
-I
; Calbiochem). Gpt negative selection was done on D980R cells in the presence of 6-
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thioguanine (1µg ml
-I
; Sigma) (Hertzig 2004; Eriksson 2008). The identities of all recombinant 
clones were confirmed by PCR and sequencing analysis. 
To construct the recombinant vaccinia virus vMHV-GP-EM encoding the vector MHV-
GP-EM the MHV-Inf-1 was modified by replacing the MHV nucleotides 21771-29623 by gpt 
using the plasmid pMHV-rec-1. This plasmid carries the E. coli-gpt gene flanked to its 5‟end by 
a sequence corresponding to MHV nucleotides 21328-21771 and to the 3‟end by a sequence 
corresponding to MHV nucleotides 29623-30115. The resulting gpt positive vaccinia virus clone 
vMHV-1b-gpt-N was used to generate the recombinant vaccinia virus containing the MHV GP-
EM cDNA by inserting the MHV spike, the GP-GFP (encoding a fusion protein comprised of 
the lymphocytic choriomeningitis virus (LCMV-WE) T cell epitope GP33-KAVYNFATC and 
the enhanced green fluorescent protein) and the MHV nucleocapsid in a second recombination 
with the plasmid pMHV-vec-2-kk. This plasmid contains 5‟- MHV nucleotides 21328-21771 
containing TRS2 –MHV 23930-27964 MHV-spike gene and containing TRS4 - GP-GFP 
containing TRS7 -MHV 29623-30115 - 3‟ end. The resulting gpt negative vaccinia virus was 
used to rescue the MHV vector MHV-GP-EM. 
In order to clone the MHV-GP vector the vaccinia virus clone vMHV-1b-gpt-N was 
again modified by inserting the MHV spike, the GP-GFP and the MHV-M and N genes in a 
second round of recombination with the plasmid pMHV-vec-10-E. This plasmid was composed 
of 5‟-MHV nucleotides 21328-21771 containing TRS2 –MHV 23930-27964 containing TRS4 - 
GP-GFP containing TRS6-MHV 28969-30114- 3‟. The resulting vaccinia virus-vMHV-GP was 
used to rescue the MHV vector MHV-GP.  
In order to insert the gene encoding the murine granulocyte colony stimulating factor 
(mGM-CSF) between the MHV replicase and spike genes, the recombinant vaccinia virus 
vMHV-GP was modified using the plasmid pMHV-rec-2-gpt composed of 5‟ MHV nucleotides 
21328-21771containing TRS2- E. coli-gpt- MHV nucleotides 23890 – 24452. The resulting gpt 
positive clone vMHV-1b-gpt-S-GP was modified in a second round of recombination with the 
plasmid pMHV-rec-2-mGM-CSF composed of 5‟ MHV nucleotides 21328-21771 containing 
TRS2- mGM-CSF-MHV nucleotides 23890 – 24452 and a gpt negative selection was performed. 
The resulting gpt negative vaccinia virus vMHV-GMGP was used to rescue the vector MHV-
GM/GP.  
To establish a stable MHV-E-expressing cell line, the MHV-E gene was amplified by 
PCR and cloned into the multiple cloning site of the plasmid pTRE2hyg-vector (Clonetech) with 
the primer pair forward 5‟-ACTGGGATCCACCATGTTTAATTTATTCCTTACAG-3‟ and 
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reverse 5‟-ACTGGCGGCCGCTTAGATATCATCCACCTCTAATAG-3‟, using the BamHI and 
NotI sites (underlined).  
 
Rescue of MHV-based vectors from cloned cDNA. Recombinant MHV-based vectors were 
rescued from cloned cDNA using purified vaccinia virus DNA as template for in vitro 
transcription of recombinant MHV-based vector genomes as described (Eriksson et al., 2006a; 
Eriksson et al., 2008; Thiel et al., 2001a). In order to rescue recombinant coronavirus-based 
vectors and package them into virus-like particles (VLPs), the full length vector RNA was 
transfected into packaging cells by electroporation or by lipofection using DMRIEC (Invitrogen) 
or using Mirus reagent (Mirusbio.com) according to the manufacturer‟s recommendation. The 
transfection was incubated in minimum essential medium supplemented with 5% Tet-approved 
FBS (Clontech), 500u penicillin/ml, 100u streptomycin/ml (Tet-induction MEM) at 37°C 5% 
CO2 for about 2 days. MHV-based vector particles released into the supernatant within the next 
24-48 hrs were collected and stored at -80°C until further usage. Titration of supernatant was 
performed on murine L929 cells as described (Zust et al., 2008). 
 
Amplification of MHV-based vector particles in 150 cm
2
 cell culture flasks. Fresh packaging 
cells were seeded in 150 cm
2
 culture flasks with packaging cell line growth medium (MEM-10 
containing 100µg/ml G418, 100µg/ml Hygromycin and 2µg/ml Doxycycline) a day before, so 
that the cells were 60% confluent the next day. The cells were transduced with MHV-vector 
particles and were incubated for at least 6hrs at 33°C. Growth medium was changed thereafter by 
adding 20ml fresh low pH DMEM medium (Dulbeco‟s modified eagle medium, supplemented 
with 0.75g/l NaHCO3, 8.45g/l NaCl, 10ml 2M hepes pH6.6 (in dH2O)/l, 5% Tet-approved FCS 
(Clontech), 5% tryptose phosphate broth, 500u penicillin/ml, 100u streptomycin/ml) and cells 
were further incubated at 33°C until full cpe became apparent (between 60 – 72hrs). MHV-
vector stocks were obtained by collecting and freezing of transduced cells and cell culture 
supernatant, followed by thawing and centrifugation at 1500 rpm, 5 min. at 4°C (Sorval). The 
cell free VLP containing supernatant was stored -80°C until further usage.  
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Generation of high titer VLP stocks. 1.2 x 10
8
 packaging cells trypsinized to make a single cell 
suspension were seeded in a roller bottle (850cm
2
 Falcon, Becton Dickinson) in 75 ml packaging 
cell line growth medium. The bottle was rotated at 0.1 rotation circle per minute overnight so as 
to obtain the best distribution of the cells. The cells were transduced with VLP supernatant at a 
low m.o.i. (0.01-0.001) and incubated for 6 hrs at 33°C 5% CO2 in minimal amount of medium 
just enough to cover the cells (20ml of VLP supernatant and fresh low pH DMEM). Thereafter 
the medium was changed by 30ml of fresh low pH DMEM. The cells were examined every day 
for signs of starvation and the rate of MHV-vector spreading. In case of signs of starvation, 2/3 
volume of the growth medium was replaced by fresh low pH DMEM. MHV-vector stocks were 
prepared when full cpe became apparent (54 - 60hrs) as described above. 
  
Polyethylene glycol VLP concentration. Polyethylene glycol 6000 (PEG-6000) was used to 
concentrate MHV-vector stocks. Briefly, 100 ml MHV-vector containing supernatant was 
centrifuged at 1500 rpm 4°C, 7 min. to clear the MHV-vector stock of remaining cell debris. The 
MHV-vector supernatant (100 ml) was introduced into a 250 ml Erlenmeyer conical flask and 
7.4ml ice cold 5M NaCl was carefully added. Thereafter, 54 ml 30% (w/v) PEG-6000 in NTE 
(10mM Tris, pH6.5: 1mM EDTA; 100mM NaCl) was slowly added and the reaction was placed 
on a magnetic stirrer at 200 rpm for 30 min at 4°C. The mixture was spun (11200 rpm, Sorvall 
SS-34 rotor or 15000xg) for 30 min. The supernatant was carefully decanted and the pellet 
resuspended in the required volume of MEM supplemented with 2%FCS. The resuspended pellet 
was transferred into a sterile falcon tube and centrifuged at 1500 rpm for 5 min at 4°C. Aliquots 
of the supernatant were frozen at -80°C. 
  
RT-PCR. RT-PCR analyses were performed in order to confirm the identity and stability of 
MHV-based vectors. To do this total RNA from MHV-vector-transduced cells was prepared 
using Trizol-reagent (Invitrogen) according to the manufacturer‟s recommendation. The RNA 
was used to synthesise cDNA using SuperScript
TM
 II RT (Invitrogen) and oligo dT primer 
(sequence 5‟TTTTTTTTTTTTTTTTT-3‟) according to the manufacturer‟s recommendation. 
PCR amplification was performed and the products were analyzed by agarose gel separation and 
sequencing using standard protocols. The following primers were used to analyze the integrity of 
the GP-GFP gene and the mGM-CSF gene. GP-GFP: forward 5‟-GTGATGAGTAG 
GAGGACACCAGG-3‟, reverse 5‟-CTCGTGTAACCGAACTGTAGTATG-3‟; mGM-CSF: 
forward 5‟–TTGTTGGCGATAGCCTAGTAAATG-3‟, reverse 5‟–CTGCACCTTCGCAAATA 
TGCCATC-3‟. Vector cDNAs were analyzed for the presence of MHV E gene Using the E-
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specific primers forward 5‟-ACTGGGATCCACCATGTTTAATTTATTCCTTACAG-3‟ and 
reverse 5‟-ACTGGCGGCCGCTTAGATATCATCCACCTCTAATAG-3‟. 
 
 Analysis of heterologous gene expression. GFP expression in MHV-vector transduced cells 
was assessed by fluorescence microscopy or fluorescence activated cell sorting (FACS) analysis. 
GM-CSF expression was assessed by ELISA (mouse GM-CSF ready-set go Cat. No. 88-7334, 
ebioscience.com) using the supernatant of MHV-vector transduced cells according to the 
manufacturer‟s recommendation.  
 
Generation of tetracycline inducible cell lines. Two mouse cell lines, 17Cl1 and L929 cells, 
were selected due to their susceptibility to MHV infection. The cells were plated in 6 wells so 
that they were 80% confluent on the day of transfection. Cells were transfected with the 
regulator plasmid pTet-off (Clontech) using lipofectin (Invitrogen) according to the 
manufacturer‟s protocol and incubated at 37°C. The cells were allowed to divide for 48 hrs 
before 400µg/ml of G418 in MEM-10 was applied as selection pressure. G418 resistant clones 
were expanded and subjected to primary screening by evaluating the luciferase activity following 
a transient transfection with the luciferase control plasmid (pTREhyg2-Luc) containing the 
tetracycline responsive element (TRE) under the minimal CMV promoter in the presence or 
absence of 10ng/ml Doxycycline. Luciferase activity was assayed using the luciferase assay 
system (Promega) as recommended by the manufacturer and measured using an automatic 
luminometer (Spectra Fluor Plus, Tecan).  
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Results 
MHV-based vector design, cloning and packaging concept 
  In order to establish a robust high titer MHV-vector stock preparation, we have carefully 
designed and cloned a number of prototype MHV-based vectors. First the MHV-GP-EM vector 
was designed such that (i) it be devoid of two structural genes in order to be propagation 
deficient (ii) to lack all accessory genes in order to attenuate the vector and (iii) to introduce a 
model antigen (GP-GFP) to assess vector-mediated heterologous gene expression (fig. 1).  
 
 
Figure 4: Overall strategy for the generation of MHV-GPEM vector and the packaging concept. Schematic 
representation of the initial design of MHV-GPEM vector and the corresponding packaging concept. The structural 
relationship and the genome organization of the MHV-A59 and the MHV-GPEM vector are shown. ORF1a and 
ORF1b encoding the replicase are depicted as light grey boxes, nonessential genes are indicated in white boxes and 
the structural genes are in dark grey boxes. Vector-encoded GP-GFP gene is indicated as white box. The bottom 
panel depicts the packaging concept. The structural proteins E and M are provided by the packaging cell in trans. 
The various vector-specific subgenomic mRNAs are depicted with a common 5‟ leader (L) sequence and a common 
3‟ polyA tail. Structural proteins expressed by the MHV-based vector (S and N) or the packaging cell (E and M) 
will finally encapsidate the full-length vector RNA and assemble into virus-like particles that are released from the 
packaging cell. 
80
                                                                                                                                      Unpublished data 
 
The GP-GFP gene is cloned downstream of the TRS of MHV gene4 to enable 
transcription of a corresponding GP-GFP subgenomic mRNA. The construction of the MHV-
GP-EM vector was facilitated by the reverse genetic system established in our laboratory as 
described in material and methods (Coley et al., 2005). 
 In order to propagate MHV-GP-EM vector, we have previously established a packaging 
cell line (17Cl1-EM-13) that stably express MHV E and M (Eriksson 2006). Although we could 
rescue MHV-GP-EM on 17Cl1-EM-13 cells, we were unable to obtain vector stocks exceeding 
10
3
 VLPs/ml. 
 
 
 
 
Figure 5: Overall strategy for the generation of MHV-GP vectors and the packaging concept. The structural 
relationship and the genome organization of the MHV-A59 and the MHV-GP vector are shown. MHV-A59 and 
MHV-GP vector encoded ORFs are depicted as boxes (figure1). Note that the MHV vector does encode the 
structural protein M but is devoid of E. Accordingly, the packaging cells do encode only E. Also note that the 
replicase encoded nsp1 in the MHV vector harbours an attenuating 99 nucleotide deletion. 
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In order to achieve high titer production of VLPs we revised our vector design reasoning 
that most likely, MHV-M protein expression in 17Cl1-EM-13 cells did not approach high 
expression levels observed in wild-type MHV-A59 infection. Therefore, we constructed MHV-
vectors that lack only one structural gene, namely the E gene (figure 2). In contrast to the 
abundant expression of M protein, the expression of E protein is much lower in MHV-A59 
infected cells. To secure highest biosafety, we deleted 99 nucleotides near the carboxy terminus 
of the replicase-encoded non-structural protein1 (nsp1). This deletion has been shown to provide 
attenuation in the context of a MHV-A59 mutant (Zust et al., 2007). In order to additionally 
assess a potential immunostimulatory effect of a cytokine, we cloned in one of the vectors 
between the replicase gene and the spike gene, the cytokine murine granulocyte colony 
stimulating factor (mGM-CSF). The resulting E MHV vectors, designated MHV-GP and 
MHV-GM/GP, were initially rescued by electroporation of the full-length vector RNA into 
17Cl1-EM-13 packaging cells. In contrast to the previously used EM vectors, we could observe 
improved spread of MHV-GP and MHV-GM/GP vectors and reached peak titers of 10
4
 
VLPs/ml, suggesting that re-introducing the M gene into the vectors improved their propagation 
using the 17Cl1-EM-13 packaging cells.  
 
Generation of an inducible MHV E expressing cell line 
The ability to effectively evaluate MHV-based vectors for their suitability as vaccine 
vectors depends heavily on the availability of high titer vector stocks. According to our revised 
vector design, we aimed to generate an inproved packaging cell line that will only express the 
MHV-E protein and that will allow more efficient propagation of MHV-based E vectors. We 
decided to use the Tet-Off system that allows for controlled inducible gene expression. 
Therefore, murine 17Cl1 and L929 cells that are susceptible to MHV infection were transfected 
with the regulator plasmid (pTet-Off vector) and a total of 61 17Cl1-based and 40 L929-based 
G418 resistant clones were selected. These clones were screened by transient transfection with 
pTRE2hyg-Luc in order to identify clones with low background and high induction of luciferase 
activity in response to the removal of tetracycline or its derivative doxycycline. All L929 cell 
clones indicated very low luciferase activity (data not shown) and therefore were discontinued. 
In contrast, most 17clone1-based Tet-Off cell lines displayed high luciferase expression (figure 
3a). In parallel, we also assessed the susceptibility of these cell lines to MHV infection. In 
particular, we assessed MHV-A59 spread, plaque size and titers following MHV-A59 infection 
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Figure 6. Development of an inducible packaging cell line based on the Tet-Off system. (A) Luciferase 
expression of 61 G418 resistant 17clone1-derived Tet-Off clones. Black bars represent luciferase expression 
under non-induced (+ Doxycycline) and white bars represent luciferase expression under induced (- 
Doxycycline) conditions. (B) Calculated fold induction of luciferase expression based on data shown in panel 
A. (*) depicts clone 17 that was selected for further usage. 
 
of these cells (data not shown). These analyses resulted in the selection of clone number 17 for 
subsequent, stable introduction of the MHV-E expression plasmid pTRE2hyg-MHV-E.  
 
 
After transfection of pTRE2hyg-MHV-E into clone number 17 and selection for 
hygromycin resistance, a total of 38 hygromycin resistant clones were isolated. These clones 
were evaluated for the genomic integration of the MHV-E by PCR. All 38 clones were positive 
by PCR for the genomic integration of MHV-E (data not shown). All clones were transduced 
with MHV-GP supernatant at a m.o.i. of 0.001 and the ease of MHV-GP spreading was carefully 
monitored (figure 4a), while supernatant was compared by titration on L929 cells to determine 
the best MHV-GP vector producing clone in terms of titer (figure 4b). Though most of the clones 
were very close to each other in MHV-GP spread and titers, subtle differences led to the 
selection of clones 3 and 20 (designated 17ECl3 and 17ECl20, respectively) to represent the best 
packaging cell clones with respect to MHV-GP production. Notably, the improved E-expressing 
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Tet-off-based cell lines greatly facilitated vector spread, propagation and we could obtain peak 
titers of up to 10
6
 VLPs/ml (figure 4b). 
 
 
 
Figure 7. Evaluation and selection of clone 17 E expressing cell clones. Tet-Off derived clone 17 was transfected 
with pTRE2hyg-MHV-E. Expanded E expressing cell clones were transduced with MHV-GP vector particles and 
evaluated on the basis of VLP spreading and titer. (A) Indicate VLP spreading in various cell clones. (B) Indicate 
the titer of VLP obtained from the supernatant of the E expressing clones. 
 
Generation of high titer VLP stocks. 
 Efficient analyses and characterization of MHV-based vaccine vectors requires sufficient 
amount of particles and in reasonable concentration as to be possible for mass immunization. 
Therefore, we aimed to optimize the MHV vector growth conditions using the 17ECl20 
packaging cell line. When we transduced 1 x 10
6
 17ECl20 packaging cells in a 6 well format 
with an m.o.i. of 0.001-0.01, at 33°C with low pH DMEM, we obtained titers of 1-3 x 10
6
pfu/ml 
at 72 hrs post transduction. With similar m.o.i in 150 cm
2
 flasks in a total volume of 20-30ml, we 
could also obtain titers of 1-3 x 10
6
pfu/ml at 72hrs post transduction, suggesting that the 
packaging strategy is also applicable to the generation of MHV vectors in a larger scale. When 
we performed a similar experiment employing roller bottle amplification with m.o.i. 0.001-0.01, 
at 33°C low pH DMEM total volume of 30ml, we obtained titers of 5 x 10
6
pfu/ml at 54hrs post 
transduction. Noteworthy, these titers obtained in roller bottles required less seed vector (lower 
moi) and less cell culture medium (30ml/10
8
cells). In order to further increase VLP stock titers 
that could be used for mass immunization, we concentrated 100 ml of a 5 x 10
6
 pfu/ml VLP 
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supernatant using PEG-6000 as described in methods. Using this procedure, it was possible to 
concentrate the VLP stocks to obtain titers of 10
7
 - 10
8 
pfu/ml. 
 
Stability and safety.  
 After having established a robust packaging system to obtain high titer stocks, we aimed 
to assess if final MHV vectors stocks that were planed to enter immunization studies retained 
their integrity. First, we analyzed by RT-PCR if MHV-based vectors have retained the cloned 
antigen and cytokine coding regions. As shown in figure 5a, RT-PCR analysis using RNA from 
vector-transduced packaging cells revealed that both, the mGM-CSF- and the GP-GFP-coding 
regions were stably maintained. Furthermore, sequencing analysis of the resulting PCR products 
revealed that these regions were also stably maintained on the nucleotide level (data not shown). 
Second, we assessed whether MHV-based vectors may have undergone a potential 
recombination with the MHV-E mRNA provided in trans by the 17ECl20 packaging cells during 
rescue and propagation. As shown in figure 5b, E gene-specific RT-PCR using RNA obtained 
from MHV-GM/GP vector-transduced 17ECl20 packaging cells (lane 1), from non-transduced 
17ECl20 packaging cells (lane 2), from  MHV-GM/GP vector-transduced 17Cl1 cells (lane 3), 
from non-transduced 17Cl1 cells (lane 4), and from MHV-infected 17Cl1 cells (lane 5) revealed 
that E gene-specific RNA is detectable from packaging cells (due to stable expression in trans) 
and from MHV, but not from the MHV-GM/GP vector. Collectively, we conclude that MHV E 
vectors grown to high titer stocks on 17ECl20 packaging stably maintain the cloned heterologous 
genes and did not acquire the E gene from packaging cells during propagation.  
 
 
Figure 5. Analysis of MHV vector integrity. (A) RT-PCR analysis of MHV vector-encoded regions containing 
mGM-CSF (lanes 1-4) and GP-GFP (lanes 5-8) genes. RNAs were derived from 17ECl20 packaging cells 
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transduced with MHV-GM/GP (lanes 1 and 5) or MHV-GP (lanes 2 and 6). Lanes 3 and 7, water controls. Lanes 4 
and 8, plasmid DNA controls. (B) MHV E gene-specific RT-PCR analysis. RNAs were derived from MHV-
GM/GP-transduced 17ECl20 packaging cells (lane 1), 17ECl20 packaging cells (lane 2), MHV-GM/GP-transduced 
17Cl1 cells (lane 3), 17Cl1 cells (lane 4), and MHV-infected 17Cl1 cells. M, DNA size marker. 
 
Vector mediated-heterologous gene expression. 
 The rationale of an MHV-based vector is to mediate heterologous gene expression in 
specific target cells in order to induce a potent immune response. Therefore, to assess MHV-
vector-mediated model antigen expression, we transduced bone marrow derived dendritic cells 
with MHV-GM/GP and MHV-GP (m.o.i=1), and 12 hrs post transduction, cells were analyzed 
by fluorescence activated cell sorting (FACS) for green fluorescence protein expression. As 
shown in figure 6a, MHV vector-mediated GFP expression was seen in both MHV-GM/GP and 
MHV-GP transduced DCs. Notably, we observed a higher proportion of surviving DCs and a 
higher proportion of green fluorescent DCs when the mGM-CSF-expressing vector MHV-
GM/GP was used for transduction. In order to assess vector-mediated mGM-CSF expression, 
17ECl20 packaging cells, bone-marrow derived DCs and peritoneal macrophages were 
transduced at an m.o.i of 0.01 with MHV-GM/GP and incubated at 37°C for 48hrs during which 
supernatant was collected at the indicated time points (figure 6b). We observed efficient vector-
mediated expression of mGM-CSF in 17ECl20 packaging cells, and more importantly, also in 
primary target cells such as DCs and macrophages (figure 6b). Taken together, these data 
demonstrate that it is possible to clone a particular antigen in the MHV-vector genome and target 
it to specific immune components capable of stimulating a potent immune response.  
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Figure 8. MHV vector-mediated heterologous protein expression in vector-transduced cells. (A) FACS analysis of 
GFP expression in CD11c
+
 murine bone marrow derived DCs 12 h post transduction with MHV-GP (middle panel) 
or MHV-GM/GP (right panel) or mock transduced (left panel). (B) mGM-CSF expression in MHV-GM/GP 
transduced (m.o.i=0.01) 17ECl20 packaging cells (left panel), CD11c
+
 murine bone marrow derived DCs (middle 
panel), and murine peritoneal macrophages (right panel). Data were assessed by using mGM-CSF ELISA at the 
indicated time points post transduction.  
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4. Discussion 
 We report here the design, development and characterization of the first murine 
coronavirus-based multigene RNA vector particles. MHV-based vectors have several inherent 
advantages that make them attractive as vaccine vector candidates. We have constructed a set of 
prototype MHV-based vectors that can mediate model antigen and cytokine expression 
simultaneously. Furthermore, we demonstrate here that MHV-based vector RNAs were stably 
maintained upon propagation and that high titer VLP stocks can be prepared using an appropriate 
packaging concept and improved growth conditions. 
In order to construct these MHV-based vectors we exploited the recombinant vaccinia 
virus vMHV-inf-1 carrying the full length cDNA of MHV-A59 (Coley et al., 2005) using the 
reverse genetic system established in our laboratory. By using genetically tailored recombination 
cassettes we systematically replaced the genes encoding the MHV ORF4, ORF5a and the gene 
encoding the small envelope protein E with the E. coli-gpt gene to enable selection of desired 
clones. In the second step we have introduced an expression cassette carrying the GP-GFP gene 
cloned downstream of MHV TRS so as to assure adequate transcription of these antigens. In 
addition, we inserted a cytokine gene, the murine GM-CSF gene, in the region between the 
MHV replicase and the MHV spike. The GM-CSF gene was cloned downstream the MHV TRS-
2 to ensure the production of a vector-derived subgenomic mRNA.  
In order to rescue and propagate MHV-based vectors it was necessary to produce a stable 
packaging cell line that will provide the deleted MHV structural proteins E and M in trans. In our 
first design (figure 4) where we aimed at a one hit vector system by deleting the MHV structural 
proteins E and M, we initially masterminded a packaging concept and developed a packaging 
cell line expressing MHV E and M in trans (figure 4). Rescue of the MHV-GP-EM vector was 
successful using this cell line but we were unable to efficiently propagate this vector using the 
initial packaging strategy. One obvious reason for this observation is that the amount of M 
protein that was provided by the cells in trans was not sufficient to enable efficient propagation 
of the MHV-GP-EM vector. 
The safety of coronaviruses as vectors has been demonstrated by several groups based on 
the deletion of the small envelope gene E (Curtis et al., 2002; Ortego et al., 2002). Recently, a 
coronavirus-based vaccine, a E-SARS vaccine has been reported to confer immunogenicity and 
protective efficacy in hamster (Lamirande et al., 2008). In fact, the lack of the E gene in TGEV 
greatly affects maturation of progeny virion in the secretory pathway indicating the importance 
of this gene for TGEV (Ortego et al., 2007). In contrast, the MHV-E gene has been shown not to 
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be absolutely necessary for replication and MHV-E has been demonstrated to produce tiny 
plaques, exhibit a low growth rate as well as yield low infectious titers when compared to the 
wild-type MHV (Kuo and Masters, 2003). Therefore, in the revised design of our vectors (figure 
5) we have deleted the MHV-A59 E gene in order to attenuate our vectors. Interestingly, it has 
been elegantly reported that coronavirus group specific genes are not essential for their 
replication in tissue culture but that their deletion is attenuating in the natural host (de Haan et 
al., 2002a; Haijema et al., 2004), therefore, we reasoned that, deleting the nonessential genes of 
MHV-A59 will provide two advantages (i) further attenuate these vectors and (ii) increase the 
capacity for heterologous antigen accommodation. In fact one way of attenuating a virulent virus 
is by knocking out a possible pathogenicity factor. SARS nsp1 has been shown to interfere with 
the first line of antiviral defence (Kamitani et al., 2006; Narayanan et al., 2008; Wathelet et al., 
2007) and a mutant SARS nsp1 virus was shown to be attenuated in interferon competent cells 
(Wathelet et al., 2007). Similarly, the disruption of MHV-A59 nsp1 has been shown not to affect 
the replication of the virus in interferon incompetent mice whereas in interferon competent 
animals, this hepatotropic virus was highly attenuated (Zust et al., 2007). Therefore, we included 
the disruption of the MHV nsp1 in our vector design in order to ensure highest biosafety. Taken 
together, these vectors devoid of all nonessential proteins, encoding a 99-nucleotides deletion in 
the replicase encoded nsp-1 region and lacking the structural protein E are considered to be 
highly biosafe vaccine vectors. 
Furthermore, we resorted to develop a new packaging concept based on the Tet-Off 
inducible system. This system provides the added advantage that we can regulate the expression 
of the trans gene therefore indirectly influencing the packaging outcome. More so the decision of 
Tet-Off as against Tet-On is backed by the fact that we avoid antibiotics into our vaccine vector 
stocks. In our revised packaging concept, therefore, we developed an inducible Tet-Off cell line 
that provides the MHV-E protein in trans. We initially transfected 17clone1 based cells with the 
Tet regulator plasmid and selected 61 G418 resistant clones. These clones were screened after 
transient transfection with a luciferase control plasmid for luciferase activity. Following a 
calculated fold of luciferase induction and infectivity screening, the clone number 17 was 
selected. This clone was transfected with a plasmid encoding the MHV-E and 38 E expressing 
hygromycin resistant clones were selected. These cell lines were screened by transduction with 
vector particles at very low multiplicity of infection and the ease of vector spreading was 
monitored. The titer of the supernatant obtained from those clones led to the selection of clone 3 
and 20 to represent the best vector producing cell lines. The use of Tet-Off-based E expressing 
packaging cell line 17ECl20 enabled us to robustly propagate the E MHV vectors.  
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In order to amplify the VLP stocks we employed a systematic upgrading of the stocks by 
first transducing 150cm
2
 tissue culture flaks and after obtaining the supernatant in sufficient 
quantity, we went on to transduce the roller bottle. We obtained titers of 5x10
6
pfu/ml. 
Furthermore, we could concentrate the VLP stocks by a coupling reaction with polyethylene 
glycol-6000 to titers of 10
8
pfu/ml. This therefore demonstrates our determined stepwise 
improvement of the VLPs stocks to such a high amount that can be employed in nearly any kind 
of vaccination schedule.  
Furthermore, the stability of MHV-based vectors was analyzed after 12 passages by RT-
PCR and we observed that these vectors are stable after 12 passages and this was confirmed by 
sequencing analyses. The vectors were equally checked for any sign of recombination with the 
MHV-E gene that is provided in the packaging cell line. The RT-PCR results, indicate that the 
vectors remain safe despite their extensive propagation on E producing packaging cells. 
The main goal of vaccine vectors is to mediate expression of their genetic cargo in 
specific target cells or tissue. Expression of multiple heterologous proteins in the context of a 
prototype vector expressing three cytoplasmic reporter markers has been described (Thiel et al., 
2003) for HCoV 299E. When we transduced murine bone marrow derived DCs with MHV-
GM/GP and MHV-GP vectors, we observed the expression of GP-GFP in these target cells. The 
heightened stringency on vaccine safety has plunged new vaccines into a situation that is often 
linked to lower immunogenicity compared to previous whole cell or virus-based vaccines. This 
calls for the necessity to employ adjuvant to induce potent and durable immune responses with 
additional benefit that less antigens and fewer injections may be needed (Guy, 2007). Currently, 
there is an evaluation spree for cytokines as adjuvants in vaccines as against most chemical 
entities because cytokines are likely to be the direct proximal mediators of the „classical‟ 
adjuvants (Pashine et al., 2005). In our design we have considered the possibility to manipulate 
the immune outcome after vaccination with our vectors therefore we cloned a cytokine the 
mGM-CSF in one of the vectors. In deed, we observed better recovery of GP-GFP positive cells 
with a percentage of 5.57 as compared to the vector without GM-CSF (2.55%). This result 
indicates that the GM-CSF encoding vector allows better survival of the target cells as compared 
to the non-GM-CSF vector. Additionally, this may have an implication in the immune outcome. 
In fact, dendritic cells and macrophages represent important target cells in terms of a vaccine 
vector since these cells can have important influence on the outcome of an immune response. 
Taken together, this result demonstrates efficient vector-mediated expression of heterologous 
genes in the context of model antigens. Overall, these experimental results provide the proof of 
principle that the generation of MHV-based vectors is feasible and that the transgenes expressed 
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by these replication competent but propagation deficient vectors can be targeted to DCs and 
macrophages.  
With the vector system established in this study it is now possible to systematically assess 
the efficacy of this novel vaccine platform. Specifically we will study the effect of mGM-CSF on 
DC activation and maturation. Furthermore, we will assess the immunogenicity of the MHV 
vectors in mice using immunization strategies against pathogenic viral challenge and 
experimental tumours expressing the relevant model tumour or viral antigen. 
It is worth noting that mouse hepatitis virus is one of the best studied viruses in the 
laboratory and this comes in hand with the availability of a variety of well characterized small 
animal models permitting the effective evaluation of the system using well established and 
generally recognised scientific procedures. Hence the murine model of coronavirus-based 
vectors represent a very important tool for the development and evaluation of the system and 
may be instructive for the development, evaluation and adaptation of coronavirus-based vaccine 
vectors for human ailments (Eriksson et al., 2006b). 
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Abstract 
Coronaviruses are large positive-stranded RNA viruses that can be exploited to 
genetically deliver multiple antigens and immunostimulatory cytokines to professional antigen-
presenting cells. Here, we report the assessment of the immunogenic potential of coronavirus-
based vectors in a murine model. We have constructed a set of bio-safe vaccine vectors based on 
mouse hepatitis virus (MHV) genomes that are devoid of accessory genes, lack one structural 
gene, and carry an attenuating deletion in the replicase gene. They have been designed to form 
virus-like particles that mediate the expression of the lymphocytic choriomeningitis virus 
(LCMV) glycoprotein (GP) or human melan-A CTL epitopes in combination with the 
immunostimulatory cytokine GM-CSF. We demonstrate selective targeting of dendritic cells 
(DCs) and macrophages resulting in vector-mediated antigen expression in vitro and in vivo, and 
efficient GM-CSF-mediated maturation of DCs. In mice, single immunization elicited strong and 
long-lasting protective cytotoxic T-cell responses against challenge with LCMV and LCMV-GP 
recombinant vaccinia virus. Furthermore, single dose application of the vaccine elicited both 
prophylactic and therapeutic immunity against metastatic melanoma. In summary, this novel 
vaccine platform mediates the delivery of antigens and immunostimulatory cytokines to the 
cellular components of the immune system that initiate and maintain protective immunity. 
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Introduction 
 
Vaccination against viral infections has saved millions of lives by protecting many 
individuals from diseases such as measles, rubella, mumps, and polio. However, there is growing 
need to develop not only improved vaccines against acute infections but also to generate 
therapeutic vaccines which may stimulate specific immune response to persistent viruses such as 
the human immunodeficiency virus or the human hepatitis C virus (McMichael, 2006; Strickland 
et al., 2008). Likewise, novel approaches for vaccination against tumours are needed which 
counteract the immunosuppression associated with cancer (Melief, 2008). There is compelling 
evidence that CD8
+
 cytotoxic T cells are crucial players in the protective immune response 
against viral infections, and tumours (Appay et al., 2008). Novel vaccine approaches should thus 
be rigorously evaluated for their ability to maximally expand antigen-specific CD8
+
 T cells, to 
induce their optimal differentiation into effector CD8
+
 T cells, and to elicit long-lasting 
protective memory (Appay et al., 2008).  
A major bottle-neck in the development of new and effective vaccines is the delivery of 
antigens to dendritic cells (DCs) (Steinman and Banchereau, 2007; Tacken et al., 2007) which 
sample antigen, transport immunogenic components to secondary lymphoid organs, and initiate 
and maintain T and B cell responses. The excellent capacity of adoptively transferred DCs to 
prime antiviral T cell responses can be readily shown in vivo; only 100 – 1000 DCs presenting a 
specific viral antigen have to reach secondary lymphoid organs for the induction of protective 
antiviral T cell responses (Ludewig et al., 1998; Ludewig et al., 2000a). DC-induced CTL 
responses develop rapidly and DC-immunized mice maintain robust memory T cell responses 
which protect against systemic and peripheral viral challenge (Ludewig et al., 1999). Likewise, 
several preclinical studies demonstrated that efficient antitumour immunity can be induced using 
adoptive transfer of DCs (Ludewig et al., 2000b; Nair et al., 1998; Ochsenbein et al., 1999; Rea 
et al., 2001a; Song et al., 1997; Specht et al., 1997). Although individualized adoptive transfer of 
antigen-loaded DCs is feasible and – to a certain extent – efficient in clinical application in 
humans (Palucka et al., 2007), off-the-shelf vaccines that permit targeted delivery of antigens to 
DCs in vivo are certainly advantageous and will eventually find their way into clinical 
application. 
The description of cell-surface molecules that exhibit a rather specific expression on DCs 
has fueled the development of antibody-based targeting strategies (Bonifaz et al., 2004; 
Bozzacco et al., 2007; Meyer-Wentrup et al., 2008; Tacken et al., 2005). Although these protein-
based vaccines generate CD4
+
 T cell and B cell responses against a range of different antigens, 
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antigen-coupling to antibodies exhibits a major limitation for the induction of CD8
+
 T cell 
response, that is the strict dependence on cross-presentation (Steinman, 2008; Tacken et al., 
2007). Viral vectors encoding for immunogenic antigens can deliver their genetic cargo directly 
into DCs thus generating antigenic peptides in the infected cell and allowing for efficient loading 
of MHC class I molecules. Among the currently most exploited viral vectors that facilitate 
antigen delivery to DCs are adenoviral (Cheng et al., 2007; Rea et al., 2001b), and lentiviral 
vectors (Ageichik et al., 2008). However, one major impediment of these vectors is the frequent 
off-target transduction resulting in antigen presentation by parenchymal cells outside secondary 
lymphoid organs. For example, the strong tropism of adenoviral vectors for hepatocytes with 
deposition of >95% of the genetic material in the liver, leads to generation of functionally 
impaired CD8
+
 T cells (Krebs et al., 2005; Yang et al., 2006). Major efforts are thus required to 
engineer adenoviral vectors with improved specificity for the relevant antigen presenting cells 
(Cheng et al., 2007; Rea et al., 2001a). Likewise, lentiviral vectors preferentially infect cells 
other than DCs and re-direction of their target cell tropism is warranted (Lopes et al., 2008; Yang 
et al., 2008). A second potential impediment for the use of this class of viral vectors in the clinics 
is their potential to integrate genomic material into the host genome (Dobbelstein, 2003). 
Coronaviral vectors display a number of features that clearly overcome these limitations: 
(i) Replication of these positive-stranded RNA viruses occurs in the cytoplasm without a DNA 
intermediary, making insertion of viral sequences into the host cell genome unlikely. (ii) The 
large RNA genomes provide a cloning capacity of more than 6 kb. (iii) The unique transcription 
process generates 6-8 subgenomic mRNAs encoding mainly for the structural genes which can 
be replaced by multiple heterologous genes (Thiel et al., 2003). (iv) Receptors of human and 
murine coronaviruses (e.g. human coronavirus (HCoV 229E, or MHV) are expressed on human 
and murine DCs, respectively (Summers et al., 2001; Zhou and Perlman, 2006) .  
We describe here the generation and evaluation of inherently safe coronavirus-based viral 
vectors that efficiently target antigens and immunostimulatory molecules to DCs. We show that 
MHV-based vectors can deliver multiple antigens and immunostimulatory cytokines almost 
exclusively to CD11c
+
 DCs within secondary lymphoid organs. Delivery of only few viral 
particles elicited potent CD8
+
 T cell responses that provided long-lasting protection against viral 
challenge. Moreover, a single application of the novel viral vectors generated prophylactic and 
therapeutic immunity against metastatic melanoma. Induction of CTL directed against the human 
Melan-A antigen in HLA-A2 transgenic mice indicates that coronavirus-mediated gene transfer 
to DCs represents a versatile approach for immunization against both viral infection and cancer. 
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Material and Methods 
 
Mice and cells. C57BL/6 mice were obtained from Charles River Laboratories (Sulzfeld, 
Germany). A2DR1 have been kindly supplied by Dr. Lemonnier (Pasteur Institute, Paris) (Pajot 
et al., 2004). All mice were maintained in individually ventilated cages and were used between 6 
and 9 weeks of age. All animal experiments were performed in accordance with the Swiss 
Federal legislation on animal protection. L929, and CV-1 cells were purchased from the 
European Collection of Cell Cultures. MC57 and BSC40 cells were obtained from Dr. 
Zinkernagel (University of Zürich, Switzerland). D980R cells were a kind gift from G. L. Smith, 
Imperial College, London, UK. 17Clone1 cells were a kind gift from S.G. Sawicki, Medical 
University of Ohio, Toledo, Ohio, USA. BHK-MHV-N cells, expressing the MHV-A59 
nucleocapsid protein under the control of the TET/ON system (Clontech), have been described 
previously (Coley et al., 2005). 
 
Production of replication-deficient, propagation-competent MHV particles. Mutant vaccinia 
viruses are based on the recombinant vaccinia virus vMHV-inf-1 (containing the full length 
MHV-A59 cDNA) and were generated using the reverse genetic system established in our 
laboratory as described previously (Coley et al., 2005; Eriksson et al., 2008). To construct the 
recombinant vaccinia virus vMHV-GP the MHV-Inf-1 was modified by replacing the MHV 
nucleotides (nts) 21771 – 29623 by gpt using the plasmid pMHV-rec-1. This plasmid carries the 
E. coli- gpt gene flanked to its 5‟end by a sequence corresponding to MHV nts 21328 – 21771 
and to the 3‟end by a sequence corresponding to MHV nts 29655 – 30114. The resulting gpt 
positive vaccinia virus clone vMHV-1b-gpt-N was used to clone the MHV-GP vector cDNA by 
inserting the MHV spike gene, the GP-GFP gene and the MHV-M and N genes in a second 
round of recombination with the plasmid pMHV-vec-10-E. This plasmid was composed of 5‟-
MHV nts 21328 – 21771, MHV nts 23930 – 27964, the GP-GFP gene, MHV 28969 – 30114-3‟. 
The resulting vaccinia virus-vMHV-GP was used to rescue the MHV vector MHV-GP.  
To construct the recombinant vaccinia virus vMHV-GM/GP the gene encoding the 
murine granulocyte colony stimulating factor (mGM-CSF) was cloned between the MHV 
replicase and spike genes. First, the recombinant vaccinia virus vMHV-GP was modified using 
the plasmid pMHV-rec-2-gpt composed of 5‟ MHV nts 21328 – 21771, the E. coli-gpt-gene, and 
MHV nts 23890 – 24452. The resulting gpt-positive clone vMHV-1b-gpt-S-GP was modified in 
a second round of recombination with the plasmid pMHV-rec-2-mGM-CSF composed of 5‟ 
MHV nts 21328 – 21771, the mGM-CSF gene, MHV nts 23890 – 24452 and a gpt negative 
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selection was performed. The resulting vaccinia virus vMHV-GMGP was used to rescue the 
vector MHV-GM/GP.  
To construct the recombinant vaccinia viruses vMHV-MelA and vMHV-GM/MelA, the 
vaccinia viruses vMHV-GP and vMHV-GM/GP were modified to replace the GP-GFP gene by 
the gene encoding a fusion protein MelA comprised of the GFP-coding region, the yeast 
ubiquitin-coding region and the Mel-A26-35A27L analog peptide derived from the human Melan-
A/MART-1 protein (Valmori et al., 1999). First, plasmid pMHV-rec3 was used to recombine 
with vMHV-GP and vMHV-GM/GP. pMHV-rec3 is composed of MHV-nts 27386 – 27964, the 
E. coli-gpt-gene, and MHV nts 28929 – 29655. The resulting recombinant vaccinia viruses 
vMHV-S-gpt-M and vMHV-GM-S-gpt-M were recombined with plasmid MHV-rec3-MelA 
composed of MHV-nts 27386 – 27964, the MelA gene, and MHV nts 28929 – 29655. The 
resulting in the recombinant vaccinia viruses vMHV-MelA and vMHV-GM/MelA were used to 
rescue the vectors MHV-MelA and MHV-GM/MelA, respectively.   
The generation of the Tet-Off expression system-based (Clontech) MHV vector 
packaging cell line 17ECl20 was done as follows. First, murine 17Cl1 cell were stably 
transduced with the plasmid pTet-Off-vector and subjected to G418 selection as recommended 
by the manufacturer (Clontech). A total number of 61 G418-resintant clones were screened for 
firefly luciferase expression under induced and non-induced conditions and clone number 20 was 
selected for the introduction of the plasmid pTRE2hyg-MHV-E. This plasmid is based on the 
pTRE2hyg-vector plasmid (Clontech) into which the MHV-E gene was cloned into the BamHI 
and NotI sites of the multiple cloning site. The MHV-E gene was obtained by PCR using the 
primers: 5‟-ACTGGGATCCACCATGTTTAATTTATTCCTTACAG-3‟ reverse 5‟-
ACTGGCGGCCGCTTAGATATCATCCACCTCTAATAG-3‟ (BamHI and NotI sites 
underlined). Following hygromycin selection a total number of 38 hygromycin-resisitant clones 
were analyzed for MHV-E gene incorporation by PCR and assayed for optimal MHV vector 
propagation. The cell clone revealing highest MHV vector titers, designated 17ECl20 was then 
used for MHV vector propagation and high titer stock preparation. 
Recombinant MHV-based vectors were rescued from cloned cDNA using purified 
vaccinia virus DNA as template for in vitro transcription of recombinant MHV-based vector 
genomes as described (Eriksson et al., 2006; Eriksson et al., 2008). In order to rescue 
recombinant coronavirus-based vectors and package them into virus-like particles (VLPs), the 
full length vector RNA was transfected into 17ECl20 packaging cells by electroporation 
(Eriksson et al., 2008). The transfection is incubated in minimum essential medium 
supplemented with 5% Tet-approved FBS (Clontech), 500 U penicillin/ml, 100u 
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streptomycin/ml (Tet-induction MEM) at 37°C 5% CO2 for about 2 days. MHV-based vector 
particles released into the supernatant within the next 24-48 hrs were collected and stored at -
80°C until further usage. High titer MHV vector stocks were produced after transduction of 10
7
 – 
10
8
 17ECl20 packaging cells with MHV vectors (moi=0.001 – 0.01). 100 ml of MHV vector 
supernatants from these cultures were subjected to polyethylenglycol (PEG) precipitation by 
adding 7.4 ml ice cold 5M NaCl, slow stirring at °C for 30 min, adding 54 ml 30% (w/v) PEG-
6000 and centrifugation (15.000g, 4°C). The MHV vector pellet was resolved in 2 ml of MEM 
containing 2% FCS. Titration of MHV vectors was performed on murine L929 cells as described 
(Zust et al., 2008). 
 
Determination of antiviral protection. LCMV-WE strain was obtained from Dr. R. 
Zinkernagel (Universität Zürich, Switzerland), propagated on L929 cells, and titered on MC-57 
cells. Recombinant vaccinia virus expressing LCMV glycprotein (VV-G2) was originally 
obtained from Dr. D.H. Bishop (Oxford, U.K.), and recombinant VV expressing vesicular 
stomatitis virus Indiana glycoprotein (VV-INDG) was originally obtained from Dr. B. Moss 
(National Institutes of Health, Bethesda). Vaccinia viruses were grown and titrated on BSC40 
cells. 
To examine anti-viral protection, unless otherwise indicated naïve mice were immunized 
with 105pfu of MHV-GP or MHV-GM/GP diluted in cold BSS and 7 days post immunization 
(p.i), mice were challenged with 200 pfu LCMV-WE i.v. or 2 x 10
6
 pfu of recombinant vaccinia 
virus encoding either the glycoprotein of LCMV-WE or of VSV intra-peritoneally (i.p.). Four 
days post challenge, mice were killed and virus titers in the spleens were determined by LCMV 
infectious focus assay on MC57 cells as previously described (Battegay et al., 1991) or five days 
post challenge, ovaries were collected and vaccinia virus plaque assay was performed as 
described (Eriksson et al., 2008).   
 
Isolation of dendritic cells and macrophages, flow cytometry and antibodies. Bone marrow–
derived cDCs were generated by 6 to 7 days of culture with granulocyte-monocyte colony 
stimulating factor (GM-CSF)-containing supernatant from the cell line X63-GM-CSF (kindly 
provided by Antonius Rolink, University of Basel, Basel, Switzerland). cDCs were further 
purified using Optiprep density gradient centrifugation. Thioglycolate-elicited macrophages were 
collected from the peritoneal cavity of mice and cultured overnight at 37°C. Non-adherent cells 
were removed by washing with ice-cold PBS. Splenic DCs were isolated from splenocyte 
suspensions of collagenase type II digested (Gibco, Invitrogen Basel, Switzerland) spleens. The 
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CD11c
+
 DC fraction was enriched using mouse CD11c (N418) microbeads (Miltenyi Biotec) as 
recommended by the manufacturer. 
Splenocytes were obtained from spleens of B6 following digestion with collagenase type 
II for 20 min at 37°C and resuspended in RPMI 5%. For isolation of the low density enriched 
population, cells were resuspended in PBS supplemented with 2% FCS, 2 mM EDTA and 
overlaid on 20% Optiprep density gradient medium (Sigma-Aldrich Co. Basel, Switzerland). 
After centrifugation at 700  g for 15 min, low density cells were recovered from the interface 
and resuspended in RPMI 5%. Cells were stained with different lineage markers and analyzed 
for GFP expression with a FACSCalibur flow
 
cytometer using the CellQuest software (BD 
Biosciences). Antibodies used in this study were purchased from BD Biosciences Pharmingen 
(CD11c-PE), Biolegend (CD19-PE, CD4-PE, B220-APC, CD3-APC, CD11b-APC, CD86 APC, 
CD40 Alexa 647), and eBiosciences (F4/80-PE, CD8-PE).  
 
Tetramer analysis and intracellular cytokine staining. Specific ex vivo production of IFN- 
was determined by intracellular cytokine staining. Organs were removed at the indicated time 
points following infection with recombinant MHV. Tetramers were synthesized and applied for 
staining of blood and splenic samples as previously described (Junt et al., 2002; Valmori et al., 
1999).  For intracellular cytokine staining, single cell suspensions of 1×10
6
 
splenocytes were 
incubated for 5 h at 37°C in 96-well round-bottom plates in 200 l culture medium containing 25 
U/ml IL-2 and 5 g/ml Brefeldin A (Sigma). Cells were stimulated with phorbolmyristateacetate 
(PMA, 50 ng/ml) and ionomycin (500 ng/ml) (both purchased from Sigma, Buchs, Switzerland) 
as positive control or left untreated as a negative control. For analysis of peptide-specific 
responses, cells were stimulated with 10
-6 
M of the indicated peptides. The percentage of CD8
+
 T 
cells producing IFN- was determined using a FACSCalibur flow cytometer. GP33 
(KAVYNFATC) and GP34 (AVYNFATC) peptides were purchased from Neosystem 
(Strasbourg, France). Melan-A peptide (ELAGIGILTV) was obtained from the Ludwig Institute 
for Cancer Research. 
 
Melanoma model. B16F10-GP melanoma cells expressing the LCMV gp33 epitope (Prevost-
Blondel et al., 1998) and parental B16F10 cells were kindly provided by Dr. H. Pircher 
(University of Freiburg, Germany). The B61F10-GP melanoma cells were cultivated under G418 
(200 µg/ml) (Life Technologies, Gaithersburg, MD) selection. B6 mice received 5×10
5
 tumour 
cells i.v. and numbers of lung metastasis were determined on day 12 post inoculation. For 
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tumour prevention experiments, B6 mice were immunized with MHV-based vectors at the 
indicated days before tumour challenge. Tumour therapy experiments were performed in an 
analogous fashion with except that MHV-GM/GP immunization was done on the same day as 
B16F10-GP melanoma cells were given or on day 4 or 8 after B16F10-GP melanoma cells were 
given.  
 
Statistical analysis. All statistical analyses were performed with Prism 4.0 (Graphpad Software 
Inc.). Data were analyzed with the paired Student's t-test assuming that the values followed a 
Gaussian distribution. A P value of < 0.05 was considered as significant. 
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Results 
 
Design and propagation of bio-safe coronavirus-based vaccine vectors. 
To assess immunogenicity and to ensure maximal safety of coronavirus-based multi-gene 
vaccine vectors, we have rationally designed a series of prototype vectors based on the mouse 
hepatitis virus, strain A59 (MHV-A59) (Fig. 1). For the generation of attenuated and 
propagation-deficient MHV-based vectors, we have (i) deleted all MHV-encoded accessory 
genes (NS2, HE, gene4, gene5a) (de Haan et al., 2002), deleted 99 nucleotides within the 
replicase-encoded sequence of the non-structural protein 1 (nsp1) (Zust et al., 2007), and deleted 
the structural gene E (Ortego et al., 2002).  
 
 
Figure 1. Generation and propagation of MHV-based vaccine vectors. (A) Schematic representation of MHV-A59 
genome and the highly attenuated MHV vectors encoding different antigen cassettes and the immunostimulatory 
cytokine GM-CSF. (B) Depiction of the GFP-antigen fusion cassettes. (C) Packaging concept for the generation of 
replication-competent but propagation-deficient MHV particles. (D) Growth kinetics of the indicated MHV vectors, 
MHV-nsp199 and MHV-A59 in 17ECl20 packaging cells. Cells were infected at an moi of 1 and titers in 
supernatants were determined at the indicated time points. 
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In order to test the coronavirus-based vaccine concept and to develop a vaccine that 
provides strong CTL responses, both in terms of magnitude and longevity, we have used the 
CTL epitopes gp33-41 derived from the lymphocytic choriomeningitis virus (LCMV) glycoprotein 
(GP), and Mel-A26-35A27L analog peptide derived from the human Melan-A/MART-1 protein 
(Valmori et al., 1999) (Fig. 1a).  
As shown in figure 1b, both CTL epitopes were cloned as fusion proteins with the green 
fluorescent protein (GFP) and the corresponding genes were cloned between the MHV-vector-
encoded spike and membrane genes. Since maturation and appropriate stimulation of DCs is 
critical for the generation of efficient T cell responses (Steinman et al., 2003) and hence an 
indispensable component of rationally designed vaccines (Chabalgoity et al., 2007), we have 
inserted the gene encoding for the murine granulocyte-macrophage colony-stimulating factor 
(GM-CSF) between the MHV-vector-encoded replicase and spike genes (Fig. 1a). 
In order to propagate the MHV-based vectors to high titers, we have produced a 
packaging cell line, designated 17ECl20, based on murine 17Cl1 cells that express the MHV E 
protein under the control of the Tet-Off system (Fig. 1c). As shown in figure 1d, all MHV-based 
vectors grew efficiently in 17ECl20 cells and reached peak titers of approximately 10
6
 VLPs/ml 
and final MHV vectors stocks of 10
8
 VLPs/ml were produced following polyethylenglycol 
precipitation.  
 
DC and macrophage-specific delivery and expression of coronavirus vector-encoded 
antigens and cytokines 
To assess MHV-vector growth kinetics on cells that do not express the MHV E protein, 
we transduced murine L929 cells, bone marrow-derived CD11c
+
 DCs, or peritoneal 
macrophages with the MHV-vectors and compared growth kinetics to that of wild-type MHV-
A59 and the nsp1 mutant MHV-nsp199. As shown in figure 2a, MHV-based vector growth was 
greatly impaired in murine L929 cells. Most importantly, in peritoneal macrophages and DCs, 
MHV-vector transduction did not result in VLP release, demonstrating that the lack of the E 
protein prevents MHV-vector propagation in primary cells. 
All MHV vectors led to significant GFP-expression in transduced cells L929 cells and 
peritoneal macrophages (data not shown), and rapid production of GM-CSF in L929 cells, 
peritoneal macrophages and DCs following exposure to the cytokine-encoding vectors (Fig. 2b), 
demonstrating that MHV vectors can be used to simultaneously express heterologous antigens 
and immunostimmulatory cytokines in susceptible target cells.  
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Figure 2. Antigen delivery to dendritic cells by MHV-based vaccine vectors. (A, B) 10
6
 L292 cells, bone marrow 
derived DCs, or peritoneal macrophages were transduced or infected with the indicated MHV-based vectors, or 
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MHV-nsp199 and MHV-A59, respectively , and MHV-based vector titers and MHV titers (A) as well as 
production of GM-CSF (B) were determined. Values represent means ±SEM from triplicate cultures. ND, not 
detectable. (C-D) In vitro and in vivo transduction of splenocytes. (C) One million splenocytes or low density cell-
enriched fractions (for cDC analysis) from B6 mice were transduced with MHV-GM/GP vector (moi=1). Cells were 
harvested 12 h later and stained for the indicated surface molecules (CD4 T cells, CD4
+
CD3
+
; CD8 T cells, 
CD8
+
CD3
+
; B cells, B220
+
CD19
+
; macrophages, CD11b
+
; cDCs, B220
-
CD11c
+
) and subjected to FACS analysis. 
(D) B6 mice were infected i.p. with 10
6
 pfu MHV-GM/GP or left untreated. Spleens were collected after 36 h, 
digested with collagenase and splenocytes or low density cells (for cDCs analysis) were stained for the indicated cell 
population as in (C) and subjected to FACS analysis. Dot plots are representative of 5 individual mice. Values in the 
upper right quadrant indicate mean percentages +SD of GFP
+
 cells for each population. (E-F) Stimulation of cDCs 
by GM-CSF expressing vectors. One million bone marrow-derived cDCs from B6 mice were infected with the 
indicated MHV-based vector (moi=1) or left untreated. Cells were harvested 12 h later, stained for CD11c and 
CD86 expression and subjected to FACS analysis. (E) Representative dot plots indicating the high transduction 
efficacy. Values in the upper right quadrant indicate of GFP
+
 cells. (F) Expression of the DC activation marker 
CD86 on untreated CD11c
+
 cells (grey shaded), on CD11c
+
GFP
+ 
(thick black line), or CD11c
+
GFP
- 
(dotted line) in 
cells exposed to either MHV-GP or MHV-GM/GP. 
 
To further determine the cellular tropism of MHV-based vectors, we transduced 
splenocytes from C57BL/6 (B6) mice with MHV-GM/GP in vitro and analyzed GFP expression 
by flow cytometry. As shown in figure 1c, neither CD4
+
, nor CD8
+
 T cells were susceptible to 
MHV-GM/GP transduction. In contrast, antigen presenting cells, such as B cells (CD19
+
), 
macrophages (CD11b
+
) and DCs (CD11C
+
), displayed green fluorescence, indicative for MHV 
vector-mediated GFP expression. In order to evaluate if targeting of DCs and macrophages is 
also achievable in vivo, we injected (i.v.) 10
6
 VLPs of MHV-GM/GP into B6 mice and analyzed 
GFP expression of splenocytes by flow cytometry. As shown in figure 2d, we could indeed 
detect GFP expression in F4/80
+
 macrophages and CD11c
+
 DC, but not in B or T cells. Finally, 
we assessed the effect of MHV vector-mediated GM-CSF expression on DC stimulation and 
activation. To this end, bone-marrow derived DCs were transduced (moi=1) with MHV-GP or 
MHV-GM/GP. Vector-mediated GM-CSF expression facilitated more efficient DC-transduction 
and permitted better survival of DCs, indicated by a higher recovery of living cells in the 12 h 
cultures (figure 2e). Furthermore, vector-mediated GM-CSF expression also resulted in DC 
activation and maturation, as shown by upregulation of CD86 on CD11c
+
 cells (Fig. 2f). This 
effect was not only apparent in the MHV-GM/GP-transduced GFP
+
 fraction, but also in the GFP
-
 
fraction of non-transduced DCs, suggesting that GM-CSF expression by vector transduced DCs 
provides a substantial bystander effect on non-transduced DCs. 
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Antiviral CTL responses following coronavirus vector immunization 
Infection with LCMV is characterized by a vigorous expansion of antiviral CTL and 
persistence of protective memory CTL (Wherry and Ahmed, 2004; Zinkernagel, 2002) which are 
directed against several epitopes. Two different epitopes are present in the gp33-41 region of the 
LCVM-GP that has been used in two of our constructs: the H2-D
b
 binding gp33-41 (Pircher et al., 
1990) and the H2-K
b
 binding gp34-41 (Hudrisier et al., 1997).  
 
 
 
Figure 3. Evaluation of antiviral CD8
+
 T cell responses. (A) B6 mice were infected i.v. with either 200 pfu LCMV 
as a control for vigorous CTL induction, 10
5
 pfu MHV-GP, or 10
5
 pfu MHV-GM/GP. At day 7 after infection 
splenocytes were analyzed for expression of CD8 and reactivity with H2-D
b
/gp33-, and H2-K
b
/gp34-tetramers. 
CD8
+
 splenocytes were also analyzed for gp33- and gp34-specific IFN- production. Values in the upper right 
quadrants represent percentages of tet
+
 cells SD (upper row) or percentages of IFN-+ cells  SD (lower row) in the 
CD8 T-cell compartment (n = 3 mice per group). (B) Efficacy of MHV-based vectors in inducing antiviral CD8
+
 T 
cell responses. B6 mice were immunized i.v. with the indicated doses of MHV-GP or MHV-GM/GP and the 
percentage of H2-K
b
/gp34-tetramer-binding CD8
+
 T cells, and the percentage of gp34-specific IFN- producing 
CD8
+
 T cells was determined on day 7 post immunization (n=6 mice per group, pooled from 2 different 
experiments). (C) Importance of the route on immunization. B6 mice were immunized with 10
5
 pfu MHV-GM/GP 
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and the percentage of H2-K
b
/gp34-tetramer-binding CD8
+
 T cells, and the percentage of gp34-specific IFN- 
producing CD8
+
 T cells was determined on day 7 post immunization (n=2-6 mice per group, pooled from 2 different 
experiments). 
 
On day 7 post LCMV infection, significant numbers of CD8
+
 T cells can be detected by 
MHC tetramer analysis and intracellular cytokine secretion (ICS) assay (Fig. 3a). It is important 
to note that the gp33 ICS records both gp33- and gp34-specific CD8
+
 T cells. It appears that the 
processing of the GP-GFP transgene in the MHV-GP and MHV-GM/GP vectors permitted the 
preferential generation of gp34-specific CD8
+
 T cells in a magnitude comparable to that seen 
during acute LCMV infection (Fig. 3a). The GM-CSF encoding MHV vector proved to be highly 
efficient in the induction of antiviral CTL, even at rather low doses of 10
4
 pfu (Fig. 4b). Since 
the intermediate dose of 10
5
 pfu of MHV-GM/GP led to optimal induction of gp34-specific CTL, 
we used this dose to assess whether application via different routes would influence the 
induction of transgene-specific CTL. As shown in Fig. 3c, all routes of immunization elicited 
robust CD8
+
 T cell responses with s.c., i.m., and i.v. application being the most efficient means 
of application.  
Protection against LCMV challenge requires high levels of appropriately activated CD8
+
 
T cells (Wherry et al., 2003; Zinkernagel, 2002). In order to assess the efficacy of MHV vector-
based immunization for protection against viral challenge, B6 mice were immunized with graded 
doses of MHV-GP or MHV-GM/GP vectors and challenged 7 d later with LCMV. Comparable 
to the high efficiency of CD8
+
 T cell induction (Fig. 3), mice were completely protected at a 
dose of 10
5
 pfu (Fig. 4a). Remarkably, as few as 10
3
 pfu of MHV-GM/GP led to a >3 log 
reduction of LCMV titers in spleens on day 4 post challenge (Fig. 4a). Protection against LCMV 
challenge was long-lasting because mice were still completely protected on day 65 post 
immunization with 10
5
 pfu MHV-GM/GP (Fig. 4b). Moreover, the MHV-GM/GP vaccine 
elicited complete protection against i.p. challenge with LCMV-GP recombinant vaccinia virus 
(Fig. 4c). Likewise, immunization with MHV-GP provided a substantial protection against this 
heterologous viral infection (Fig. 4c). It is important to indicate that the MHV-based vaccine, 
even when GM-CSF was encoded by the vector, provided specific protection because replication 
of the unrelated VSV-G recombinant vaccinia virus (VV-INDG) was not affected (Fig. 4c).  
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Figure 4. Induction of long-lasting protective immunity. (A) B6 mice were either left untreated (CTRL) or 
immunized (i.v.) with the indicated doses of MHV-GP or MHV-GM/GP. Seven days later, mice were challenged 
i.v. with 200 pfu LCMV-WE. Viral titers in spleens (means ±SEM) were determined 4 days after LCMV-WE 
challenge using focus-forming assay of MC57 cells (n = 4-6 mice per group, pooled from 2 different experiments). 
(B) Duration of protective antiviral immunity. B6 mice were immunized with 10
5
 pfu MHV-GM/GP and challenged 
i.v. with 200 pfu LCMV-WE at the indicated time points Viral titers in spleens (means ±SEM) were determined 4 
days after LCMV-WE challenge using focus-forming assay of MC57 cells (n = 4-6 mice per group). (C) Female B6 
mice were either left untreated (CTRL) or immunized (i.v.) with the 10
5
 pfu MHV-GP or 10
5
 pfu MHV-GM/GP. 
Seven days later, mice were challenged i.p. with 2×10
6
 pfu LCMV-GP recombinant (VV-G2), or vesicular 
stomatitis virus glycoprotein recombinant (VV-INDG) vaccinia viruses. Vaccina virus titers (means ±SEM) in 
ovaries were determined 5 days after challenge infection (n = 6 mice per group, pooled from 2 different 
experiments). 
 
Taken together, these results revealed that the MHV-based vector system is highly 
efficient in generating protective antiviral immunity and that the incorporation of GM-CSF into 
the vaccine significantly augmented its immunogenicity, most likely via the activation of DCs 
(Fig. 2f). 
 
Prophylactic and therapeutic antitumour immunization 
In order to evaluate whether MHV vector-based vaccination elicits prophylactic and 
therapeutic tumour immunity, we resorted to a rapidly growing B16 melanoma model which 
provides compatibility with the LCMV-GP system through expression of a gp33 minigene 
(B16F10-GP) (Prevost-Blondel et al., 1998). I.v. injection of 5×10
5
 B16F10-GP or parental 
B16F10 cells in control B6 mice resulted in metastatic growth of tumour cells in lungs (Fig. 5a).  
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Figure 5. Prevention and immunotherapeutical treatment of metastatic melanoma. (A) B6 mice were either left 
untreated (CTRL) or immunized (i.v.) with either 10
5
 pfu MHV-GP or MHV-GM/GP. Seven days later, mice were 
challenged with 5×10
5
 LCMV gp33-recombinant B16F10-GP tumour cells or parental B16F10 tumours cells i.v. 
Tumor growth in lungs was recorded on day 12 post tumour challenge. Macroscopic pictures show representative 
lungs from 1 out of 3 mice per group. (B) Efficacy of MHV-based vectors in generating prophylactic tumour 
immunity. B6 mice were immunized i.v. with the indicated doses of MHV-GP or MHV-GM/GP and challenged 8 
days later with 5×10
5
 LCMV gp33-recombinant B16F10-GP tumour cells. Numbers of lung foci were determined 
on day 12. Data indicate means ±SEM (n=6 mice per group, pooled from 2 different experiments). (C) Duration of 
protective antitumour immunity. B6 mice were immunized with 10
5
 pfu MHV-GM/GP and challenged at the 
indicated time points with 5×10
5
 LCMV gp33-recombinant B16F10-GP tumour cells. Numbers of lung foci were 
determined on day 12 with data indicate means ±SEM (n=4-6 mice per group, pooled from 2 different experiments). 
(D) Therapeutic antitumour immunity. B6 mice received 5×10
5
 LCMV gp33-recombinant B16F10-GP tumour cells 
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i.v. and were immunized with 10
5
 pfu MHV-GM/GP i.v. either at the same day (day 0), or 4 or 8 days later. 
Numbers of lung foci were determined on day 12 post tumour inoculation; data indicate means ±SEM (n=4-6 mice 
per group, pooled from 2 different experiments). Statistical analysis was performed using Student's t test (***, 
p<0.001; **, p<0.01; *, p<0.05; ns, p>0.05). ND, not detectable. 
 
 
Immunization with either 10
5
 pfu MHV-GP or 10
5
 pfu MHV-GM/GP resulted in a 
complete block of B16F10-GP growth, whereas metastasis formation of the parental B16F10 
cells was not affected (Fig. 5a). Application of graded doses of MHV-GP or MHV-GM/GP 
revealed the high efficacy of this vaccination approach in the prophylactic setting, i.e. 10
4
 MHV-
GP or only 10
3
 pfu MHV-GM/GP were sufficient to completely block growth of the melanoma 
cells (Fig. 5b). A long-lasting memory response had been generated following MHV-GM/GP 
immunization that provided full protection against B16F10-GP challenge (Fig. 5c). Moreover, 
the potent CD8
+
 T cell response elicited through MHV-GM/GP immunization mediated 
therapeutic tumour immunity (Fig. 5d), i.e. the tumour burden in lungs of B6 mice was 
significantly reduced even when the vaccine was applied after the tumours had started to form 
metastatic nodules, indicating that CD8
+
 T cell responses elicited by the novel MHV vectors can 
exert forceful antitumour activity. 
To further substantiate the finding that MHV vectors can induce potent and relevant 
antitumour CD8
+
 T cell responses, we employed the human HLA-A2-restricted Melan-
A/MART1 system where immune responses against the Mel-A26-35A27L analog peptide 
(Valmori et al., 1999) can be followed in HLA-A2.1 transgenic (A2DR1) mice (Pajot et al., 
2004). A2DR1 mice were immunized i.v. with either 10
5
 pfu MHV-MelA or 10
5
 pfu MHV-
GM/MelA, and Mel-A-specific CD8
+
 T cell responses were recorded using tetramer analysis and 
ICS. As shown in Fig. 6a, both vectors elicited substantial CD8
+
 T cell responses. Time course 
experiments following i.v. application of MHV-GM/MelA revealed a strong global expansion of 
CD8
+
 T cells (nearly 10-fold) and a massive expansion of Mel-A-specific CD8
+
 T cells with 
6×10
6
 cells per spleen being tetramer-positive and 2×10
6
 cells per spleen secreting IFN- 
following short-term in vitro restimulation (Fig. 6b). The Mel-A-specific CD8
+
 T cell population 
showed a typical contraction after day 7 and a stable memory population on day 28 post 
immunization (Fig. 6b). During the acute phase following MHV-GM/GP immunization, >90% 
of the Mel-A-specific CD8
+
 T cells had down-regulated CD62L (Fig. 6c). As expected, memory 
CD8
+
 T cell re-acquired CD62L-expression indicating establishment of a central memory CD8
+
 
T cell population. Overall, these results underline that the coronavirus-based vaccination 
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approach, particularly in combination with the immunostimulatory cytokine GM-CSF, provides 
efficient means for the induction of protective CD8
+
 T cell responses. 
 
 
 
Figure 6. Assessment of anti-Melan-A/MART1 CD8
+
 T cells in A2DR1 mice. (A) Transgenic mice expressing the 
human HLA-A2.1 molecule were immunized i.v. with 10
5
 pfu MHV-MelA or MHV-GM/MelA. At day 7 post 
infection, splenocytes and mononuclear blood cells were analyzed for expression of CD8 and reactivity with HLA-
A2/Mel-A26-35A27L tetramers, and for Mel-A26-35A27L-specific IFN- production. Values in the upper right 
quandrants represent mean percentages of tet
+
 cells SD in blood and spleen, or percentages of IFN-+ cells  SD  in 
the CD8+ T-cell compartment (n = 3 mice per group). (B) Time course of Mel-A26-35A27L-specific CD8
+
 T-cell 
responses in A2DR1 mice following i.v. immunization with 10
5
 pfu MHV-GM/MelA. Total numbers of CD8
+
 T-
cells, tetramer-binding Mel-A26-35A27L-specific CD8
+
 T-cells, and Mel-A26-35A27L-specific IFN-
+
CD8
+
 T-cells 
cells were determined at the indicated time points post immunization (means SD, n = 3 mice per group). (C) 
Differentiation of tetramer-binding Mel-A26-35A27L-specific CD8
+
 T-cells as determined by CD62L expression at 
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the indicated time points post immunization (means SD, n = 3 mice per group). Data in A-C are from one 
representative experiment out of three. 
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Discussion 
 
This study describes a novel vaccination approach that facilitates delivery of viral or 
tumour antigens to DCs in vivo. Concomitant immunostimulation – here via the cytokine GM-
CSF – was achieved through targeted delivery by the same viral vector. Single immunization 
with only 10
4
 – 105 particles was sufficient to elicit (i) vigorous expansion and optimal 
differentiation of CD8
+
 T cells, (ii) protective and long-lasting antiviral immunity, (iii) 
prophylactic and therapeutic tumour immunity.  
Targeting of antigen to DCs in vivo can be achieved by several means (Tacken et al., 
2007) whereby the use of viral vectors appears to be the superior strategy to elicit innate 
activation of the immune system and optimal induction CD8
+
 T cells. However, many virus 
vector systems are still limited in their ability to induce broad and long-lasting immune 
responses. For example, recombinant adenoviruses have been studied intensively as vaccine 
candidates mainly because they can be produced to high titers. Nevertheless, high doses of 
recombinant adenovirus vectors have to be applied to induce an immune response, most 
probably because they target antigens mainly to non-lymphoid organs such as the liver 
(Engelhardt et al., 1994; Yang et al., 2006). In contrast to viral vectors based on DNA viruses 
(Trono, 2003), positive-stranded RNA virus-based vectors that replicate in the cytoplasm are 
considered as safe vectors. The safety is well documented for vectors based on widely used 
vaccine strains such as poliovirus (Crotty et al., 1999) or virus like particles (VLPs) that contain 
replicon RNAs devoid of structural genes (Davis et al., 2000; Harvey et al., 2003). Although 
some of these vectors are able to target DC, their cloning capacity is generally restricted and the 
expression of multiple tumour antigens and/or immunostimulatory cytokines is limited.  
A number of reasons probably account for the high potency of the novel coronavirus-
based vaccine. Following the reasoning of several recent publications (Hickman et al., 2008; Junt 
et al., 2007; Junt et al., 2008), it is the pronounced tropism of the MHV-based vectors for 
transduction of not only DCs, but also macrophages within secondary lymphoid organs that 
guarantees efficient activation of primary CD8
+
 T cell responses. In vivo imaging studies have 
shown that CD169
+
CD11c
+
 DCs at the subcapsular sinus of lymph nodes efficiently present viral 
antigen to naïve T cells (Hickman et al., 2008). Likewise, CD169
+ 
macrophages at the same 
location are able to collect viral antigen from the lymph and present antigen to follicular B cells 
(Junt et al., 2007). Morevover, a recent study from our laboratory has revealed that type IFN-
mediated protection of DCs and macrophages from cytopathic effects of MHV infection is 
essential to buy time for mounting a protective CD8
+
 T cell response (Cervantes-Barragan, in 
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press). It remains to be resolved which factors – besides the presence of the MHV receptor on 
DCs (Zhou and Perlman, 2006) – confers the preferential infection of the relevant antigen 
presenting cells within secondary lymphoid organs. For the further adaptation of the coronavirus-
based vectors to the human system, some of the essential parameters have been clarified, i.e. the 
receptor of HCoV 229E is expressed mainly on monocytes and DCs within secondary lymphoid 
organs (Summers et al., 2001) and recombinant HCoV 229E transduces human DCs irrespective 
of their maturation status (Thiel et al., 2003).  
A second major advantage of the coronavirus-based vaccination strategy is the large 
cloning capacity that offers the possibility to incorporate immunostimulatory cytokines. GM-
CSF encoding MHV-based vectors led to strong production of this cytokine in both macrophages 
and DCs in vitro. In vivo, however, GM-CSF expression appeared to be restricted to locally 
transduced cells since elevated GM-CSF levels could be observed neither in sera, nor in spleen 
homogenates of i.v. immunized animals (data not shown). It is most likely that GM-CSF-induced 
changes within the microenvironment of transduced macrophages and DCs are decisive for the 
optimal induction of maximal effector and memory CD8
+
 T cell responses. Indeed, it is the 
optimally stimulated expression of co-stimulatory molecules on antigen presenting cells such as 
DCs and macrophages together with sufficient innate immune stimulation, that determines the 
primary expansion and the maintenance of antiviral CD8
+
 T cells (Harty and Badovinac, 2008). 
Accordingly, such non-TCR signals (“signal 2 and 3”) are considered as key components of 
rationally designed vaccines (Appay et al., 2008). The lack of such optimally composed stimuli 
in a vector-based vaccine most likely requires substantially increased doses to achieve efficacy, 
as for example in vaccination with latest versions of DC-adapted lentivirus vectors: application 
or 5–10×107 particles was required to achieve significant expansion of ovalbumin-specific CD8+ 
T cells (Yang et al., 2008).  
Taken together, the efficient generation of protective immunity by the coronavirus-based 
vaccine, shown as long-lasting memory against viral challenge and induction of both 
prophylactic and therapeutic tumour immunity, indicates that this inherently safe RNA viral 
vector-strategy harbors a great potential for future development. 
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7 Discussion and future direction  
The modification of attenuated viruses and bacteria to carry genes encoding antigenic-
proteins from other pathogenic organisms in their genome is greatly facilitated by the 
identification and availability of immunogenic antigens. Vectors provide an efficient means to 
deliver antigens from pathogens which themselves might be considered as high risk despite 
attenuation and hence may never be allowed for vaccination. Viral vectors provide several 
advantages over naked nucleic acid and immunogenic peptides in their heightened strategy to 
deliver antigens and or cytokines to specific target cells. For some reasons however, many viral 
vectors are still limited in their ability to induce a broad and long-lasting immune response. 
Furthermore the safety concerns of DNA based vectors such as adeno-associated, retroviral or 
lentiviral vectors raise a number of questions with regards to integration and possible 
modification of the host cell genome (Dobbelstein, 2003; Trono, 2003). Though recombinant 
adenoviruses have been extensively studied because they easily yield high titers, the extremely 
high doses required for immunization in order to induce an immune response indicate that they 
may be targeting their genetic load to the wrong organs such as the liver (Engelhardt et al., 1994; 
Yang et al., 2006). In principle the use of positive stranded-RNA vectors with a replication that 
is completely restricted to the cytosol of the infected cells is considered very safe because it is 
unlikely that viral derived sequences integrate into the host cell genome. Additionally, this safety 
profile is properly substantiated for vectors based on widely used vaccine strains like poliovirus 
(Crotty et al., 1999) or VLPs that are devoid of all structural genes and contain only replicon 
RNAs. Furthermore several such vectors can target their genetic load to DCs but their limited 
cloning capacity may be a handicap restricting the cloning and simultaneous expression of 
multiple antigens. Coronaviruses possess a number of intrinsic properties making them to pose 
as very promising vaccine vector candidates. 
7.1 What has been done 
We have developed a new class of multigene-RNA vaccine vectors based on mouse 
hepatitis coronavirus. The successfull rescue of these vectors necessitates a special packaging 
cell line that is capable of providing the necessary structural protein(s) needed for efficient 
propagation in trans. We could demonstrate efficient targeting of pAPCs such as dendritic cells 
and macrophages. Vector-mediated heterologous protein expression in the target cells was 
evaluated using standard protocols. This efficient targeting and antigen expression provides the 
proof of principle that it is possible to insert the antigen of interest in MHV-based vector genome 
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and efficiently target the genetic cargo to professional determinants of the immune response. 
Furthermore, these MHV-based VLPs have demonstrated a very strong and specific induction of 
CTL-responses towards the encoded GP33 CTL epitope as well as towards the human melan-A 
CTL epitope. 
The specific CTL response induced by MHV-based VLPs was very high after a single 
immunization with only 10
5
 VLPs as compared to other vector systems like the modified 
vaccinia Ankara (MVA) wherein doses of 10
7
-10
8
 particles are usually utilized to achieve a 
much lower response. In fact vaccine strategies such as those based on attenuated vaccinia 
recombinant NYVAC (Tartaglia et al., 1992) and the modified vaccinia Ankara have entered into 
several clinical trials. Foreign genes such as those for HIV env or gag-pol are encoded by these 
vectors (Robinson et al., 2006); however, clinical trials have indicated that several vectors and 
adjuvants may be needed to achieve efficacious responses in humans towards the encoded 
antigens (Cebere et al., 2006; Mwau et al., 2004; Robinson et al., 2006). Additionally, lentivirus 
based vector particle expressing the same human melan-A CTL epitope as encoded in MHV-
based VLPs, needed 4 x10
6
 particles to achieve a very low CTL response as against the single 
dose of 10
5
 MHV-based VLPs.  
The stringency for vaccine safety has resulted in several viral vaccine vectors with only 
very low immunogenicity necessitating in most cases two to three boosts in order to increase 
potency (Cebere et al., 2006). Therefore, these MHV-based vectors reported here have been 
designed to demonstrate a high biosafety profile when compared to attenuated viral vaccines. 
Furthermore, we did not employ any boosting regimen simply because the immune response 
observed was strong enough to provide complete protection against a pathogenic high dose virus 
challenge and against a lethal rapidly metastasizing tumour model.  
Several optimization strategies exist to increase the immunogenicity of a viral vaccine 
vector in addition to altering the vector itself. For instance immunogenicity can be improved 
following a careful systematic evaluation of critical steps such as (i) the route and method of 
vaccine delivery (ii) the number of vaccinations and their timing (iii) the dose utilized and lastly 
(iv) the choice of adjuvant which may make a difference. In this study, we have examined the 
outcome of different routes of immunization using MHV-based VLPs and the observed result 
demonstrated that we could virtually immunize by any of the chosen routes and the induction of 
immune response will be equally protective. Amazing, is the fact that, our system induces one of 
the highest immune induction using the intramuscular or intravenous routes. It must be stressed 
here that in human immunizations strategies the intramuscular as well as intravenous routes are 
the most preferred vaccination routes in standard protocols. 
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In fact, the expression of the cytokine GM-CSF in our constructs indicated enhanced T 
cell response as compared to vectors that do not encode this cytokine. This means the 
manipulation of the immune outcome is possible especially in a situation where we are able to 
effectively target the vaccine to specific immune activators such as DCs and macrophages. 
Additionally, we will exploit this system by using different cytokines either on their own or in 
combination to induce maturation and influence the stimulatory capacity of specific immune 
components. 
The maturation and proper stimulation of T cells is crucial for the generation of potent T 
cell responses (Steinman et al., 2003) meanwhile the ability of DCs to drive antigen-specific 
immunity can be modulated by adjuvants. Furthermore, most adjuvants work through the 
activation of innate immune activators such as NK cells and DCs. For instance, Toll-like 
receptor (TLRs) ligands such as bacteria DNA are capable of stimulating DCs (Sparwasser et al., 
1998) leading to a more improved activation of tumour specific CTL response (Ludewig et al., 
2000). A major setback of TLR ligands as immunological adjuvants is their broad and systemic 
activity that may cause unwanted side effects (Heikenwalder et al., 2004). Cytokines on the other 
hand are molecules having well defined effects on both the innate and adaptive immune cells. In 
fact GM-CSF is an important mediator of DC maturation (Heufler et al., 1988) and survival 
(Witmer-Pack et al., 1987). Furthermore the fms-liks tyrosine kinase 3-ligand (Flt3-L) is a 
cytokine with strong stimulatory effect leading to DC proliferation and accumulation in vivo 
(Maraskovsky et al., 1996). Interestingly both GM-CSF (Chiodoni et al., 1999; Nakamura et al., 
2002) and Flt3-L (Lynch et al., 1997) have been used successfully as adjuvants in antitumour 
vaccine. Other cytokines function more downstream of the immune activation cascade. The T 
cell stimulatory cytokines IL-2 and IL-15 for instance, are known to enhance proliferation of T 
cells as well as facilitate the differentiation of CTL. However, there are distinct points of action 
where these cytokines impact on T cell differentiation despite sharing a common gamma chain 
and the IL-2/IL-15 receptor. IL-2 is highly important during the early expansion of T cells and 
through activation induced cell death it leads to the limitation of the T cell overshoot (Marks-
Konczalik et al., 2000). IL-15 on its part is important for the survival of high-affinity T cells 
during the memory phase (Ku et al., 2000) and thereby ensures the maintenance of protective T 
cell memory response. Therefore, it is very important to note that both IL-2 and IL-15 are highly 
efficient adjuvants that greatly enhance tumour-specific T cell responses (Waldmann, 2006). The 
generation of highly efficient T cell responses is possible if these cytokines are incorporated 
either singly or in combination as adjuvants in an antigen-specific tumour vaccine. Using the 
MHV-based vector system reported here for example, we will clone various cytokines into the 
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vector genome and we will systematically study their specific effects and in addition assess any 
synergistic effects on immunologically important target cells. 
7.2 Possible way out of vector-mediated neutralizing antibody or pre-existing immunity 
Significant efforts are being expended to demonstrate whether the pre-existing immunity 
weakens the effectiveness of vectors such as with adenovirus-based vectors. For instance, the 
adenovirus serotype 5 is the most explored in terms of vaccine vectors but the seroprevalence in 
the world is high against this particular type of the virus (Shiver and Emini, 2004). Since our 
vaccine strategy is based on a mouse pathogen, we strongly believe that there is no pre-existing 
immunity in the human population towards this virus. Tropism and species specificity is dictated 
by the coronavirus spike glycoprotein therefore, the humanization of the MHV-based VLPs to 
target human cells will necessitate the altering of the MHV spike protein by chimerisation. This 
will be achieved by exchanging the ectodomain of the MHV spike protein with that of a potential 
HCoV with the lowest prevalence in the human population. Employing the strategy of swapping 
the ectodomain of the MHV-based VLPs with that of a HCoV, we can additionally, avoid vector-
mediated neutralizing antibodies in case a boost is absolutely needed. Furthermore, since 
coronaviruses are responsible for most of the human common cold, a mucosal administration of 
humanized particles could be considered as a strategy to overcome systemic antivector 
preimmunity. In fact mucosal administration of measles and measles-rubella vaccines has been 
demonstrated to be safe and more efficient than subcutaneous vaccination in preimmunized 
humans (Dilraj et al., 2000; Gans et al., 2003).  
7.3 Relevance of this work to science 
This study has demonstrated that the generation of coronavirus-based-VLPs is feasible and that 
the transgenes expressed by these replication-competent but propagation deficient vectors can be 
targeted to DCs and the resulting immune response is protective. Furthermore, MHV being the 
most studied coronavirus in the laboratory coupled to the availability of a variety of properly 
characterized small animal models (the mice) and the demonstration that MHV-based VLPs can 
infect murine DCs, indicate that this model will serve as a valuable tool for the development, 
evaluation and characterization of coronavirus-based vaccine vectors geared towards human 
disease. 
126
                                                                                                                                                  Appendix 
 
8 Apendix 
8.1 References 
Abbas, A.K., Murphy, K.M., and Sher, A. (1996). Functional diversity of helper T lymphocytes. 
Nature 383, 787-793. 
Akira, S. (2004). Toll receptor families: structure and function. Semin Immunol 16, 1-2. 
Almazan, F., Gonzalez, J.M., Penzes, Z., Izeta, A., Calvo, E., Plana-Duran, J., and Enjuanes, L. (2000). 
Engineering the largest RNA virus genome as an infectious bacterial artificial chromosome. Proc Natl 
Acad Sci U S A 97, 5516-5521. 
Alonso, S., Izeta, A., Sola, I., and Enjuanes, L. (2002a). Transcription regulatory sequences and mRNA 
expression levels in the coronavirus transmissible gastroenteritis virus. J Virol 76, 1293-1308. 
Alonso, S., Sola, I., Teifke, J.P., Reimann, I., Izeta, A., Balasch, M., Plana-Duran, J., Moormann, R.J., 
and Enjuanes, L. (2002b). In vitro and in vivo expression of foreign genes by transmissible gastroenteritis 
coronavirus-derived minigenomes. J Gen Virol 83, 567-579. 
Arlen, P.M., Kaufman, H.L., and DiPaola, R.S. (2005). Pox viral vaccine approaches. Semin Oncol 32, 
549-555. 
Asensio, V.C., and Campbell, I.L. (1997). Chemokine gene expression in the brains of mice with 
lymphocytic choriomeningitis. J Virol 71, 7832-7840. 
Ashley, D.M., Faiola, B., Nair, S., Hale, L.P., Bigner, D.D., and Gilboa, E. (1997). Bone marrow-
generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against 
central nervous system tumors. J Exp Med 186, 1177-1182. 
Bachmann, M.F., and Zinkernagel, R.M. (1996). The influence of virus structure on antibody responses 
and virus serotype formation. Immunol Today 17, 553-558. 
Bachmann, M.F., and Zinkernagel, R.M. (1997). Neutralizing antiviral B cell responses. Annu Rev 
Immunol 15, 235-270. 
Banchereau, J., Bazan, F., Blanchard, D., Briere, F., Galizzi, J.P., van Kooten, C., Liu, Y.J., Rousset, F., 
and Saeland, S. (1994). The CD40 antigen and its ligand. Annu Rev Immunol 12, 881-922. 
Banchereau, J., and Palucka, A.K. (2005). Dendritic cells as therapeutic vaccines against cancer. Nat Rev 
Immunol 5, 296-306. 
Banchereau, J., Schuler-Thurner, B., Palucka, A.K., and Schuler, G. (2001). Dendritic cells as vectors for 
therapy. Cell 106, 271-274. 
Banchereau, J., and Steinman, R.M. (1998). Dendritic cells and the control of immunity. Nature 392, 245-
252. 
Barro, M., and Patton, J.T. (2007). Rotavirus NSP1 inhibits expression of type I interferon by 
antagonizing the function of interferon regulatory factors IRF3, IRF5, and IRF7. J Virol 81, 4473-4481. 
127
                                                                                                                                                  Appendix 
 
Barthold, S.W., Beck, D.S., and Smith, A.L. (1993). Enterotropic coronavirus (mouse hepatitis virus) in 
mice: influence of host age and strain on infection and disease. Lab Anim Sci 43, 276-284. 
Barton, G.M., and Medzhitov, R. (2002). Toll-like receptors and their ligands. Curr Top Microbiol 
Immunol 270, 81-92. 
Baudoux, P., Carrat, C., Besnardeau, L., Charley, B., and Laude, H. (1998). Coronavirus pseudoparticles 
formed with recombinant M and E proteins induce alpha interferon synthesis by leukocytes. J Virol 72, 
8636-8643. 
Beauchemin, N., Draber, P., Dveksler, G., Gold, P., Gray-Owen, S., Grunert, F., Hammarstrom, S., 
Holmes, K.V., Karlsson, A., Kuroki, M., et al. (1999). Redefined nomenclature for members of the 
carcinoembryonic antigen family. Exp Cell Res 252, 243-249. 
Belay, E.D., Erdman, D.D., Anderson, L.J., Peret, T.C., Schrag, S.J., Fields, B.S., Burns, J.C., and 
Schonberger, L.B. (2005). Kawasaki disease and human coronavirus. J Infect Dis 192, 352-353; author 
reply 353. 
Bergelson, J.M., Cunningham, J.A., Droguett, G., Kurt-Jones, E.A., Krithivas, A., Hong, J.S., Horwitz, 
M.S., Crowell, R.L., and Finberg, R.W. (1997). Isolation of a common receptor for Coxsackie B viruses 
and adenoviruses 2 and 5. Science 275, 1320-1323. 
Bergmann, C., McMillan, M., and Stohlman, S. (1993). Characterization of the Ld-restricted cytotoxic T-
lymphocyte epitope in the mouse hepatitis virus nucleocapsid protein. J Virol 67, 7041-7049. 
Bergmann, C.C., Altman, J.D., Hinton, D., and Stohlman, S.A. (1999). Inverted immunodominance and 
impaired cytolytic function of CD8+ T cells during viral persistence in the central nervous system. J 
Immunol 163, 3379-3387. 
Bergmann, C.C., Parra, B., Hinton, D.R., Chandran, R., Morrison, M., and Stohlman, S.A. (2003). 
Perforin-mediated effector function within the central nervous system requires IFN-gamma-mediated 
MHC up-regulation. J Immunol 170, 3204-3213. 
Beutler, B., Hoebe, K., Du, X., and Ulevitch, R.J. (2003). How we detect microbes and respond to them: 
the Toll-like receptors and their transducers. J Leukoc Biol 74, 479-485. 
Blander, J.M., and Medzhitov, R. (2006). Toll-dependent selection of microbial antigens for presentation 
by dendritic cells. Nature 440, 808-812. 
Boczkowski, D., Nair, S.K., Snyder, D., and Gilboa, E. (1996). Dendritic cells pulsed with RNA are 
potent antigen-presenting cells in vitro and in vivo. J Exp Med 184, 465-472. 
Bos, E.C., Luytjes, W., van der Meulen, H.V., Koerten, H.K., and Spaan, W.J. (1996). The production of 
recombinant infectious DI-particles of a murine coronavirus in the absence of helper virus. Virology 218, 
52-60. 
Boscarino, J.A., Logan, H.L., Lacny, J.J., and Gallagher, T.M. (2008). Envelope protein palmitoylations 
are crucial for murine coronavirus assembly. J Virol 82, 2989-2999. 
Brave, A., Ljungberg, K., Wahren, B., and Liu, M.A. (2007). Vaccine delivery methods using viral 
vectors. Mol Pharm 4, 18-32. 
128
                                                                                                                                                  Appendix 
 
Bredenbeek, P.J., Noten, A.F., Horzinek, M.C., and Spaan, W.J. (1990). Identification and stability of a 
30-kDa nonstructural protein encoded by mRNA 2 of mouse hepatitis virus in infected cells. Virology 
175, 303-306. 
Brockway, S.M., and Denison, M.R. (2005). Mutagenesis of the murine hepatitis virus nsp1-coding 
region identifies residues important for protein processing, viral RNA synthesis, and viral replication. 
Virology 340, 209-223. 
Brooker, S., Clements, A.C., and Bundy, D.A. (2006). Global epidemiology, ecology and control of soil-
transmitted helminth infections. Adv Parasitol 62, 221-261. 
Brossart, P., Zobywalski, A., Grunebach, F., Behnke, L., Stuhler, G., Reichardt, V.L., Kanz, L., and 
Brugger, W. (2000). Tumor necrosis factor alpha and CD40 ligand antagonize the inhibitory effects of 
interleukin 10 on T-cell stimulatory capacity of dendritic cells. Cancer Res 60, 4485-4492. 
Burioni, R., Williamson, R.A., Sanna, P.P., Bloom, F.E., and Burton, D.R. (1994). Recombinant human 
Fab to glycoprotein D neutralizes infectivity and prevents cell-to-cell transmission of herpes simplex 
viruses 1 and 2 in vitro. Proc Natl Acad Sci U S A 91, 355-359. 
Butcher, E.C., Williams, M., Youngman, K., Rott, L., and Briskin, M. (1999). Lymphocyte trafficking 
and regional immunity. Adv Immunol 72, 209-253. 
Campbell, E.M., Kunkel, S.L., Strieter, R.M., and Lukacs, N.W. (1998). Temporal role of chemokines in 
a murine model of cockroach allergen-induced airway hyperreactivity and eosinophilia. J Immunol 161, 
7047-7053. 
Campbell, J.J., and Butcher, E.C. (2000). Chemokines in tissue-specific and microenvironment-specific 
lymphocyte homing. Curr Opin Immunol 12, 336-341. 
Campbell, J.J., Murphy, K.E., Kunkel, E.J., Brightling, C.E., Soler, D., Shen, Z., Boisvert, J., Greenberg, 
H.B., Vierra, M.A., Goodman, S.B., et al. (2001). CCR7 expression and memory T cell diversity in 
humans. J Immunol 166, 877-884. 
Carrat, F., and Flahault, A. (2007). Influenza vaccine: the challenge of antigenic drift. Vaccine 25, 6852-
6862. 
Caux, C., Ait-Yahia, S., Chemin, K., de Bouteiller, O., Dieu-Nosjean, M.C., Homey, B., Massacrier, C., 
Vanbervliet, B., Zlotnik, A., and Vicari, A. (2000). Dendritic cell biology and regulation of dendritic cell 
trafficking by chemokines. Springer Semin Immunopathol 22, 345-369. 
Cavanagh, D., Brian, D.A., Enjuanes, L., Holmes, K.V., Lai, M.M., Laude, H., Siddell, S.G., Spaan, W., 
Taguchi, F., and Talbot, P.J. (1990). Recommendations of the Coronavirus Study Group for the 
nomenclature of the structural proteins, mRNAs, and genes of coronaviruses. Virology 176, 306-307. 
Cebere, I., Dorrell, L., McShane, H., Simmons, A., McCormack, S., Schmidt, C., Smith, C., Brooks, M., 
Roberts, J.E., Darwin, S.C., et al. (2006). Phase I clinical trial safety of DNA- and modified virus Ankara-
vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-
boost regime to healthy HIV-1-uninfected volunteers. Vaccine 24, 417-425. 
129
                                                                                                                                                  Appendix 
 
Cella, M., Salio, M., Sakakibara, Y., Langen, H., Julkunen, I., and Lanzavecchia, A. (1999). Maturation, 
activation, and protection of dendritic cells induced by double-stranded RNA. J Exp Med 189, 821-829. 
Cervantes-Barragan, L., Zust, R., Weber, F., Spiegel, M., Lang, K.S., Akira, S., Thiel, V., and Ludewig, 
B. (2007). Control of coronavirus infection through plasmacytoid dendritic-cell-derived type I interferon. 
Blood 109, 1131-1137. 
Chen, S.T., Iida, A., Guo, L., Friedmann, T., and Yee, J.K. (1996). Generation of packaging cell lines for 
pseudotyped retroviral vectors of the G protein of vesicular stomatitis virus by using a modified 
tetracycline inducible system. Proc Natl Acad Sci U S A 93, 10057-10062. 
Chesnut, R.W., and Grey, H.M. (1981). Studies on the capacity of B cells to serve as antigen-presenting 
cells. J Immunol 126, 1075-1079. 
Chiodoni, C., Paglia, P., Stoppacciaro, A., Rodolfo, M., Parenza, M., and Colombo, M.P. (1999). 
Dendritic cells infiltrating tumors cotransduced with granulocyte/macrophage colony-stimulating factor 
(GM-CSF) and CD40 ligand genes take up and present endogenous tumor-associated antigens, and prime 
naive mice for a cytotoxic T lymphocyte response. J Exp Med 190, 125-133. 
Chunling, M., Kun, Y., Jian, X., Jian, Q., Hua, S., and Minsheng, Z. (2006). Enhanced induction of 
SARS-CoV nucleocapsid protein-specific immune response using DNA vaccination followed by 
adenovirus boosting in BALB/c mice. Intervirology 49, 307-318. 
Coley, S.E., Lavi, E., Sawicki, S.G., Fu, L., Schelle, B., Karl, N., Siddell, S.G., and Thiel, V. (2005). 
Recombinant mouse hepatitis virus strain A59 from cloned, full-length cDNA replicates to high titers in 
vitro and is fully pathogenic in vivo. J Virol 79, 3097-3106. 
Constant, S.L. (1999). B lymphocytes as antigen-presenting cells for CD4+ T cell priming in vivo. J 
Immunol 162, 5695-5703. 
Corse, E., and Machamer, C.E. (2000). Infectious bronchitis virus E protein is targeted to the Golgi 
complex and directs release of virus-like particles. J Virol 74, 4319-4326. 
Corse, E., and Machamer, C.E. (2002). The cytoplasmic tail of infectious bronchitis virus E protein 
directs Golgi targeting. J Virol 76, 1273-1284. 
Cox, J.C., and Coulter, A.R. (1997). Adjuvants--a classification and review of their modes of action. 
Vaccine 15, 248-256. 
Crotty, S., Lohman, B.L., Lu, F.X., Tang, S., Miller, C.J., and Andino, R. (1999). Mucosal immunization 
of cynomolgus macaques with two serotypes of live poliovirus vectors expressing simian 
immunodeficiency virus antigens: stimulation of humoral, mucosal, and cellular immunity. J Virol 73, 
9485-9495. 
Culp, T.D., Budgeon, L.R., and Christensen, N.D. (2006). Human papillomaviruses bind a basal 
extracellular matrix component secreted by keratinocytes which is distinct from a membrane-associated 
receptor. Virology 347, 147-159. 
Curtis, K.M., Yount, B., and Baric, R.S. (2002). Heterologous gene expression from transmissible 
gastroenteritis virus replicon particles. J Virol 76, 1422-1434. 
130
                                                                                                                                                  Appendix 
 
Daniel, C., Anderson, R., Buchmeier, M.J., Fleming, J.O., Spaan, W.J., Wege, H., and Talbot, P.J. (1993). 
Identification of an immunodominant linear neutralization domain on the S2 portion of the murine 
coronavirus spike glycoprotein and evidence that it forms part of complex tridimensional structure. J 
Virol 67, 1185-1194. 
Daniel, C., Lacroix, M., and Talbot, P.J. (1994). Mapping of linear antigenic sites on the S glycoprotein 
of a neurotropic murine coronavirus with synthetic peptides: a combination of nine prediction algorithms 
fails to identify relevant epitopes and peptide immunogenicity is drastically influenced by the nature of 
the protein carrier. Virology 202, 540-549. 
Danthinne, X., and Imperiale, M.J. (2000). Production of first generation adenovirus vectors: a review. 
Gene Ther 7, 1707-1714. 
Davis, I.D., Jefford, M., Parente, P., and Cebon, J. (2003). Rational approaches to human cancer 
immunotherapy. J Leukoc Biol 73, 3-29. 
Davis, N.L., Caley, I.J., Brown, K.W., Betts, M.R., Irlbeck, D.M., McGrath, K.M., Connell, M.J., 
Montefiori, D.C., Frelinger, J.A., Swanstrom, R., et al. (2000). Vaccination of macaques against 
pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles. 
J Virol 74, 371-378. 
de Groot, R.J., ter Haar, R.J., Horzinek, M.C., and van der Zeijst, B.A. (1987). Intracellular RNAs of the 
feline infectious peritonitis coronavirus strain 79-1146. J Gen Virol 68 ( Pt 4), 995-1002. 
de Haan, C.A., Masters, P.S., Shen, X., Weiss, S., and Rottier, P.J. (2002a). The group-specific murine 
coronavirus genes are not essential, but their deletion, by reverse genetics, is attenuating in the natural 
host. Virology 296, 177-189. 
de Haan, C.A., Volders, H., Koetzner, C.A., Masters, P.S., and Rottier, P.J. (2002b). Coronaviruses 
maintain viability despite dramatic rearrangements of the strictly conserved genome organization. J Virol 
76, 12491-12502. 
De Jesus, N.H. (2007). Epidemics to eradication: the modern history of poliomyelitis. Virol J 4, 70. 
Delon, J., Bercovici, N., Raposo, G., Liblau, R., and Trautmann, A. (1998). Antigen-dependent and -
independent Ca2+ responses triggered in T cells by dendritic cells compared with B cells. J Exp Med 188, 
1473-1484. 
Denzel, A., Maus, U.A., Rodriguez Gomez, M., Moll, C., Niedermeier, M., Winter, C., Maus, R., 
Hollingshead, S., Briles, D.E., Kunz-Schughart, L.A., et al. (2008). Basophils enhance immunological 
memory responses. Nat Immunol 9, 733-742. 
Deregt, D., Sabara, M., and Babiuk, L.A. (1987). Structural proteins of bovine coronavirus and their 
intracellular processing. J Gen Virol 68 ( Pt 11), 2863-2877. 
Desai, D.D., Harbers, S.O., Flores, M., Colonna, L., Downie, M.P., Bergtold, A., Jung, S., and Clynes, R. 
(2007). Fc gamma receptor IIB on dendritic cells enforces peripheral tolerance by inhibiting effector T 
cell responses. J Immunol 178, 6217-6226. 
131
                                                                                                                                                  Appendix 
 
Dhodapkar, M.V., Steinman, R.M., Krasovsky, J., Munz, C., and Bhardwaj, N. (2001). Antigen-specific 
inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med 
193, 233-238. 
Dilraj, A., Cutts, F.T., de Castro, J.F., Wheeler, J.G., Brown, D., Roth, C., Coovadia, H.M., and Bennett, 
J.V. (2000). Response to different measles vaccine strains given by aerosol and subcutaneous routes to 
schoolchildren: a randomised trial. Lancet 355, 798-803. 
Dobbelstein, M. (2003). Viruses in therapy--royal road or dead end? Virus Res 92, 219-221. 
Dorries, R. (2001). The role of T-cell-mediated mechanisms in virus infections of the nervous system. 
Curr Top Microbiol Immunol 253, 219-245. 
Drosten, C., Gunther, S., Preiser, W., van der Werf, S., Brodt, H.R., Becker, S., Rabenau, H., Panning, 
M., Kolesnikova, L., Fouchier, R.A., et al. (2003). Identification of a novel coronavirus in patients with 
severe acute respiratory syndrome. N Engl J Med 348, 1967-1976. 
Dubois, S., Mariner, J., Waldmann, T.A., and Tagaya, Y. (2002). IL-15Ralpha recycles and presents IL-
15 In trans to neighboring cells. Immunity 17, 537-547. 
Dudek, T., and Knipe, D.M. (2006). Replication-defective viruses as vaccines and vaccine vectors. 
Virology 344, 230-239. 
Dudziak, D., Kamphorst, A.O., Heidkamp, G.F., Buchholz, V.R., Trumpfheller, C., Yamazaki, S., 
Cheong, C., Liu, K., Lee, H.W., Park, C.G., et al. (2007). Differential antigen processing by dendritic cell 
subsets in vivo. Science 315, 107-111. 
Dustin, M.L., and Cooper, J.A. (2000). The immunological synapse and the actin cytoskeleton: molecular 
hardware for T cell signaling. Nat Immunol 1, 23-29. 
Engelhardt, J.F., Ye, X., Doranz, B., and Wilson, J.M. (1994). Ablation of E2A in recombinant 
adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc 
Natl Acad Sci U S A 91, 6196-6200. 
Enjuanes, L., Sola, I., Almazan, F., Ortego, J., Izeta, A., Gonzalez, J.M., Alonso, S., Sanchez, J.M., 
Escors, D., Calvo, E., et al. (2001). Coronavirus derived expression systems. J Biotechnol 88, 183-204. 
Eriksson, K.K., Makia, D., Maier, R., Cervantes, L., Ludewig, B., and Thiel, V. (2006a). Efficient 
transduction of dendritic cells using coronavirus-based vectors. Adv Exp Med Biol 581, 203-206. 
Eriksson, K.K., Makia, D., Maier, R., Ludewig, B., and Thiel, V. (2006b). Towards a coronavirus-based 
HIV multigene vaccine. Clin Dev Immunol 13, 353-360. 
Eriksson, K.K., Makia, D., and Thiel, V. (2008). Generation of Recombinant Coronaviruses Using 
Vaccinia Virus as the Cloning Vector and Stable Cell Lines Containing Coronaviral Replicon RNAs. In 
SARS and Other Coronaviruses, D. Cavanagh, ed. (Humana Press). 
Esposito, J.J., and Murphy, F.A. (1989). Infectious recombinant vectored virus vaccines. Adv Vet Sci 
Comp Med 33, 195-247. 
Figdor, C.G., de Vries, I.J., Lesterhuis, W.J., and Melief, C.J. (2004). Dendritic cell immunotherapy: 
mapping the way. Nat Med 10, 475-480. 
132
                                                                                                                                                  Appendix 
 
Fischer, F., Stegen, C.F., Koetzner, C.A., and Masters, P.S. (1997). Analysis of a recombinant mouse 
hepatitis virus expressing a foreign gene reveals a novel aspect of coronavirus transcription. J Virol 71, 
5148-5160. 
Fischer, F., Stegen, C.F., Masters, P.S., and Samsonoff, W.A. (1998). Analysis of constructed E gene 
mutants of mouse hepatitis virus confirms a pivotal role for E protein in coronavirus assembly. J Virol 72, 
7885-7894. 
Flarend, R.E., Hem, S.L., White, J.L., Elmore, D., Suckow, M.A., Rudy, A.C., and Dandashli, E.A. 
(1997). In vivo absorption of aluminium-containing vaccine adjuvants using 26Al. Vaccine 15, 1314-
1318. 
Florence, W.C., Bhat, R.K., and Joyce, S. (2008). CD1d-restricted glycolipid antigens: presentation 
principles, recognition logic and functional consequences. Expert Rev Mol Med 10, e20. 
Frazer, I.H., Lowy, D.R., and Schiller, J.T. (2007). Prevention of cancer through immunization: Prospects 
and challenges for the 21st century. Eur J Immunol 37 Suppl 1, S148-155. 
Fujinami, R.S., and Oldstone, M.B. (1979). Antiviral antibody reacting on the plasma membrane alters 
measles virus expression inside the cell. Nature 279, 529-530. 
Gans, H., DeHovitz, R., Forghani, B., Beeler, J., Maldonado, Y., and Arvin, A.M. (2003). Measles and 
mumps vaccination as a model to investigate the developing immune system: passive and active 
immunity during the first year of life. Vaccine 21, 3398-3405. 
Gardiner, D.L., McCarthy, J.S., and Trenholme, K.R. (2005). Malaria in the post-genomics era: light at 
the end of the tunnel or just another train? Postgrad Med J 81, 505-509. 
Gardner, J.P., Frolov, I., Perri, S., Ji, Y., MacKichan, M.L., zur Megede, J., Chen, M., Belli, B.A., Driver, 
D.A., Sherrill, S., et al. (2000). Infection of human dendritic cells by a sindbis virus replicon vector is 
determined by a single amino acid substitution in the E2 glycoprotein. J Virol 74, 11849-11857. 
Garwes, D.J., and Reynolds, D.J. (1981). The polypeptide structure of canine coronavirus and its 
relationship to porcine transmissible gastroenteritis virus. J Gen Virol 52, 153-157. 
Gauvrit, A., Brandler, S., Sapede-Peroz, C., Boisgerault, N., Tangy, F., and Gregoire, M. (2008). Measles 
virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specific 
CD8 response. Cancer Res 68, 4882-4892. 
Geijtenbeek, T.B., Krooshoop, D.J., Bleijs, D.A., van Vliet, S.J., van Duijnhoven, G.C., Grabovsky, V., 
Alon, R., Figdor, C.G., and van Kooyk, Y. (2000). DC-SIGN-ICAM-2 interaction mediates dendritic cell 
trafficking. Nat Immunol 1, 353-357. 
Gerhard, W. (2001). The role of the antibody response in influenza virus infection. Curr Top Microbiol 
Immunol 260, 171-190. 
Girard, M.P., Osmanov, S.K., and Kieny, M.P. (2006). A review of vaccine research and development: 
the human immunodeficiency virus (HIV). Vaccine 24, 4062-4081. 
Glass, W.G., Chen, B.P., Liu, M.T., and Lane, T.E. (2002). Mouse hepatitis virus infection of the central 
nervous system: chemokine-mediated regulation of host defense and disease. Viral Immunol 15, 261-272. 
133
                                                                                                                                                  Appendix 
 
Gluck, R., Burri, K.G., and Metcalfe, I. (2005). Adjuvant and antigen delivery properties of virosomes. 
Curr Drug Deliv 2, 395-400. 
Godet, M., L'Haridon, R., Vautherot, J.F., and Laude, H. (1992). TGEV corona virus ORF4 encodes a 
membrane protein that is incorporated into virions. Virology 188, 666-675. 
Goldrath, A.W., and Bevan, M.J. (1999). Selecting and maintaining a diverse T-cell repertoire. Nature 
402, 255-262. 
Good, M.F., Stanisic, D., Xu, H., Elliott, S., and Wykes, M. (2004). The immunological challenge to 
developing a vaccine to the blood stages of malaria parasites. Immunol Rev 201, 254-267. 
Gordon, S. (2002). Pattern recognition receptors: doubling up for the innate immune response. Cell 111, 
927-930. 
Griffin, D.E. (2003). Immune responses to RNA-virus infections of the CNS. Nat Rev Immunol 3, 493-
502. 
Guermonprez, P., Valladeau, J., Zitvogel, L., Thery, C., and Amigorena, S. (2002). Antigen presentation 
and T cell stimulation by dendritic cells. Annu Rev Immunol 20, 621-667. 
Gupta, R.K., and Siber, G.R. (1995). Adjuvants for human vaccines--current status, problems and future 
prospects. Vaccine 13, 1263-1276. 
Guy, B. (2007). The perfect mix: recent progress in adjuvant research. Nat Rev Microbiol 5, 505-517. 
Haijema, B.J., Volders, H., and Rottier, P.J. (2003). Switching species tropism: an effective way to 
manipulate the feline coronavirus genome. J Virol 77, 4528-4538. 
Haijema, B.J., Volders, H., and Rottier, P.J. (2004). Live, attenuated coronavirus vaccines through the 
directed deletion of group-specific genes provide protection against feline infectious peritonitis. J Virol 
78, 3863-3871. 
Hamann, D., Baars, P.A., Rep, M.H., Hooibrink, B., Kerkhof-Garde, S.R., Klein, M.R., and van Lier, 
R.A. (1997). Phenotypic and functional separation of memory and effector human CD8+ T cells. J Exp 
Med 186, 1407-1418. 
Harui, A., Suzuki, S., Kochanek, S., and Mitani, K. (1999). Frequency and stability of chromosomal 
integration of adenovirus vectors. J Virol 73, 6141-6146. 
Heikenwalder, M., Polymenidou, M., Junt, T., Sigurdson, C., Wagner, H., Akira, S., Zinkernagel, R., and 
Aguzzi, A. (2004). Lymphoid follicle destruction and immunosuppression after repeated CpG 
oligodeoxynucleotide administration. Nat Med 10, 187-192. 
Hertzig, T., Scandella, E., Schelle, B., Ziebuhr, J., Siddell, S.G., Ludewig, B., and Thiel, V. (2004). Rapid 
identification of coronavirus replicase inhibitors using a selectable replicon RNA. J Gen Virol 85, 1717-
1725. 
Heufler, C., Koch, F., and Schuler, G. (1988). Granulocyte/macrophage colony-stimulating factor and 
interleukin 1 mediate the maturation of murine epidermal Langerhans cells into potent 
immunostimulatory dendritic cells. J Exp Med 167, 700-705. 
134
                                                                                                                                                  Appendix 
 
Hida, S., Tadachi, M., Saito, T., and Taki, S. (2005). Negative control of basophil expansion by IRF-2 
critical for the regulation of Th1/Th2 balance. Blood 106, 2011-2017. 
Hilleman, M.R. (2002). Realities and enigmas of human viral influenza: pathogenesis, epidemiology and 
control. Vaccine 20, 3068-3087. 
Hocknell, P.K., Wiley, R.D., Wang, X., Evans, T.G., Bowers, W.J., Hanke, T., Federoff, H.J., and 
Dewhurst, S. (2002). Expression of human immunodeficiency virus type 1 gp120 from herpes simplex 
virus type 1-derived amplicons results in potent, specific, and durable cellular and humoral immune 
responses. J Virol 76, 5565-5580. 
Hofmann, M.A., Chang, R.Y., Ku, S., and Brian, D.A. (1993). Leader-mRNA junction sequences are 
unique for each subgenomic mRNA species in the bovine coronavirus and remain so throughout 
persistent infection. Virology 196, 163-171. 
Hogue, B.G., and Brian, D.A. (1986). Structural proteins of human respiratory coronavirus OC43. Virus 
Res 5, 131-144. 
Howland, S.W., Tsuji, T., Gnjatic, S., Ritter, G., Old, L.J., and Wittrup, K.D. (2008). Inducing efficient 
cross-priming using antigen-coated yeast particles. J Immunother 31, 607-619. 
Hunter, R.L. (2002). Overview of vaccine adjuvants: present and future. Vaccine 20 Suppl 3, S7-12. 
Iwasaki, A., and Medzhitov, R. (2004). Toll-like receptor control of the adaptive immune responses. Nat 
Immunol 5, 987-995. 
Jacob, J., and Baltimore, D. (1999). Modelling T-cell memory by genetic marking of memory T cells in 
vivo. Nature 399, 593-597. 
Johnson, P.R., Schnepp, B.C., Connell, M.J., Rohne, D., Robinson, S., Krivulka, G.R., Lord, C.I., Zinn, 
R., Montefiori, D.C., Letvin, N.L., et al. (2005). Novel adeno-associated virus vector vaccine restricts 
replication of simian immunodeficiency virus in macaques. J Virol 79, 955-965. 
Jonuleit, H., Schmitt, E., Schuler, G., Knop, J., and Enk, A.H. (2000). Induction of interleukin 10-
producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with 
allogeneic immature human dendritic cells. J Exp Med 192, 1213-1222. 
Julius, M.H., Masuda, T., and Herzenberg, L.A. (1972). Demonstration that antigen-binding cells are 
precursors of antibody-producing cells after purification with a fluorescence-activated cell sorter. Proc 
Natl Acad Sci U S A 69, 1934-1938. 
Kadowaki, N., Ho, S., Antonenko, S., Malefyt, R.W., Kastelein, R.A., Bazan, F., and Liu, Y.J. (2001). 
Subsets of human dendritic cell precursors express different toll-like receptors and respond to different 
microbial antigens. J Exp Med 194, 863-869. 
Kaech, S.M., and Ahmed, R. (2001). Memory CD8+ T cell differentiation: initial antigen encounter 
triggers a developmental program in naive cells. Nat Immunol 2, 415-422. 
Kamitani, W., Narayanan, K., Huang, C., Lokugamage, K., Ikegami, T., Ito, N., Kubo, H., and Makino, 
S. (2006). Severe acute respiratory syndrome coronavirus nsp1 protein suppresses host gene expression 
by promoting host mRNA degradation. Proc Natl Acad Sci U S A 103, 12885-12890. 
135
                                                                                                                                                  Appendix 
 
Kaur, A., Sanford, H.B., Garry, D., Lang, S., Klumpp, S.A., Watanabe, D., Bronson, R.T., Lifson, J.D., 
Rosati, M., Pavlakis, G.N., et al. (2007). Ability of herpes simplex virus vectors to boost immune 
responses to DNA vectors and to protect against challenge by simian immunodeficiency virus. Virology 
357, 199-214. 
Kazi, L., Lissenberg, A., Watson, R., de Groot, R.J., and Weiss, S.R. (2005). Expression of hemagglutinin 
esterase protein from recombinant mouse hepatitis virus enhances neurovirulence. J Virol 79, 15064-
15073. 
Kienzle, T.E., Abraham, S., Hogue, B.G., and Brian, D.A. (1990). Structure and orientation of expressed 
bovine coronavirus hemagglutinin-esterase protein. J Virol 64, 1834-1838. 
King, B., Potts, B.J., and Brian, D.A. (1985). Bovine coronavirus hemagglutinin protein. Virus Res 2, 53-
59. 
Konings, D.A., Bredenbeek, P.J., Noten, J.F., Hogeweg, P., and Spaan, W.J. (1988). Differential 
premature termination of transcription as a proposed mechanism for the regulation of coronavirus gene 
expression. Nucleic Acids Res 16, 10849-10860. 
Korber, B., Gaschen, B., Yusim, K., Thakallapally, R., Kesmir, C., and Detours, V. (2001). Evolutionary 
and immunological implications of contemporary HIV-1 variation. Br Med Bull 58, 19-42. 
Koren, G., King, S., Knowles, S., and Phillips, E. (2003). Ribavirin in the treatment of SARS: A new 
trick for an old drug? CMAJ 168, 1289-1292. 
Ku, C.C., Murakami, M., Sakamoto, A., Kappler, J., and Marrack, P. (2000). Control of homeostasis of 
CD8+ memory T cells by opposing cytokines. Science 288, 675-678. 
Kuo, L., Godeke, G.J., Raamsman, M.J., Masters, P.S., and Rottier, P.J. (2000). Retargeting of 
coronavirus by substitution of the spike glycoprotein ectodomain: crossing the host cell species barrier. J 
Virol 74, 1393-1406. 
Kuo, L., and Masters, P.S. (2003). The small envelope protein E is not essential for murine coronavirus 
replication. J Virol 77, 4597-4608. 
Kursar, M., Bonhagen, K., Fensterle, J., Kohler, A., Hurwitz, R., Kamradt, T., Kaufmann, S.H., and 
Mittrucker, H.W. (2002). Regulatory CD4+CD25+ T cells restrict memory CD8+ T cell responses. J Exp 
Med 196, 1585-1592. 
Lai, M.M., and Cavanagh, D. (1997). The molecular biology of coronaviruses. Adv Virus Res 48, 1-100. 
Lambert, P.H., and Siegrist, C.A. (1997). Science, medicine, and the future. Vaccines and vaccination. 
BMJ 315, 1595-1598. 
Lamirande, E.W., DeDiego, M.L., Roberts, A., Jackson, J.P., Alvarez, E., Sheahan, T., Shieh, W.J., Zaki, 
S.R., Baric, R., Enjuanes, L., et al. (2008). A live attenuated severe acute respiratory syndrome 
coronavirus is immunogenic and efficacious in golden Syrian hamsters. J Virol 82, 7721-7724. 
Lampe, R.M., Weir, M.R., Scott, R.M., and Weeks, J.L. (1985). Measles reimmunization in children 
immunized before 1 year of age. Am J Dis Child 139, 33-35. 
136
                                                                                                                                                  Appendix 
 
Lanzavecchia, A. (1990). Receptor-mediated antigen uptake and its effect on antigen presentation to class 
II-restricted T lymphocytes. Annu Rev Immunol 8, 773-793. 
Lanzavecchia, A., Lezzi, G., and Viola, A. (1999). From TCR engagement to T cell activation: a kinetic 
view of T cell behavior. Cell 96, 1-4. 
Lanzavecchia, A., and Sallusto, F. (2001). Regulation of T cell immunity by dendritic cells. Cell 106, 
263-266. 
Lassila, O., Vainio, O., and Matzinger, P. (1988). Can B cells turn on virgin T cells? Nature 334, 253-
255. 
Laude, H., Gelfi, J., Lavenant, L., and Charley, B. (1992). Single amino acid changes in the viral 
glycoprotein M affect induction of alpha interferon by the coronavirus transmissible gastroenteritis virus. 
J Virol 66, 743-749. 
Leadbetter, E.A., Brigl, M., Illarionov, P., Cohen, N., Luteran, M.C., Pillai, S., Besra, G.S., and Brenner, 
M.B. (2008). NK T cells provide lipid antigen-specific cognate help for B cells. Proc Natl Acad Sci U S 
A 105, 8339-8344. 
Leibowitz, J.L., Weiss, S.R., Paavola, E., and Bond, C.W. (1982). Cell-free translation of murine 
coronavirus RNA. J Virol 43, 905-913. 
Leitner, W.W., Hwang, L.N., deVeer, M.J., Zhou, A., Silverman, R.H., Williams, B.R., Dubensky, T.W., 
Ying, H., and Restifo, N.P. (2003). Alphavirus-based DNA vaccine breaks immunological tolerance by 
activating innate antiviral pathways. Nat Med 9, 33-39. 
Lenardo, M., Chan, K.M., Hornung, F., McFarland, H., Siegel, R., Wang, J., and Zheng, L. (1999). 
Mature T lymphocyte apoptosis--immune regulation in a dynamic and unpredictable antigenic 
environment. Annu Rev Immunol 17, 221-253. 
Levine, B., Hardwick, J.M., Trapp, B.D., Crawford, T.O., Bollinger, R.C., and Griffin, D.E. (1991). 
Antibody-mediated clearance of alphavirus infection from neurons. Science 254, 856-860. 
Li, L., and Wu, C.Y. (2008). CD4+ CD25+ Treg cells inhibit human memory gammadelta T cells to 
produce IFN-gamma in response to M tuberculosis antigen ESAT-6. Blood 111, 5629-5636. 
Li, S., Locke, E., Bruder, J., Clarke, D., Doolan, D.L., Havenga, M.J., Hill, A.V., Liljestrom, P., Monath, 
T.P., Naim, H.Y., et al. (2007). Viral vectors for malaria vaccine development. Vaccine 25, 2567-2574. 
Liao, Y., Yuan, Q., Torres, J., Tam, J.P., and Liu, D.X. (2006). Biochemical and functional 
characterization of the membrane association and membrane permeabilizing activity of the severe acute 
respiratory syndrome coronavirus envelope protein. Virology 349, 264-275. 
Liljestrom, P., and Garoff, H. (1991). A new generation of animal cell expression vectors based on the 
Semliki Forest virus replicon. Biotechnology (N Y) 9, 1356-1361. 
Lim, K.P., and Liu, D.X. (2001). The missing link in coronavirus assembly. Retention of the avian 
coronavirus infectious bronchitis virus envelope protein in the pre-Golgi compartments and physical 
interaction between the envelope and membrane proteins. J Biol Chem 276, 17515-17523. 
137
                                                                                                                                                  Appendix 
 
Lin, M.Y., Selin, L.K., and Welsh, R.M. (2000). Evolution of the CD8 T-cell repertoire during infections. 
Microbes Infect 2, 1025-1039. 
Liniger, M., Zuniga, A., and Naim, H.Y. (2007). Use of viral vectors for the development of vaccines. 
Expert Rev Vaccines 6, 255-266. 
Lipsitch, M., and O'Hagan, J.J. (2007). Patterns of antigenic diversity and the mechanisms that maintain 
them. J R Soc Interface 4, 787-802. 
Lissenberg, A., Vrolijk, M.M., van Vliet, A.L., Langereis, M.A., de Groot-Mijnes, J.D., Rottier, P.J., and 
de Groot, R.J. (2005). Luxury at a cost? Recombinant mouse hepatitis viruses expressing the accessory 
hemagglutinin esterase protein display reduced fitness in vitro. J Virol 79, 15054-15063. 
Liu, D.X., and Inglis, S.C. (1991). Association of the infectious bronchitis virus 3c protein with the virion 
envelope. Virology 185, 911-917. 
Liu, Y., Hu, R., Zhang, S., Zhang, F., Li, Z., Wei, X., and Chen, L. (2006). Expression of the Foot-and-
Mouth Disease Virus VP1 protein using a replication-competent recombinant canine adenovirus type 2 
elicits a humoral antibody response in a porcine model. Viral Immunol 19, 202-209. 
Liu, Y.J. (2001). Dendritic cell subsets and lineages, and their functions in innate and adaptive immunity. 
Cell 106, 259-262. 
Livermore, D.M. (2007). Introduction: the challenge of multiresistance. Int J Antimicrob Agents 29 Suppl 
3, S1-7. 
Lopez, L.A., Riffle, A.J., Pike, S.L., Gardner, D., and Hogue, B.G. (2008). Importance of conserved 
cysteine residues in the coronavirus envelope protein. J Virol 82, 3000-3010. 
Lore, K., Betts, M.R., Brenchley, J.M., Kuruppu, J., Khojasteh, S., Perfetto, S., Roederer, M., Seder, 
R.A., and Koup, R.A. (2003). Toll-like receptor ligands modulate dendritic cells to augment 
cytomegalovirus- and HIV-1-specific T cell responses. J Immunol 171, 4320-4328. 
Lorin, C., Delebecque, F., Labrousse, V., Da Silva, L., Lemonnier, F., Brahic, M., and Tangy, F. (2005). 
A recombinant live attenuated measles vaccine vector primes effective HLA-A0201-restricted cytotoxic T 
lymphocytes and broadly neutralizing antibodies against HIV-1 conserved epitopes. Vaccine 23, 4463-
4472. 
Lorin, C., Mollet, L., Delebecque, F., Combredet, C., Hurtrel, B., Charneau, P., Brahic, M., and Tangy, F. 
(2004). A single injection of recombinant measles virus vaccines expressing human immunodeficiency 
virus (HIV) type 1 clade B envelope glycoproteins induces neutralizing antibodies and cellular immune 
responses to HIV. J Virol 78, 146-157. 
Lu, W., Arraes, L.C., Ferreira, W.T., and Andrieu, J.M. (2004). Therapeutic dendritic-cell vaccine for 
chronic HIV-1 infection. Nat Med 10, 1359-1365. 
Luckashenak, N., Schroeder, S., Endt, K., Schmidt, D., Mahnke, K., Bachmann, M.F., Marconi, P., Deeg, 
C.A., and Brocker, T. (2008). Constitutive crosspresentation of tissue antigens by dendritic cells controls 
CD8+ T cell tolerance in vivo. Immunity 28, 521-532. 
138
                                                                                                                                                  Appendix 
 
Ludewig, B., Barchiesi, F., Pericin, M., Zinkernagel, R.M., Hengartner, H., and Schwendener, R.A. 
(2000). In vivo antigen loading and activation of dendritic cells via a liposomal peptide vaccine mediates 
protective antiviral and anti-tumour immunity. Vaccine 19, 23-32. 
Luft, T., Jefford, M., Luetjens, P., Toy, T., Hochrein, H., Masterman, K.A., Maliszewski, C., Shortman, 
K., Cebon, J., and Maraskovsky, E. (2002). Functionally distinct dendritic cell (DC) populations induced 
by physiologic stimuli: prostaglandin E(2) regulates the migratory capacity of specific DC subsets. Blood 
100, 1362-1372. 
Luytjes, W., Bredenbeek, P.J., Noten, A.F., Horzinek, M.C., and Spaan, W.J. (1988). Sequence of mouse 
hepatitis virus A59 mRNA 2: indications for RNA recombination between coronaviruses and influenza C 
virus. Virology 166, 415-422. 
Lynch, D.H., Andreasen, A., Maraskovsky, E., Whitmore, J., Miller, R.E., and Schuh, J.C. (1997). Flt3 
ligand induces tumor regression and antitumor immune responses in vivo. Nat Med 3, 625-631. 
Machamer, C.E., and Youn, S. (2006). The transmembrane domain of the infectious bronchitis virus E 
protein is required for efficient virus release. Adv Exp Med Biol 581, 193-198. 
Mack, M., Schneider, M.A., Moll, C., Cihak, J., Bruhl, H., Ellwart, J.W., Hogarth, M.P., Stangassinger, 
M., and Schlondorff, D. (2005). Identification of antigen-capturing cells as basophils. J Immunol 174, 
735-741. 
Mackaness, G.B. (1969). The influence of immunologically committed lymphoid cells on macrophage 
activity in vivo. J Exp Med 129, 973-992. 
MacNamara, K.C., Chua, M.M., Phillips, J.J., and Weiss, S.R. (2005). Contributions of the viral genetic 
background and a single amino acid substitution in an immunodominant CD8+ T-cell epitope to murine 
coronavirus neurovirulence. J Virol 79, 9108-9118. 
Maeda, J., Maeda, A., and Makino, S. (1999). Release of coronavirus E protein in membrane vesicles 
from virus-infected cells and E protein-expressing cells. Virology 263, 265-272. 
Mailliard, R.B., Wankowicz-Kalinska, A., Cai, Q., Wesa, A., Hilkens, C.M., Kapsenberg, M.L., 
Kirkwood, J.M., Storkus, W.J., and Kalinski, P. (2004). alpha-type-1 polarized dendritic cells: a novel 
immunization tool with optimized CTL-inducing activity. Cancer Res 64, 5934-5937. 
Maldonado-Lopez, R., De Smedt, T., Michel, P., Godfroid, J., Pajak, B., Heirman, C., Thielemans, K., 
Leo, O., Urbain, J., and Moser, M. (1999). CD8alpha+ and CD8alpha- subclasses of dendritic cells direct 
the development of distinct T helper cells in vivo. J Exp Med 189, 587-592. 
Manz, R.A., Thiel, A., and Radbruch, A. (1997). Lifetime of plasma cells in the bone marrow. Nature 
388, 133-134. 
Maraskovsky, E., Brasel, K., Teepe, M., Roux, E.R., Lyman, S.D., Shortman, K., and McKenna, H.J. 
(1996). Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated 
mice: multiple dendritic cell subpopulations identified. J Exp Med 184, 1953-1962. 
139
                                                                                                                                                  Appendix 
 
Marconi, P., Krisky, D., Oligino, T., Poliani, P.L., Ramakrishnan, R., Goins, W.F., Fink, D.J., and 
Glorioso, J.C. (1996). Replication-defective herpes simplex virus vectors for gene transfer in vivo. Proc 
Natl Acad Sci U S A 93, 11319-11320. 
Marconi, P., Simonato, M., Zucchini, S., Bregola, G., Argnani, R., Krisky, D., Glorioso, J.C., and 
Manservigi, R. (1999). Replication-defective herpes simplex virus vectors for neurotrophic factor gene 
transfer in vitro and in vivo. Gene Ther 6, 904-912. 
Marks-Konczalik, J., Dubois, S., Losi, J.M., Sabzevari, H., Yamada, N., Feigenbaum, L., Waldmann, 
T.A., and Tagaya, Y. (2000). IL-2-induced activation-induced cell death is inhibited in IL-15 transgenic 
mice. Proc Natl Acad Sci U S A 97, 11445-11450. 
Marten, N.W., Stohlman, S.A., and Bergmann, C.C. (2001). MHV infection of the CNS: mechanisms of 
immune-mediated control. Viral Immunol 14, 1-18. 
Marten, N.W., Stohlman, S.A., Zhou, J., and Bergmann, C.C. (2003). Kinetics of virus-specific CD8+ -T-
cell expansion and trafficking following central nervous system infection. J Virol 77, 2775-2778. 
Masopust, D., Vezys, V., Marzo, A.L., and Lefrancois, L. (2001). Preferential localization of effector 
memory cells in nonlymphoid tissue. Science 291, 2413-2417. 
Masters, P.S. (1999). Reverse genetics of the largest RNA viruses. Adv Virus Res 53, 245-264. 
Mastrangelo, M.J., Eisenlohr, L.C., Gomella, L., and Lattime, E.C. (2000). Poxvirus vectors: orphaned 
and underappreciated. J Clin Invest 105, 1031-1034. 
Matrosovich, M.N., Matrosovich, T.Y., Gray, T., Roberts, N.A., and Klenk, H.D. (2004). Human and 
avian influenza viruses target different cell types in cultures of human airway epithelium. Proc Natl Acad 
Sci U S A 101, 4620-4624. 
Mays, L.E., and Chen, Y.H. (2007). Maintaining immunological tolerance with Foxp3. Cell Res 17, 904-
918. 
McCullough, K.C., Parkinson, D., and Crowther, J.R. (1988). Opsonization-enhanced phagocytosis of 
foot-and-mouth disease virus. Immunology 65, 187-191. 
Mercado, R., Vijh, S., Allen, S.E., Kerksiek, K., Pilip, I.M., and Pamer, E.G. (2000). Early programming 
of T cell populations responding to bacterial infection. J Immunol 165, 6833-6839. 
Merten, O.W., Geny-Fiamma, C., and Douar, A.M. (2005). Current issues in adeno-associated viral 
vector production. Gene Ther 12 Suppl 1, S51-61. 
Molinier-Frenkel, V., Prevost-Blondel, A., Hong, S.S., Lengagne, R., Boudaly, S., Magnusson, M.K., 
Boulanger, P., and Guillet, J.G. (2003). The maturation of murine dendritic cells induced by human 
adenovirus is mediated by the fiber knob domain. J Biol Chem 278, 37175-37182. 
Monson, N.L. (2008). The natural history of B cells. Curr Opin Neurol 21 Suppl 1, S3-8. 
Morenweiser, R. (2005). Downstream processing of viral vectors and vaccines. Gene Ther 12 Suppl 1, 
S103-110. 
Murphy, F.A. (1989). The promise and challenge of vaccinia-vectored vaccines. Res Virol 140, 463-465. 
140
                                                                                                                                                  Appendix 
 
Mwau, M., Cebere, I., Sutton, J., Chikoti, P., Winstone, N., Wee, E.G., Beattie, T., Chen, Y.H., Dorrell, 
L., McShane, H., et al. (2004). A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical 
trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus 
Ankara (MVA) vaccines in humans. J Gen Virol 85, 911-919. 
Nakamura, M., Iwahashi, M., Nakamori, M., Ueda, K., Matsuura, I., Noguchi, K., and Yamaue, H. 
(2002). Dendritic cells genetically engineered to simultaneously express endogenous tumor antigen and 
granulocyte macrophage colony-stimulating factor elicit potent therapeutic antitumor immunity. Clin 
Cancer Res 8, 2742-2749. 
Nanda, A., Lynch, D.M., Goudsmit, J., Lemckert, A.A., Ewald, B.A., Sumida, S.M., Truitt, D.M., 
Abbink, P., Kishko, M.G., Gorgone, D.A., et al. (2005). Immunogenicity of recombinant fiber-chimeric 
adenovirus serotype 35 vector-based vaccines in mice and rhesus monkeys. J Virol 79, 14161-14168. 
Narayanan, K., Huang, C., Lokugamage, K., Kamitani, W., Ikegami, T., Tseng, C.T., and Makino, S. 
(2008). Severe Acute Respiratory Syndrome Coronavirus Nsp1 Suppresses Host Gene Expression, 
Including Type I Interferon, in Infected Cells. J Virol. 
Naslund, T.I., Uyttenhove, C., Nordstrom, E.K., Colau, D., Warnier, G., Jondal, M., Van den Eynde, B.J., 
and Liljestrom, P. (2007). Comparative prime-boost vaccinations using Semliki Forest virus, adenovirus, 
and ALVAC vectors demonstrate differences in the generation of a protective central memory CTL 
response against the P815 tumor. J Immunol 178, 6761-6769. 
Navas, S., Seo, S.H., Chua, M.M., Sarma, J.D., Lavi, E., Hingley, S.T., and Weiss, S.R. (2001). Murine 
coronavirus spike protein determines the ability of the virus to replicate in the liver and cause hepatitis. J 
Virol 75, 2452-2457. 
Nestle, F.O. (2000). Dendritic cell vaccination for cancer therapy. Oncogene 19, 6673-6679. 
O'Garra, A. (1998). Cytokines induce the development of functionally heterogeneous T helper cell 
subsets. Immunity 8, 275-283. 
Ochsenbein, A.F., Pinschewer, D.D., Odermatt, B., Ciurea, A., Hengartner, H., and Zinkernagel, R.M. 
(2000). Correlation of T cell independence of antibody responses with antigen dose reaching secondary 
lymphoid organs: implications for splenectomized patients and vaccine design. J Immunol 164, 6296-
6302. 
Oertli, D., Marti, W.R., Norton, J.A., and Tsung, K. (1996). Non-replicating recombinant vaccinia virus 
encoding murine B-7 molecules elicits effective costimulation of naive CD4+ splenocytes in vitro. J Gen 
Virol 77 ( Pt 12), 3121-3125. 
Oh, K., Shen, T., Le Gros, G., and Min, B. (2007). Induction of Th2 type immunity in a mouse system 
reveals a novel immunoregulatory role of basophils. Blood 109, 2921-2927. 
Okada, N., Saito, T., Masunaga, Y., Tsukada, Y., Nakagawa, S., Mizuguchi, H., Mori, K., Okada, Y., 
Fujita, T., Hayakawa, T., et al. (2001). Efficient antigen gene transduction using Arg-Gly-Asp fiber-
mutant adenovirus vectors can potentiate antitumor vaccine efficacy and maturation of murine dendritic 
cells. Cancer Res 61, 7913-7919. 
141
                                                                                                                                                  Appendix 
 
Opferman, J.T., Ober, B.T., and Ashton-Rickardt, P.G. (1999). Linear differentiation of cytotoxic 
effectors into memory T lymphocytes. Science 283, 1745-1748. 
Ortego, J., Ceriani, J.E., Patino, C., Plana, J., and Enjuanes, L. (2007). Absence of E protein arrests 
transmissible gastroenteritis coronavirus maturation in the secretory pathway. Virology 368, 296-308. 
Ortego, J., Escors, D., Laude, H., and Enjuanes, L. (2002). Generation of a replication-competent, 
propagation-deficient virus vector based on the transmissible gastroenteritis coronavirus genome. J Virol 
76, 11518-11529. 
Ossevoort, M.A., Feltkamp, M.C., van Veen, K.J., Melief, C.J., and Kast, W.M. (1995). Dendritic cells as 
carriers for a cytotoxic T-lymphocyte epitope-based peptide vaccine in protection against a human 
papillomavirus type 16-induced tumor. J Immunother Emphasis Tumor Immunol 18, 86-94. 
Oxenius, A., Campbell, K.A., Maliszewski, C.R., Kishimoto, T., Kikutani, H., Hengartner, H., 
Zinkernagel, R.M., and Bachmann, M.F. (1996). CD40-CD40 ligand interactions are critical in T-B 
cooperation but not for other anti-viral CD4+ T cell functions. J Exp Med 183, 2209-2218. 
Pantaleo, G., Demarest, J.F., Vaccarezza, M., Graziosi, C., Bansal, G.P., Koenig, S., and Fauci, A.S. 
(1995). Effect of anti-V3 antibodies on cell-free and cell-to-cell human immunodeficiency virus 
transmission. Eur J Immunol 25, 226-231. 
Parker, D.C. (1993). T cell-dependent B cell activation. Annu Rev Immunol 11, 331-360. 
Parra, B., Hinton, D.R., Marten, N.W., Bergmann, C.C., Lin, M.T., Yang, C.S., and Stohlman, S.A. 
(1999). IFN-gamma is required for viral clearance from central nervous system oligodendroglia. J 
Immunol 162, 1641-1647. 
Parrino, J., and Graham, B.S. (2006). Smallpox vaccines: Past, present, and future. J Allergy Clin 
Immunol 118, 1320-1326. 
Pasare, C., and Medzhitov, R. (2004). Toll-dependent control mechanisms of CD4 T cell activation. 
Immunity 21, 733-741. 
Pashine, A., Valiante, N.M., and Ulmer, J.B. (2005). Targeting the innate immune response with 
improved vaccine adjuvants. Nat Med 11, S63-68. 
Peiser, L., Mukhopadhyay, S., and Gordon, S. (2002). Scavenger receptors in innate immunity. Curr Opin 
Immunol 14, 123-128. 
Peng, Z. (2005). Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of 
cancers. Hum Gene Ther 16, 1016-1027. 
Perlman, S. (1998). Pathogenesis of coronavirus-induced infections. Review of pathological and 
immunological aspects. Adv Exp Med Biol 440, 503-513. 
Perri, S., Greer, C.E., Thudium, K., Doe, B., Legg, H., Liu, H., Romero, R.E., Tang, Z., Bin, Q., 
Dubensky, T.W., Jr., et al. (2003). An alphavirus replicon particle chimera derived from venezuelan 
equine encephalitis and sindbis viruses is a potent gene-based vaccine delivery vector. J Virol 77, 10394-
10403. 
142
                                                                                                                                                  Appendix 
 
Phillips, J.J., Chua, M.M., Lavi, E., and Weiss, S.R. (1999). Pathogenesis of chimeric MHV4/MHV-A59 
recombinant viruses: the murine coronavirus spike protein is a major determinant of neurovirulence. J 
Virol 73, 7752-7760. 
Picker, L.J., and Butcher, E.C. (1992). Physiological and molecular mechanisms of lymphocyte homing. 
Annu Rev Immunol 10, 561-591. 
Polo, J.M., Belli, B.A., Driver, D.A., Frolov, I., Sherrill, S., Hariharan, M.J., Townsend, K., Perri, S., 
Mento, S.J., Jolly, D.J., et al. (1999). Stable alphavirus packaging cell lines for Sindbis virus and Semliki 
Forest virus-derived vectors. Proc Natl Acad Sci U S A 96, 4598-4603. 
Popova, R., and Zhang, X. (2002). The spike but not the hemagglutinin/esterase protein of bovine 
coronavirus is necessary and sufficient for viral infection. Virology 294, 222-236. 
Potsch, C., Vohringer, D., and Pircher, H. (1999). Distinct migration patterns of naive and effector CD8 T 
cells in the spleen: correlation with CCR7 receptor expression and chemokine reactivity. Eur J Immunol 
29, 3562-3570. 
Preston, A., Parkhill, J., and Maskell, D.J. (2004). The bordetellae: lessons from genomics. Nat Rev 
Microbiol 2, 379-390. 
Probst, H.C., McCoy, K., Okazaki, T., Honjo, T., and van den Broek, M. (2005). Resting dendritic cells 
induce peripheral CD8+ T cell tolerance through PD-1 and CTLA-4. Nat Immunol 6, 280-286. 
Publicover, J., Ramsburg, E., and Rose, J.K. (2005). A single-cycle vaccine vector based on vesicular 
stomatitis virus can induce immune responses comparable to those generated by a replication-competent 
vector. J Virol 79, 13231-13238. 
Pulendran, B., and Ahmed, R. (2006). Translating innate immunity into immunological memory: 
implications for vaccine development. Cell 124, 849-863. 
Pulendran, B., Kumar, P., Cutler, C.W., Mohamadzadeh, M., Van Dyke, T., and Banchereau, J. (2001). 
Lipopolysaccharides from distinct pathogens induce different classes of immune responses in vivo. J 
Immunol 167, 5067-5076. 
Pulendran, B., Smith, J.L., Caspary, G., Brasel, K., Pettit, D., Maraskovsky, E., and Maliszewski, C.R. 
(1999). Distinct dendritic cell subsets differentially regulate the class of immune response in vivo. Proc 
Natl Acad Sci U S A 96, 1036-1041. 
Quiroz, E., Moreno, N., Peralta, P.H., and Tesh, R.B. (1988). A human case of encephalitis associated 
with vesicular stomatitis virus (Indiana serotype) infection. Am J Trop Med Hyg 39, 312-314. 
Raamsman, M.J., Locker, J.K., de Hooge, A., de Vries, A.A., Griffiths, G., Vennema, H., and Rottier, P.J. 
(2000). Characterization of the coronavirus mouse hepatitis virus strain A59 small membrane protein E. J 
Virol 74, 2333-2342. 
Reinhardt, R.L., Khoruts, A., Merica, R., Zell, T., and Jenkins, M.K. (2001). Visualizing the generation of 
memory CD4 T cells in the whole body. Nature 410, 101-105. 
Reis e Sousa, C. (2001). Dendritic cells as sensors of infection. Immunity 14, 495-498. 
143
                                                                                                                                                  Appendix 
 
Reiss, C.S., Plakhov, I.V., and Komatsu, T. (1998). Viral replication in olfactory receptor neurons and 
entry into the olfactory bulb and brain. Ann N Y Acad Sci 855, 751-761. 
Roberts, D.M., Nanda, A., Havenga, M.J., Abbink, P., Lynch, D.M., Ewald, B.A., Liu, J., Thorner, A.R., 
Swanson, P.E., Gorgone, D.A., et al. (2006). Hexon-chimaeric adenovirus serotype 5 vectors circumvent 
pre-existing anti-vector immunity. Nature 441, 239-243. 
Robinson, H.L. (2002). New hope for an AIDS vaccine. Nat Rev Immunol 2, 239-250. 
Robinson, H.L., Montefiori, D.C., Villinger, F., Robinson, J.E., Sharma, S., Wyatt, L.S., Earl, P.L., 
McClure, H.M., Moss, B., and Amara, R.R. (2006). Studies on GM-CSF DNA as an adjuvant for 
neutralizing Ab elicited by a DNA/MVA immunodeficiency virus vaccine. Virology 352, 285-294. 
Romano, G. (2003). Gene transfer in experimental medicine. Drug News Perspect 16, 267-276. 
Romano, G. (2005). Current development of adeno-associated viral vectors. Drug News Perspect 18, 311-
316. 
Romano, G. (2006). The controversial role of adenoviral-derived vectors in gene therapy programs: 
where do we stand? Drug News Perspect 19, 99-106. 
Roos, M.T., van Lier, R.A., Hamann, D., Knol, G.J., Verhoofstad, I., van Baarle, D., Miedema, F., and 
Schellekens, P.T. (2000). Changes in the composition of circulating CD8+ T cell subsets during acute 
epstein-barr and human immunodeficiency virus infections in humans. J Infect Dis 182, 451-458. 
Roost, H.P., Bachmann, M.F., Haag, A., Kalinke, U., Pliska, V., Hengartner, H., and Zinkernagel, R.M. 
(1995). Early high-affinity neutralizing anti-viral IgG responses without further overall improvements of 
affinity. Proc Natl Acad Sci U S A 92, 1257-1261. 
Russell, N.D., Graham, B.S., Keefer, M.C., McElrath, M.J., Self, S.G., Weinhold, K.J., Montefiori, D.C., 
Ferrari, G., Horton, H., Tomaras, G.D., et al. (2007). Phase 2 study of an HIV-1 canarypox vaccine 
(vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial. 
J Acquir Immune Defic Syndr 44, 203-212. 
Sakaguchi, S. (2000). Regulatory T cells: key controllers of immunologic self-tolerance. Cell 101, 455-
458. 
Salazar-Mather, T.P., Lewis, C.A., and Biron, C.A. (2002). Type I interferons regulate inflammatory cell 
trafficking and macrophage inflammatory protein 1alpha delivery to the liver. J Clin Invest 110, 321-330. 
Sallusto, F., Lanzavecchia, A., and Mackay, C.R. (1998a). Chemokines and chemokine receptors in T-cell 
priming and Th1/Th2-mediated responses. Immunol Today 19, 568-574. 
Sallusto, F., Lenig, D., Forster, R., Lipp, M., and Lanzavecchia, A. (1999). Two subsets of memory T 
lymphocytes with distinct homing potentials and effector functions. Nature 401, 708-712. 
Sallusto, F., Mackay, C.R., and Lanzavecchia, A. (2000). The role of chemokine receptors in primary, 
effector, and memory immune responses. Annu Rev Immunol 18, 593-620. 
Sallusto, F., Schaerli, P., Loetscher, P., Schaniel, C., Lenig, D., Mackay, C.R., Qin, S., and Lanzavecchia, 
A. (1998b). Rapid and coordinated switch in chemokine receptor expression during dendritic cell 
maturation. Eur J Immunol 28, 2760-2769. 
144
                                                                                                                                                  Appendix 
 
Salomon, B., and Bluestone, J.A. (2001). Complexities of CD28/B7: CTLA-4 costimulatory pathways in 
autoimmunity and transplantation. Annu Rev Immunol 19, 225-252. 
Saparov, A., Wagner, F.H., Zheng, R., Oliver, J.R., Maeda, H., Hockett, R.D., and Weaver, C.T. (1999). 
Interleukin-2 expression by a subpopulation of primary T cells is linked to enhanced memory/effector 
function. Immunity 11, 271-280. 
Sawicki, S.G., and Sawicki, D.L. (1998). A new model for coronavirus transcription. Adv Exp Med Biol 
440, 215-219. 
Sawicki, S.G., Sawicki, D.L., and Siddell, S.G. (2007). A contemporary view of coronavirus 
transcription. J Virol 81, 20-29. 
Scandella, E., Men, Y., Gillessen, S., Forster, R., and Groettrup, M. (2002). Prostaglandin E2 is a key 
factor for CCR7 surface expression and migration of monocyte-derived dendritic cells. Blood 100, 1354-
1361. 
Schindler, C., Fooks, A., Stephenson, J., and Liebert, U.G. (1994). Replication-incompetent adenoviruses 
as vectors for protective immunization against measles virus infection. Behring Inst Mitt, 109-115. 
Schlesinger, S., and Dubensky, T.W. (1999). Alphavirus vectors for gene expression and vaccines. Curr 
Opin Biotechnol 10, 434-439. 
Schwartz, E., Hatz, C., and Blum, J. (2006). New world cutaneous leishmaniasis in travellers. Lancet 
Infect Dis 6, 342-349. 
Schwarz, B., Routledge, E., and Siddell, S.G. (1990). Murine coronavirus nonstructural protein ns2 is not 
essential for virus replication in transformed cells. J Virol 64, 4784-4791. 
Schwarz, K., Storni, T., Manolova, V., Didierlaurent, A., Sirard, J.C., Rothlisberger, P., and Bachmann, 
M.F. (2003). Role of Toll-like receptors in costimulating cytotoxic T cell responses. Eur J Immunol 33, 
1465-1470. 
Seder, R.A., and Paul, W.E. (1994). Acquisition of lymphokine-producing phenotype by CD4+ T cells. 
Annu Rev Immunol 12, 635-673. 
Seewaldt, S., Alferink, J., and Forster, I. (2002). Interleukin-10 is crucial for maintenance but not for 
developmental induction of peripheral T cell tolerance. Eur J Immunol 32, 3607-3616. 
Sethna, P.B., Hung, S.L., and Brian, D.A. (1989). Coronavirus subgenomic minus-strand RNAs and the 
potential for mRNA replicons. Proc Natl Acad Sci U S A 86, 5626-5630. 
Shevach, E.M. (2000). Regulatory T cells in autoimmmunity*. Annu Rev Immunol 18, 423-449. 
Shieh, C.K., Lee, H.J., Yokomori, K., La Monica, N., Makino, S., and Lai, M.M. (1989). Identification of 
a new transcriptional initiation site and the corresponding functional gene 2b in the murine coronavirus 
RNA genome. J Virol 63, 3729-3736. 
Shiver, J.W., and Emini, E.A. (2004). Recent advances in the development of HIV-1 vaccines using 
replication-incompetent adenovirus vectors. Annu Rev Med 55, 355-372. 
Shortman, K., and Liu, Y.J. (2002). Mouse and human dendritic cell subtypes. Nat Rev Immunol 2, 151-
161. 
145
                                                                                                                                                  Appendix 
 
Siddell, S. (1983). Coronavirus JHM: coding assignments of subgenomic mRNAs. J Gen Virol 64 (Pt 1), 
113-125. 
Siddell, S., Wege, H., Barthel, A., and ter Meulen, V. (1981). Coronavirus JHM: intracellular protein 
synthesis. J Gen Virol 53, 145-155. 
Smits, S.L., Gerwig, G.J., van Vliet, A.L., Lissenberg, A., Briza, P., Kamerling, J.P., Vlasak, R., and de 
Groot, R.J. (2005). Nidovirus sialate-O-acetylesterases: evolution and substrate specificity of coronaviral 
and toroviral receptor-destroying enzymes. J Biol Chem 280, 6933-6941. 
Sokol, C.L., Barton, G.M., Farr, A.G., and Medzhitov, R. (2008). A mechanism for the initiation of 
allergen-induced T helper type 2 responses. Nat Immunol 9, 310-318. 
Song, W., Kong, H.L., Carpenter, H., Torii, H., Granstein, R., Rafii, S., Moore, M.A., and Crystal, R.G. 
(1997). Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model 
antigen induce protective and therapeutic antitumor immunity. J Exp Med 186, 1247-1256. 
Spaan, W., Delius, H., Skinner, M., Armstrong, J., Rottier, P., Smeekens, S., van der Zeijst, B.A., and 
Siddell, S.G. (1983). Coronavirus mRNA synthesis involves fusion of non-contiguous sequences. EMBO 
J 2, 1839-1844. 
Spaete, R.R., and Frenkel, N. (1982). The herpes simplex virus amplicon: a new eucaryotic defective-
virus cloning-amplifying vector. Cell 30, 295-304. 
Sparwasser, T., Koch, E.S., Vabulas, R.M., Heeg, K., Lipford, G.B., Ellwart, J.W., and Wagner, H. 
(1998). Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of 
murine dendritic cells. Eur J Immunol 28, 2045-2054. 
Speak, A.O., Cerundolo, V., and Platt, F.M. (2008). CD1d presentation of glycolipids. Immunol Cell 
Biol. 
Specht, J.M., Wang, G., Do, M.T., Lam, J.S., Royal, R.E., Reeves, M.E., Rosenberg, S.A., and Hwu, P. 
(1997). Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective 
against established pulmonary metastases. J Exp Med 186, 1213-1221. 
Sprent, J., and Surh, C.D. (2001). Generation and maintenance of memory T cells. Curr Opin Immunol 
13, 248-254. 
Srivastava, P. (2002). Roles of heat-shock proteins in innate and adaptive immunity. Nat Rev Immunol 2, 
185-194. 
Srivastava, P.K. (2000). Immunotherapy of human cancer: lessons from mice. Nat Immunol 1, 363-366. 
Stadler, K., Masignani, V., Eickmann, M., Becker, S., Abrignani, S., Klenk, H.D., and Rappuoli, R. 
(2003). SARS--beginning to understand a new virus. Nat Rev Microbiol 1, 209-218. 
Stanberry, L.R., Spruance, S.L., Cunningham, A.L., Bernstein, D.I., Mindel, A., Sacks, S., Tyring, S., 
Aoki, F.Y., Slaoui, M., Denis, M., et al. (2002). Glycoprotein-D-adjuvant vaccine to prevent genital 
herpes. N Engl J Med 347, 1652-1661. 
Stapleton, A. (2003). Novel approaches to prevention of urinary tract infections. Infect Dis Clin North 
Am 17, 457-471. 
146
                                                                                                                                                  Appendix 
 
Steinman, R.M. (1991). The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 9, 
271-296. 
Steinman, R.M., and Banchereau, J. (2007). Taking dendritic cells into medicine. Nature 449, 419-426. 
Steinman, R.M., and Cohn, Z.A. (1973). Identification of a novel cell type in peripheral lymphoid organs 
of mice. I. Morphology, quantitation, tissue distribution. J Exp Med 137, 1142-1162. 
Steinman, R.M., Hawiger, D., and Nussenzweig, M.C. (2003). Tolerogenic dendritic cells. Annu Rev 
Immunol 21, 685-711. 
Steinman, R.M., and Pope, M. (2002). Exploiting dendritic cells to improve vaccine efficacy. J Clin 
Invest 109, 1519-1526. 
Steinman, R.M., Turley, S., Mellman, I., and Inaba, K. (2000). The induction of tolerance by dendritic 
cells that have captured apoptotic cells. J Exp Med 191, 411-416. 
Steitz, J., Bruck, J., Lenz, J., Knop, J., and Tuting, T. (2001). Depletion of CD25(+) CD4(+) T cells and 
treatment with tyrosinase-related protein 2-transduced dendritic cells enhance the interferon alpha-
induced, CD8(+) T-cell-dependent immune defense of B16 melanoma. Cancer Res 61, 8643-8646. 
Stern, D.F., and Sefton, B.M. (1982). Coronavirus proteins: structure and function of the oligosaccharides 
of the avian infectious bronchitis virus glycoproteins. J Virol 44, 804-812. 
Strauss, J.H., and Strauss, E.G. (1994). The alphaviruses: gene expression, replication, and evolution. 
Microbiol Rev 58, 491-562. 
Sullivan, N.J., Geisbert, T.W., Geisbert, J.B., Xu, L., Yang, Z.Y., Roederer, M., Koup, R.A., Jahrling, 
P.B., and Nabel, G.J. (2003). Accelerated vaccination for Ebola virus haemorrhagic fever in non-human 
primates. Nature 424, 681-684. 
Sutmuller, R.P., van Duivenvoorde, L.M., van Elsas, A., Schumacher, T.N., Wildenberg, M.E., Allison, 
J.P., Toes, R.E., Offringa, R., and Melief, C.J. (2001). Synergism of cytotoxic T lymphocyte-associated 
antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative 
pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 194, 823-832. 
Sutter, G., and Staib, C. (2003). Vaccinia vectors as candidate vaccines: the development of modified 
vaccinia virus Ankara for antigen delivery. Curr Drug Targets Infect Disord 3, 263-271. 
Talbot, P.J., and Buchmeier, M.J. (1985). Antigenic variation among murine coronaviruses: evidence for 
polymorphism on the peplomer glycoprotein, E2. Virus Res 2, 317-328. 
Tao, X., Constant, S., Jorritsma, P., and Bottomly, K. (1997). Strength of TCR signal determines the 
costimulatory requirements for Th1 and Th2 CD4+ T cell differentiation. J Immunol 159, 5956-5963. 
Tartaglia, J., Perkus, M.E., Taylor, J., Norton, E.K., Audonnet, J.C., Cox, W.I., Davis, S.W., van der 
Hoeven, J., Meignier, B., Riviere, M., et al. (1992). NYVAC: a highly attenuated strain of vaccinia virus. 
Virology 188, 217-232. 
Taylor, J., and Paoletti, E. (1988). Pox viruses as eukaryotic cloning and expression vectors: future 
medical and veterinary vaccines. Prog Vet Microbiol Immunol 4, 197-217. 
147
                                                                                                                                                  Appendix 
 
Thiel, V., Herold, J., Schelle, B., and Siddell, S.G. (2001a). Infectious RNA transcribed in vitro from a 
cDNA copy of the human coronavirus genome cloned in vaccinia virus. J Gen Virol 82, 1273-1281. 
Thiel, V., Herold, J., Schelle, B., and Siddell, S.G. (2001b). Viral replicase gene products suffice for 
coronavirus discontinuous transcription. J Virol 75, 6676-6681. 
Thiel, V., Karl, N., Schelle, B., Disterer, P., Klagge, I., and Siddell, S.G. (2003). Multigene RNA vector 
based on coronavirus transcription. J Virol 77, 9790-9798. 
Thorner, A.R., Lemckert, A.A., Goudsmit, J., Lynch, D.M., Ewald, B.A., Denholtz, M., Havenga, M.J., 
and Barouch, D.H. (2006). Immunogenicity of heterologous recombinant adenovirus prime-boost vaccine 
regimens is enhanced by circumventing vector cross-reactivity. J Virol 80, 12009-12016. 
Todryk, S.M., Bejon, P., Mwangi, T., Plebanski, M., Urban, B., Marsh, K., Hill, A.V., and Flanagan, K.L. 
(2008). Correlation of memory T cell responses against TRAP with protection from clinical malaria, and 
CD4 CD25 high T cells with susceptibility in Kenyans. PLoS ONE 3, e2027. 
Trombetta, E.S., and Mellman, I. (2005). Cell biology of antigen processing in vitro and in vivo. Annu 
Rev Immunol 23, 975-1028. 
Trono, D. (2003). Virology. Picking the right spot. Science 300, 1670-1671. 
Truckenmiller, M.E., and Norbury, C.C. (2004). Viral vectors for inducing CD8+ T cell responses. Expert 
Opin Biol Ther 4, 861-868. 
Tubulekas, I., Berglund, P., Fleeton, M., and Liljestrom, P. (1997). Alphavirus expression vectors and 
their use as recombinant vaccines: a minireview. Gene 190, 191-195. 
Ulmer, J.B., Valley, U., and Rappuoli, R. (2006). Vaccine manufacturing: challenges and solutions. Nat 
Biotechnol 24, 1377-1383. 
van der Veen, R.C. (1996). Immunogenicity of JHM virus proteins: characterization of a CD4+ T cell 
epitope on nucleocapsid protein which induces different T-helper cell subsets. Virology 225, 339-346. 
van Stipdonk, M.J., Lemmens, E.E., and Schoenberger, S.P. (2001). Naive CTLs require a single brief 
period of antigenic stimulation for clonal expansion and differentiation. Nat Immunol 2, 423-429. 
Vennema, H., Godeke, G.J., Rossen, J.W., Voorhout, W.F., Horzinek, M.C., Opstelten, D.J., and Rottier, 
P.J. (1996). Nucleocapsid-independent assembly of coronavirus-like particles by co-expression of viral 
envelope protein genes. Embo J 15, 2020-2028. 
Viguier, M., Lemaitre, F., Verola, O., Cho, M.S., Gorochov, G., Dubertret, L., Bachelez, H., Kourilsky, 
P., and Ferradini, L. (2004). Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in 
human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 173, 
1444-1453. 
Villadangos, J.A., and Schnorrer, P. (2007). Intrinsic and cooperative antigen-presenting functions of 
dendritic-cell subsets in vivo. Nat Rev Immunol 7, 543-555. 
Waldmann, T.A. (2006). The biology of interleukin-2 and interleukin-15: implications for cancer therapy 
and vaccine design. Nat Rev Immunol 6, 595-601. 
148
                                                                                                                                                  Appendix 
 
Wang, H.Y., Lee, D.A., Peng, G., Guo, Z., Li, Y., Kiniwa, Y., Shevach, E.M., and Wang, R.F. (2004). 
Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy. 
Immunity 20, 107-118. 
Warden, M.P., and Weir, J.P. (1996). Inducible gene expression of the human immunodeficiency virus 
LTR in a replication-incompetent herpes simplex virus vector. Virology 226, 127-131. 
Wathelet, M.G., Orr, M., Frieman, M.B., and Baric, R.S. (2007). Severe acute respiratory syndrome 
coronavirus evades antiviral signaling: role of nsp1 and rational design of an attenuated strain. J Virol 81, 
11620-11633. 
Weiner, L.P. (1973). Pathogenesis of demyelination induced by a mouse hepatitis. Arch Neurol 28, 298-
303. 
White, A.C., and Garcia, H.H. (1999). Recent Developments in the Epidemiology, Diagnosis, Treatment, 
and Prevention of Neurocysticercosis. Curr Infect Dis Rep 1, 434-440. 
Wickham, T.J., Mathias, P., Cheresh, D.A., and Nemerow, G.R. (1993). Integrins alpha v beta 3 and 
alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell 73, 309-319. 
Wild, T.F. (1999). Measles vaccines, new developments and immunization strategies. Vaccine 17, 1726-
1729. 
Witmer-Pack, M.D., Olivier, W., Valinsky, J., Schuler, G., and Steinman, R.M. (1987). 
Granulocyte/macrophage colony-stimulating factor is essential for the viability and function of cultured 
murine epidermal Langerhans cells. J Exp Med 166, 1484-1498. 
Woo, E.Y., Chu, C.S., Goletz, T.J., Schlienger, K., Yeh, H., Coukos, G., Rubin, S.C., Kaiser, L.R., and 
June, C.H. (2001). Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-
small cell lung cancer and late-stage ovarian cancer. Cancer Res 61, 4766-4772. 
Xin, K.Q., Jounai, N., Someya, K., Honma, K., Mizuguchi, H., Naganawa, S., Kitamura, K., Hayakawa, 
T., Saha, S., Takeshita, F., et al. (2005). Prime-boost vaccination with plasmid DNA and a chimeric 
adenovirus type 5 vector with type 35 fiber induces protective immunity against HIV. Gene Ther 12, 
1769-1777. 
Xue, S., Jaszewski, A., and Perlman, S. (1995). Identification of a CD4+ T cell epitope within the M 
protein of a neurotropic coronavirus. Virology 208, 173-179. 
Yang, T.C., Millar, J., Groves, T., Grinshtein, N., Parsons, R., Takenaka, S., Wan, Y., and Bramson, J.L. 
(2006). The CD8+ T cell population elicited by recombinant adenovirus displays a novel partially 
exhausted phenotype associated with prolonged antigen presentation that nonetheless provides long-term 
immunity. J Immunol 176, 200-210. 
Yang, Y., Xiong, Z., Zhang, S., Yan, Y., Nguyen, J., Ng, B., Lu, H., Brendese, J., Yang, F., Wang, H., et 
al. (2005). Bcl-xL inhibits T-cell apoptosis induced by expression of SARS coronavirus E protein in the 
absence of growth factors. Biochem J 392, 135-143. 
149
                                                                                                                                                  Appendix 
 
Yewdell, J.W., Norbury, C.C., and Bennink, J.R. (1999). Mechanisms of exogenous antigen presentation 
by MHC class I molecules in vitro and in vivo: implications for generating CD8+ T cell responses to 
infectious agents, tumors, transplants, and vaccines. Adv Immunol 73, 1-77. 
Yokomori, K., Asanaka, M., Stohlman, S.A., Makino, S., Shubin, R.A., Gilmore, W., Weiner, L.P., 
Wang, F.I., and Lai, M.M. (1995). Neuropathogenicity of mouse hepatitis virus JHM isolates differing in 
hemagglutinin-esterase protein expression. J Neurovirol 1, 330-339. 
Yokomori, K., Banner, L.R., and Lai, M.M. (1991). Heterogeneity of gene expression of the 
hemagglutinin-esterase (HE) protein of murine coronaviruses. Virology 183, 647-657. 
Yokomori, K., Stohlman, S.A., and Lai, M.M. (1993). The detection and characterization of multiple 
hemagglutinin-esterase (HE)-defective viruses in the mouse brain during subacute demyelination induced 
by mouse hepatitis virus. Virology 192, 170-178. 
Yount, B., Curtis, K.M., and Baric, R.S. (2000). Strategy for systematic assembly of large RNA and DNA 
genomes: transmissible gastroenteritis virus model. J Virol 74, 10600-10611. 
Yount, B., Roberts, R.S., Lindesmith, L., and Baric, R.S. (2006). Rewiring the severe acute respiratory 
syndrome coronavirus (SARS-CoV) transcription circuit: engineering a recombination-resistant genome. 
Proc Natl Acad Sci U S A 103, 12546-12551. 
Yu, X., Bi, W., Weiss, S.R., and Leibowitz, J.L. (1994). Mouse hepatitis virus gene 5b protein is a new 
virion envelope protein. Virology 202, 1018-1023. 
Zheng, L., Fisher, G., Miller, R.E., Peschon, J., Lynch, D.H., and Lenardo, M.J. (1995). Induction of 
apoptosis in mature T cells by tumour necrosis factor. Nature 377, 348-351. 
Zhi, Y., Figueredo, J., Kobinger, G.P., Hagan, H., Calcedo, R., Miller, J.R., Gao, G., and Wilson, J.M. 
(2006). Efficacy of severe acute respiratory syndrome vaccine based on a nonhuman primate adenovirus 
in the presence of immunity against human adenovirus. Hum Gene Ther 17, 500-506. 
Zhou, H., and Perlman, S. (2006). Preferential infection of mature dendritic cells by mouse hepatitis virus 
strain JHM. J Virol 80, 2506-2514. 
Zhou, J., Stohlman, S.A., Hinton, D.R., and Marten, N.W. (2003). Neutrophils promote mononuclear cell 
infiltration during viral-induced encephalitis. J Immunol 170, 3331-3336. 
Zinkernagel, R.M. (2000). On immunological memory. Philos Trans R Soc Lond B Biol Sci 355, 369-
371. 
Zinkernagel, R.M. (2003). On natural and artificial vaccinations. Annu Rev Immunol 21, 515-546. 
Zinkernagel, R.M., and Doherty, P.C. (1974). Immunological surveillance against altered self components 
by sensitised T lymphocytes in lymphocytic choriomeningitis. Nature 251, 547-548. 
Zitvogel, L., Mayordomo, J.I., Tjandrawan, T., DeLeo, A.B., Clarke, M.R., Lotze, M.T., and Storkus, 
W.J. (1996). Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, 
B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med 183, 87-97. 
Zoltick, P.W., Leibowitz, J.L., Oleszak, E.L., and Weiss, S.R. (1990). Mouse hepatitis virus ORF 2a is 
expressed in the cytosol of infected mouse fibroblasts. Virology 174, 605-607. 
150
                                                                                                                                                  Appendix 
 
Zuniga, A., Wang, Z., Liniger, M., Hangartner, L., Caballero, M., Pavlovic, J., Wild, P., Viret, J.F., 
Glueck, R., Billeter, M.A., et al. (2007). Attenuated measles virus as a vaccine vector. Vaccine 25, 2974-
2983. 
Zust, R., Cervantes-Barragan, L., Kuri, T., Blakqori, G., Weber, F., Ludewig, B., and Thiel, V. (2007). 
Coronavirus non-structural protein 1 is a major pathogenicity factor: implications for the rational design 
of coronavirus vaccines. PLoS Pathog 3, e109. 
Zust, R., Miller, T.B., Goebel, S.J., Thiel, V., and Masters, P.S. (2008). Genetic interactions between an 
essential 3' cis-acting RNA pseudoknot, replicase gene products, and the extreme 3' end of the mouse 
coronavirus genome. J Virol 82, 1214-1228. 
151
                                                                                                                                                  Appendix 
 
8.2 Abbreviations 
 
AAV   Adeno-associated virus 
ADCC   Antibody-dependent cellular cytotoxicity 
AIDS   Acquired immunodeficiency syndrom 
ALT   Alanine aminotransferase 
APC   Antigen presenting cell 
BCV   Bovine coronavirus 
Bp   Base pairs 
C-terminal  Carboxy terminal 
CAT   Chloramphenicol acetyltransferace 
Ceacam1a  Carcino-embryonic antigen related cell adhession molecule 1° 
CTL   Cytolytic T lymphocytes 
CCR7   Chemokine receptor 7 
CDC   Complement-dependent cytotoxicity 
cDNA   Complementary deoxyribonucleic acid 
CMV   Cytomegalovirus 
CNS   Central nervous system 
DC   Dendritic cell 
DNA   Deoxyribonucleic acid 
E   Envelope glycoprotein 
EBV   Epstein-Bar virus 
ELC   EBV-induced molecule 1 ligand chemokine 
FPV   Fowl-pox virus 
FIPV   Feline infectious peritonitis virus 
Fc   Fragment crystallizable 
FMDV  Foot and mouth disease virus 
GP   Glycoprotein 
GM-CSF  Granulocyte macrophage colony stimulating factor 
GFP   Green fluorescence protein 
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GTP   Guanine phosphoribosyltransferase 
H‟APN  Human aminopeptidase N 
HA1   Hemagglutinin fusion protein 1 
HE   Hemagglutinin-estarase  
HCV   Human coronavirus 
HCoV   Human coronavirus 
HLA   Human leukocyte antigen 
HIV   Human immunodeficiency virus 
HSV   Herpes simplex virus 
Ig   Immunoglobulin 
IL   Interleukin 
IFN   Interferon 
IBV   Infectious bronchitis virus 
JHM   John Howard Müller 
LCMV  Lymphocytic choriomeningitis virus 
LUC   Luciferase 
LAMP   Lysosomal associated membrane protein-3 
M   Membrane glycoprotein 
MHV   Mouse hepatitis virus 
MHC   Major histocompatibility complex 
MMR   Measles mumps rubella 
MIP3   Macrophage inflammatory protein 
MV   Measles virus 
mRNA  Messenger ribonucleic acid 
N   Nucleocapsid 
NKT   Natural killer T cell 
Nsp1   Non-structural protein 1 
ORF   Open reading frame 
pAPC   Professional antigen presenting cell 
P.i   Post infection 
PFU   Plaque forming unit 
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pDCs   Plasmacytoid dendritic cells 
PRL   Pattern recognition ligand 
RNA   Ribonucleic acid 
S   Spike 
SIV   Simian immunodeficiency virus 
SIN   Sindbis virus 
SFV   Semliki forest virus 
SLC   Secondary lymphoid tissue chemokine 
SARS   Seviere acute respiratory syndrome 
TCR   T cell receptor 
TH   T helper 
TNF-β   Tumour necrosis factor-beta 
TCV   Turkey coronavirus 
TGEV   Transmissible gastroenteritis virus 
TLRs   Toll like receptors 
Treg   T regulatory 
TRS   Transcription regulatory sequence 
TEM   T effector memory 
TCM   T central memory 
VLPs   Virus like particles 
VSV   Vesicular stomatitis virus 
VSV-G  Vesicular stomatitis virus glycoprotein 
VEEV   Venezuelan equine encephalitis virus 
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